

PACTALS 2025



Theme:

Towards Precision in ALS/MND Treatments and Care

SOUVENIR PROGRAMME BOOK

7 - 9 September 2025

Melbourne Convention and Exhibition Centre, Australia

Organised by:



About PACTALS



The Pan-Asian Consortium for Treatment and Research in ALS (PACTALS) was established in December, 2014. The concept is similar to other regional existing Consortia namely the North-East Amyotrophic Lateral Sclerosis (NEALS) in the United States and European Network for the Cure of ALS (ENCALS). PACTALS represents a large ALS/Motor Neurone Disease (MND) community including the very active research groups in the Asia – Pacific region.

Our objectives include:

1. Developing an Asia-Pacific network of researchers and clinicians working with ALS/MND that:
 - Is recognised within the international ALS/MND network.
 - Can work collaboratively in an efficient and effective manner.
 - Will attract pharmaceutical companies to conduct trials in Asia-Pacific region.
 - Will support the education and training of members to achieve the overall objectives.
2. Establishing a Patient Registry within the Asia-Pacific region that will facilitate the collection/ storage of clinical data.
3. Initiating collaboration between funding agencies in Asia-Pacific to collectively sponsor investigator initiated clinical trials.



About MND Australia



MND Australia is the national peak body for people living with motor neurone disease (MND). Over 2,700 Australians are currently living with MND. Every day two Australians are diagnosed with MND and two die from the disease.

MND is a relentless disease which attacks the nerves that communicate between the brain and the muscles. People with MND lose the ability to move, walk, speak, swallow and ultimately breathe.

Together with our members, the State MND Associations, we work to advance MND care, advocacy and research.

For over 35 years our research grants program has funded world-class MND research to uncover the causes, improve care and discover new treatments.



Congress Information

Official Congress Venue:

Melbourne Convention and Exhibition Centre (MCEC)
1 Convention Centre Pl, South Wharf VIC 3006, Australia

How to get to MCEC:

Driving:

Use Google or Waze to search Melbourne Convention and Exhibition Centre (MCEC)

Parking:

Wilson Parking offer affordable & secure parking at Melbourne Exhibition Centre Car Park, located at 16 Normanby Rd in the heart of Southbank.

Hourly rate, Early Bird rate, Night rate, Weekend rate and Event rate are available based on the date and time of entrance.

Prepay online to secure lower parking rates (from AUD 13 per hour): <https://www.wilsonparking.com.au/parking-locations/victoria/southbank/melbourne-exhibition-centre-car-park/>

E-hailing:

MCEC is approximately 30 minutes from Melbourne Airport with smooth traffic. E-hailing service is widely available in Melbourne. You may use the 13cabs or Uber app to move around.

Public Transport:

Tram: Tram routes 96, 109, and 12 stop directly at the MCEC (Stop D5: Clarendon Street/Jacobs Street). Trams within Melbourne's central business district are free, including the routes to MCEC.

Train: Southern Cross Station is a 10-minute walk from MCEC, offering connections to regional and metropolitan rail networks.

Registration:

The registration and information desk will be located in the Goldfields Theatre Foyer of Ground floor of the MCEC. Upon arrival, kindly show your registration confirmation email at the registration counter to collect your congress name badge. The name badge will be your entry to conference sessions and the industry exhibition. Help desk is also available at Level 1 in front of the Clarendon Auditorium on 9th September 2025.

Delegate and Speaker Registration Counter, Speaker Ready Room (Ground Floor Entry via Convention Centre Place)

7th September 2025 (Sunday): 0700 – 1800 hours

8th September 2025 (Monday): 0700 – 1800 hours

9th September 2025 (Tuesday): 0700 – 1800 hours

E-Certificate of Attendance and Presentation, Invoice and Receipt


E-Certificate of Attendance, and Presentation as well as Invoice and Receipt will be available on your delegate dashboard for 1 month post congress. Please download the documents needed before 10th October 2025.

Facilities Available at Ground Floor:

- Prayer Room
- Accessible Toilet
- Parents Room

Congress Floorplan

Ground Floor



- A** = Eureka Rooms 1-3 | Workshops & Congress Track 2
- B** = Goldfields Theatre Door 13 | Congress Plenary & Track 1
- C** = Goldfields Event Space Bay 21B & 22B Door 11 | Exhibition & Catering
- D** = Registration

- E** = Clarendon Auditorium (Upstairs to Level 1) | Care Forum*
- F** = Chairman's Boardroom | Regeneron Pharmaceutical
- G** = Courtyard Room 1 | QurAlis Corporation

* Please note that the Clarendon Auditorium is located approximately 400m from the PACTALS Congress and Exhibition Hall.

7th September 2025 (Sunday)

- Goldfields Theatre Foyer: Registration
- Eureka Room 2 & 3: Patient Advocacy Group Session & Workshop 1: NEUROPHYS – LMN, NEUROPHYS - UMN/TMS, ADVANCED IMAGING
- Eureka Room 1: Workshop 2: OMICS PRIMER & Workshop 3: RESPIRATORY CARE IN ALS

8th September 2025 (Monday)


- Goldfields Theatre Foyer: Registration
- Goldfields Theatre: PACTALS Main Congress Track 1
- Eureka Room 1-3: PACTALS Main Congress Track 2
- Courtyard Room 2: INARC Gathering
- Goldfields Event Space Bay 21B & 22B Door 11 : Exhibition & Catering

9th September 2025 (Tuesday)

- Goldfields Theatre Foyer: Registration
- Goldfields Theatre: PACTALS Main Congress Track 1
- Eureka Room 1-3: PACTALS Main Congress Track 2
- Clarendon Auditorium (Level 1): Care Forum
- Goldfields Event Space Bay 21B & 22B Door 11 : Exhibition & Catering

Congress Floorplan

Exhibition Hall *(Goldfields Event Space Bay 21B & 22B)*



Diamond Sponsors

- 4 - Biogen Australia
- 1 - CorestemChemon Inc.

Platinum Sponsors

- 9 - FightMND
- 2 - Teva Pharma Australia

Gold Sponsors

- 3 - Mitsubishi Tanabe Pharma Corporation
- G - QurAlis Corporation (Courtyard Room 1)

Silver Sponsor

- F - Regeneron Pharmaceuticals (Chairman's Boardroom)

Standard Sponsors

- 8 - AlMedical International
- 7 - Natus Medical

5 - MND Australia Lounge

6 - MND Victoria

10 - PACTALS Lounge

11 - Photowall

Welcome Message from Convenor of PACTALS 2025



Dear Colleagues,

On behalf of the organising committee, it is with great pleasure that we invite you to join us at the PACTALS 2025 Conference, taking place from 7th to 9th September 2025 in the vibrant city of Melbourne, Australia. Under the theme “Towards Precision in ALS/MND Treatments,” this conference promises to be a pivotal event in the field of ALS and motor neurone disease (MND) research and treatment.

PACTALS 2025 will bring together leading experts, researchers, clinicians, and advocates from across the globe, all driven by a shared commitment to advancing our understanding of ALS/MND and improving the lives of those affected by these conditions. The conference will feature the latest research, innovative therapeutic approaches, and inspiring discussions aimed at pushing the boundaries of precision medicine in ALS/MND treatment.

Melbourne, renowned as a dynamic multicultural society, provides the perfect backdrop for this gathering. We are confident that the scientific program, coupled with the unique networking opportunities and international collaborative spirit, will make PACTALS 2025 an unforgettable and enriching experience. for all.

We warmly encourage you to join us in Melbourne for this landmark event. Together, we can advance the future of ALS/MND care and create meaningful progress in the journey towards precision treatments. We look forward to welcoming you in 2025!

Paul Talman
Convenor of PACTALS 2025

Dear Colleagues,

On behalf of MND Australia, I welcome you to the PACTALS meeting in Australia on 7-9 September this year.

Pioneering research to further our understanding of MND and accelerating research to find treatments and care for people living with MND is a key priority for MND Australia.

MND Australia is the national peak body of state organizations that support those living with MND. We are passionate about helping people living with this terrible disease.

Collectively we, and our member organisations, help the almost 2,700 people in Australia suffering from this horrendous disease. We have 140 staff across the country helping people diagnosed with MND and their carers, providing over 8,570 pieces of equipment, advising on navigating complex health systems and supporting access \$400 million per year in government aged care and NDIS funding.

The speakers and programme for this year’s PACTALS meeting are exceptional. We are bringing together world leaders in MND research and science, it is going to be a meeting not to miss.

I look forward to seeing you in Melbourne.

Clare Sullivan
Convenor of PACTALS 2025



Welcome Message from President of PACTALS



Amyotrophic lateral sclerosis (ALS) has long been synonymous with neurological diseases for which there is no cure. However, recent advances in molecular biology, genomic research, and therapeutic intervention techniques have expanded the possibilities for therapeutic development. ALS is now one of the most active neurodegenerative diseases in the field of therapeutic development research. A wealth of knowledge and data has been accumulated in medical treatment and care, and appropriate interventions have been identified. There is much we can and should do for people with ALS.

Although it is assumed that there are many commonalities among patients worldwide, it is also becoming clear that the etiology, pathophysiology, and course of the disease vary considerably from region to region and from patient to patient. Both international collaboration and country-specific efforts are needed to advance the development of ALS treatments and improve medical care. In Asia and Oceania, where the number of patients is expected to increase in the future, there is a need for a consortium to share information and promote international collaborative efforts in each country.

The concept of Pan-Asian Consortium for Treatment and Research in ALS (PACTALS) was established in December 2014 as a research consortium for ALS in the Asia-Pacific region. Since then, the PACTALS members have been working to promote research collaborations in the region. After the success of the PACTALS 2018 meeting in Seoul (Convener: Prof. Seung H Kim), the PACTALS 2020 meeting was planned to be held in Nagoya, Japan in September 2020. Unfortunately, due to the covid-19 pandemic, we decided to hold it as PACTALS 2021 on the full web (Convener: Prof. Gen Sobue). And the PACTALS 2023 meeting (Convener: Prof. Nortina Shahrizaila) was held in Kuala Lumpur, Malaysia, with great success.

The next PACTALS 2025 will be held in Melbourne, Australia, with Prof. Paul Talman as Convener. The theme will be “Towards Precision in ALS/MND Treatments”. We are confident that this will be a wonderful opportunity to learn about the latest developments in ALS treatment and to gain guidance to advance our efforts based on local realities. To all those working with ALS, welcome to PACTALS 2025.

Gen Sobue
President of PACTALS

Welcome Message from President-Elect of PACTALS



On behalf of the Pan-Asian Consortium for Treatment and Research in ALS (PACTALS), together with our local hosts, Professor Paul Talman, Professor Matthew Kiernan as well as MND Australia, it is a pleasure to welcome you to PACTALS 2025 which will be held in Melbourne, Australia.

The theme of PACTALS 2025, “Towards Precision in ALS/MND Treatments”, aims to facilitate and enhance discussions and collaborations centered around personalised drug discovery in ALS/MND, as well as other areas of research and care.

As our network of Asia-Pacific ALS/MND community continues to grow and gain strides in uncovering knowledge of the disease in our unique cohorts, we look forward to sharing this knowledge in the hopes of moving us closer towards a world free of MND/ALS.

Nortina Shahrizaila
President-Elect of PACTALS

Welcome Message from Immediate Past President of PACTALS



Dear Colleagues,

On behalf of the Pan-Asian Consortium for the Treatment and Research in ALS (PACTALS), it is my pleasure to invite you to attend the PACTALS 2025 Meeting, scheduled to be held in Melbourne, Australia, from September 7th to 9th, 2025.

Asia is home to more than half of the world’s population, and consequently, it represents the largest cohort of ALS patients. Despite this, our understanding of ALS, particularly in terms of the disease’s prevalence and characteristics within and across Asian populations, remains insufficient. To address this, PACTALS was founded in 2014 to advance treatment development and foster novel research initiatives in the region. Since 2016, the PACTALS meeting has become a cornerstone event, with previous gatherings successfully hosted in Seoul (2018), Nagoya (2021), and Kuala Lumpur (2023). Following the highly successful meeting in Kuala Lumpur, I am confident that the 2025 PACTALS meeting in Melbourne will continue this legacy, offering an excellent platform to connect, collaborate, and share the latest advancements in ALS research and treatment.

As our consortium grows, this is an opportune time to deepen our collective knowledge of ALS in the Asia-Pacific region. The PACTALS 2025 Scientific Committee has worked diligently to curate a world-class program featuring renowned experts in ALS from around the globe alongside esteemed clinicians and researchers from across Asia.

Your participation will undoubtedly enrich the discussions and drive forward our shared goals in ALS research and treatment. I extend my heartfelt gratitude to the PACTALS 2025 organizing committee for their efforts in preparing this meeting and to all PACTALS members for their ongoing dedication and contributions.

We look forward to welcoming you to the vibrant city of Melbourne for what promises to be an exceptional event. I hope to see you there!
Warm regards,

Seung Hyun Kim
Immediate Past President of PACTALS



PACTALS 2025 Committee

Convenor:

Paul TALMAN & Clare SULLIVAN

Scientific Programme Committee:

Co-chairs: Paul TALMAN & Shyuan NGO

1. Gen SOBUE
2. Nortina SHAHRIZAILA
3. Seung Hyun KIM
4. Mathew KIERNAN

Local Organising Committee:

Co-chairs: Paul Talman & Thanuja Dharmadasa

- | | |
|---------------------------|-----------------------|
| 1. Bradley TURNER | 9. Mary-Louise ROGERS |
| 2. Clare SULLIVAN | 10. Merrilee NEEDHAM |
| 3. David SCHULTZ | 11. Robert HENDERSON |
| 4. Frederik (Derik) STEYN | 12. Shyuan NGO |
| 5. Fleur GARTON | 13. Steve VUCIC |
| 6. Jo WHITEHOUSE | 14. Sicong TU |
| 7. Madeleine CATLIN | 15. Susan MATHERS |
| 8. Marnie GRACO | 16. Tom JENKINS |

International Advisory Committee:

International Alliance of ALS/MND Associations:

Catherine CUMMINGS & Jessica MABE

China:

Liyong CUI, Dongsheng FAN

India:

Hemangi SANE, Atcharayam NALINI

Indonesia:

Ahmad Yanuar SYAFRI, Manfaluthy HAKIM, Sheila AGUSTINI

Japan:

Satoshi KUWABARA, Naoki ATSUTA

Korea:

Jung-Joon SUNG, Bugyeong SON, Yoon-Ho HONG

Malaysia:

Rabani REMLI, Steve NG, Dhayalen KRISHNAN

Myanmar:

Phyu Phyu LAY, Win Min THIT, Zin Nwe WIN

Philippines:

Mario PRADO, Raymond ROSALES

Singapore:

Josiah CHAI, Kay NG

Taiwan:

Yi Chung LI, Chaur Jong HU, Chih Chao YANG

Thailand:

Kongkiat KULKANTRAKORN, Arada ROJANA-UDOMSART

Vietnam:

Tu Quoc Le TUAN

Faculty

Aicee CALMA, *Australia*
Allan MCRAE, *Australia*
Alicia EDWARDS, *Australia*
Ammar AL-CHALABI, *United Kingdom*
Andrew COLLINS, *Australia*
Angela GENGE, *Canada*
Antony WINKEL, *Canada*
Arada ROJANA-UDOMSART, *Thailand*
Atchayaram NALINI, *India*
Azlina Ahmad ANNUAR, *Malaysia*
Billy KARNAROS, *Australia*
Bradley TURNER, *Australia*
Bugyeong SON, *Korea*
Calaneet BALAS, *USA*
Catherine CUMMINGS, *Canada*
Cindy (Shin-Yi) LIN, *Australia*
David COX, *Australia*
Davor STANIC, *Australia*
Dongsheng FAN, *China*
Elizabeth KAPUR, *Australia*
Emma SCOTTER, *New Zealand*
Emma GRAY, *Australia*
Frederik STEYN, *Australia*
Gaye ALCORN, *Australia*
Gen SOBUE, *Japan*
Gerald PFEFFER, *Canada*
Giulia VALENTE, *Australia*
Hannes ALMGREN, *Australia*
Harry LIPSCOMBE, *Australia*
Hazmir MOHAMADAN, *Australia*
Hideyuki OKANO, *Japan*
Janet HOUGH, *Australia*
Jean DOWNTOWN, *Australia*
Jeremy SHEFNER, *USA*
Jeryn CHANG, *Australia*
Jessica AUDINO, *Australia*
Jinsy ANDREWS, *USA*
José MATAMALA, *Chile*
Josiah CHAI, *Singapore*
Jo WHITEHOUSE, *Australia*
Julie ATKIN, *Australia*
Julie LABRA, *Australia*
Jun-An CHEN, *Taiwan*
Jung-Joon SUNG, *Korea*
Karen HUTCHINSON, *Australia*
Ki-Wook OH, *Korea*
Laura BIRKS, *Australia*
Leanne SKLAVENITIS, *Canada*
Leonard VAN DEN BERG, *The Netherlands*
Lezanne OOI, *Australia*
Marina KENNERSON, *Australia* Mario PRADO JR, *Philippines* Manish RAISINGHANI, *USA*
Marnie GRACO, *Australia*
Mary-Louise ROGERS, *Australia* Matthew KIERNAN, *Australia*
Merit CUDKOWICZ, *USA*
Michelle FARRAR, *Australia* Michal TOTH, *Australia*
Naoki ATSUTA, *Japan*
Nicole SHEERS, *Australia*
Nortina SHAHRIZAILA, *Malaysia* Nicholas CRUMP, *Australia*
Olivia ONG, *Australia*
Osamu KANO, *Japan*
Parvathi MENON, *Australia*
Paul TALMAN, *Australia*
Paula TREFIAK, *Canada*
Pete RUSSO, *Australia*
Peter ALLCROFT, *Australia*
Phyu Phyu LAY, *Myanmar*
Prue GRAY, *Australia*
Rachel TAN, *Australia*
Rebecca FRANCIS, *Australia* Robert CAPSTICK, *Australia* Robert HENDERSON, *Australia* Ruben VAN EIJK, *The Netherlands*
Ryuji KAJI, *Japan*
Savannah JEWELL, *Australia* Seung Hyun KIM, *Korea*
Sheila AGUSTINI, *Indonesia*
Shi-Yan NG, *Singapore*
Shuangwu LIU, *China*
Shuo-Chien LING, *Singapore* Shyuan NGO, *Australia*
Sicong TU, *Australia*
Stephanie HOWE, *Australia*
Susan MATHERS, *Australia*
Susanna PARK, *Australia*
Thanuja DHARMADASA, *Australia* Thomas SHAW, *Australia*
Todd JOHNSON, *Australia*
Tu Quoc Le TUAN, *Vietnam*
Victoria TULL, *Australia*
Vinod AIYAPPAN, *Australia* Woojin Scott KIM, *Australia*
Yi-Chung LEE, *Taiwan*

Programme Overview

SEPT 7 SUNDAY

DAY 1: PRE-CONGRESS WORKSHOPS			
0700 - 0800	REGISTRATION		
ROOM	EUREKA ROOM 2 + 3	ROOM	EUREKA ROOM 1
0800 - 1000	PATIENT ADVOCACY SESSION	0800 - 1245	PACTALS WORKSHOP 2
1000 - 1030	BREAK	0800 - 1000	WORKSHOP: OMICS PRIMER
1030 - 1800	PACTALS WORKSHOP 1	1000 - 1030	BREAK
1030 - 1245	WORKSHOP: NEUROPHYS - LMN	1030 - 1245	WORKSHOP: OMICS PRIMER
1245 - 1400	BREAK		
1400 - 1530	WORKSHOP: ADVANCED NEUROPHYS - UMN/TMS	1400 - 1730	PACTALS WORKSHOP 3
		1400 - 1530	WORKSHOP: RESPIRATORY CARE IN ALS
1530 - 1600	BREAK		
1600 - 1800	WORKSHOP: ADVANCED IMAGING	1600 - 1730	WORKSHOP: RESPIRATORY CARE IN ALS
END OF DAY 1			

Programme Overview

SEPT 8 MONDAY

DAY 2: PACTALS CONGRESS		
0700 - 1800	REGISTRATION	
HALL	GOLDFIELDS THEATRE	
0800 - 0830	OPENING CEREMONY	
0830 - 1030	PLENARY 1 - GLOBAL REVIEW ALS/MND	
1030 - 1100	BREAK	
1100 - 1230	PLENARY 2 - CURRENT KNOWLEDGE UPDATES	
1230 - 1300	BREAK	
1300 - 1400	INDUSTRY LUNCH SYMPOSIA by CorestemChemon Inc. 	
HALL / ROOM	GOLDFIELDS THEATRE	EUREKA ROOMS
1400 - 1530	SESSION 3: SYMPOSIA 1A - NEUROPHYSIOLOGY AND CLINICAL TRIALS	SESSION 4: SYMPOSIA 1B - OMICS AND BIOMARKERS
HALL	GOLDFIELDS THEATRE	
1530 - 1600	TEA SYMPOSIA by TEVA 	
HALL / ROOM	EXHIBITION BAY (21B & 22B)	COURTYARD ROOM 2
1600 - 1800	POSTER TOUR, POSTER JUDGING SESSION, WELCOME RECEPTION	INARC GATHERING
END OF DAY 2		

Programme Overview

SEPT 9 TUESDAY

DAY 3: PACTALS CONGRESS			
0700 - 1800	REGISTRATION		
HALL	EUREKA ROOMS		
0700 - 0800	PACTALS AGM <i>(Closed Event)</i>		
HALL	GOLDFIELDS THEATRE		
0800 - 0830	MORNING SYMPOSIA by FightMND 		
0830 - 1000	PLENARY 3 - PATHWAYS TO DISCOVERY		
1000 - 1030	BREAK		
HALL	GOLDFIELDS THEATRE	ROOM	EUREKA ROOMS
1030 - 1245	SESSION 6: SYMPOSIA 2A - CLINICAL TRIALS, DISEASE STRATIFICATION, PALLIATIVE CARE	1030 - 1245	SESSION 7: SYMPOSIA 2B - MOLECULAR AND CELLULAR PATHOLOGY
1245 - 1300	BREAK		
HALL	GOLDFIELDS THEATRE		
1300 - 1400	INDUSTRY LUNCH SYMPOSIA by BIOGEN 		
HALL	GOLDFIELDS THEATRE	ROOM	EUREKA ROOMS
1400 - 1530	SESSION 8: SYMPOSIA 3A - IMAGING AND BIO-MARKERS	1400 - 1530	SESSION 9: SYMPOSIA 3B - DISEASE MODELS AND THERAPEUTICS
HALL	GOLDFIELDS THEATRE		
1530 - 1600	TEA SYMPOSIA by QURALIS 		
1600 - 1730	PLENARY 4 - CLINICAL PROGRESS		
1730 - 1800	CLOSING CEREMONY		
END OF CONGRESS			

Programme Overview

SEPT **9** **TUESDAY**

DAY 3: MND CARE FORUM	
0700 - 1800	REGISTRATION
HALL	CLARENDON AUDITORIUM (LEVEL 1)
0900 - 1030	SESSION 1 - OPENING KEYNOTE
1030 - 1100	BREAK
1100 - 1230	SESSION 2 - WELLBEING AND COMMUNICATION
1230 - 1330	BREAK
1330 - 1430	SESSION 3 - THE LATEST IN EVIDENCE-BASED CARE
1430 - 1505	SESSION 4 - INTERNATIONAL PERSPECTIVES IN CARE AND SUPPORT
1505 - 1530	BREAK
1530 - 1615	SESSION 5 - INNOVATIONS AND NEW HORIZONS
1615 - 1700	SESSION 6 - CLOSING KEYNOTE
HALL	GOLDFIELDS THEATRE
1730 - 1800	CLOSING CEREMONY
END OF CONGRESS	

DAY 1: PRE-CONGRESS WORKSHOPS			
0700 - 1830	REGISTRATION		
ROOM	EUREKA ROOM 2 + 3	ROOM	EUREKA ROOM 1
0800 - 1000	PATIENT ADVOCACY SESSION <i>Chairpersons:</i> <i>Catherine CUMMINGS, Canada & Bugyeong SON, Korea</i>	0800 - 1245	PACTALS WORKSHOP 2
		0800 - 1000	WORKSHOP: OMICS PRIMER <i>Chairperson:</i> <i>Mary-Louise ROGERS, Australia</i>
0800 - 0810	Welcome & Opening Remarks	0800 - 0830	UTILITY OF GENOMICS IN ALS
0810 - 0830	Lightening Introductions	0800 - 0830	Lecture: Unveiling Gene Discoveries Through The 3D Genome: A New Era for Genomic Insight <i>Marina KENNERSON, Australia</i>
0830 - 0900	Thematic Discussion Part I	0830 - 0915	MENDELIAN GENETICS - MINI LECTURE & DEMONSTRATION
0900 - 0910	Summary Part I	0830 - 0850	The Pangenome - Variant Filtering With PanGenie <i>Marina KENNERSON, Australia</i>
0910 - 0940	Thematic Discussion Part 2	0850 - 0910	Variant Interpretation Tools <i>Azlina AHMAD ANNUAR, Malaysia</i>
0940 - 0950	Summary Part 2	0910 - 0915	Questions
0950 - 1000	Closing Remarks & Next Steps	0915 - 1000	COMPLEX GENETICS: MINI LECTURE & DEMONSTRATION
1000 - 1030	BREAK	0915 - 1000	Prioritisation Of Causal Genes From Genome-Wide Association Studies <i>Allan MCRAE, Australia</i>
1030 - 1800	PACTALS WORKSHOP 1	1000 - 1030	BREAK
1030 - 1245	WORKSHOP: NEUROPHYS - LMN	1030 - 1245	WORKSHOP: OMICS PRIMER <i>Chairperson:</i> <i>Frederik STEYN, Australia</i>
1030 - 1100	Lecture: Diagnosis Of ALS In 2025 <i>Jeremy SHEFNER, USA</i>	1030 - 1045	Lecture: Utility Of Spatial Transcriptomics In ALS <i>Frederik STEYN, Australia</i>

DAY 1: PRE-CONGRESS WORKSHOPS			
1100 - 1245	Hands-on Practical	1045 - 1100	Lecture: Utility Of Lipidomics In ALS <i>Woojin Scott KIM, Australia</i>
	Station 1: MScan Fit Motor Unit Number Estimation <i>Susanna PARK, Australia</i> <i>Cindy Shin-Yi LIN, Australia</i>	1100 - 1115	Lecture: Proteomics: Application In Biomarker Discovery for ALS <i>Mary-Louise ROGERS, Australia</i>
	Station 2: MUNIX <i>Antony WINKLE, Australia</i>	1115 - 1245	Hands-on Practical <i>Billy KARNAROS, Australia</i> <i>Jeryn CHANG, Australia</i> <i>Stephanie HOWE, Australia</i>
Station 3: Muscle And nerve Ultrasound <i>Nicholas CRUMP, Australia</i>			
1245 - 1400	BREAK	1245 - 1400	BREAK
1400 - 1530	WORKSHOP: ADVANCED NEUROPHYS - UMN/TMS	1400 - 1730	PACTALS WORKSHOP 3
		1400 - 1530	WORKSHOP: RESPIRATORY CARE IN ALS <i>Chairpersons:</i> <i>Marnie GRACO, Australia</i> <i>Nicole SHEERS, Australia</i>
1400 - 1430	Lecture: Diagnostic Utility Of TMS In ALS <i>Parvathi MENON, Australia</i>	1400 - 1410	Welcome, Introductions & Housekeeping <i>Nicole SHEERS, Australia</i>
		1410 - 1430	Presentation: Respiratory Physiology & Evidence For NIV <i>Vinod AIYAPPAN, Australia</i>
1430 - 1530	Hands-on Practical - Demonstrate Different SICI Techniques - CSP Measurement - MEP Amplitude and MEP Curve	1430 - 1440	Presentation: Respiratory Care Across MND Journey (Focus On NIV) <i>Marnie GRACO, Australia</i>
		1440 - 1530	Panel Discussion: Models of NIV Care In Australia, Japan And Other Countries <i>Osamu KANO, Japan</i> <i>Vinod AIYAPPAN, Australia</i> <i>Nicole SHEERS, Australia</i>
1530 - 1600	BREAK	1530 - 1600	BREAK

DAY 1: PRE-CONGRESS WORKSHOPS			
1600 - 1800	WORKSHOP: ADVANCED IMAGING		1600 - 1730 WORKSHOP: RESPIRATORY CARE IN ALS <i>Chairpersons: Marnie GRACO, Australia Nicole SHEERS, Australia</i>
1600 - 1630	Clinical Utility And Translation Of MRI Biomarkers In ALS <i>Thanuja DHARMADASA, Australia Sicong TU, Australia</i>		1600 - 1610 Presentation: End Of Life Care And Withdrawal Of NIV (Latest Evidence) <i>Peter ALLCROFT, Australia</i>
1630 - 1800	Hands-on Practical		1610 - 1640 Panel Discussion: Ventilation And End Of Life Care In Australia, Japan And Other Countries <i>Peter ALLCROFT, Australia Osamu KANO, Japan Janet HOUGH, Australia</i>
	- Neurodesk - Cortical Thickness / Segmentation	<i>Thomas SHAW, Australia Michal TOH, Australia</i>	Practical Demonstration: How To Discuss NIV And End Of Life Care With A Patient <i>Peter ALLCROFT, Australia Janet HOUGH, Australia</i>
	Tractography	<i>Hannes ALMGREN, Australia Sicong TU, Australia</i>	1610 - 1640 Presentation: Airway Clearance & Complementary Respiratory Care <i>Nicole SHEERS, Australia</i>
	Q&A		Practical Demonstration: Selected Respiratory Therapies <i>Nicole SHEERS, Australia Janet HOUGH, Australia</i>
			1720 - 1730 Final Q&A Wrap up and Close
END OF DAY 1			

DAY 2: PACTALS CONGRESS		
0700 - 1830	REGISTRATION	
HALL	GOLDFIELDS THEATRE	
0800 - 0830	OPENING CEREMONY Chairpersons: <i>Paul TALMAN, Australia & Clare SULLIVAN, Australia</i>	
0800 - 0810	Welcome To Country	Wurundjeri Woi-Wurung Cultural Heritage Aboriginal Corporation
0810 - 0815	Opening Remarks By President Of PACTALS	<i>Gen SOBUE, Australia</i>
0815 - 0820	Opening Remarks By MND Australia	<i>Andrew DANSON, Australia</i>
0820 - 0830	PLWALS From Australia	<i>Leanne SKLAVENITIS, Australia</i>
0830 - 1030	PLENARY 1 - GLOBAL REVIEW ALS/MND Chairpersons: <i>Paul TALMAN, Australia & Nortina SHAHRIZAILA, Malaysia</i>	
0830 - 0940	Overview In Australia	<i>Steve VUCIC, Australia</i>
	Overview In China	<i>Dongsheng FAN, China</i>
	Overview In India	<i>Atchayaram NALINI, India</i>
	Overview In Indonesia	<i>Sheila AGUSTINI, Indonesia</i>
	Overview In Japan	<i>Naoki ATSUTA, Japan</i>
	Overview In Korea	<i>Jung-Joon SUNG, Korea</i>
	Overview In Malaysia	<i>Nortina SHAHRIZAILA, Malaysia</i>
	Overview In Myanmar	<i>Phyu Phyu LAY, Myanmar</i>
	Overview In Philippines	<i>Mario PRADO JR, Philippines</i>
	Overview In Singapore	<i>Josiah CHAI, Singapore</i>
	Overview In Taiwan	<i>Yi Chung LEE, Taiwan</i>
	Overview In Thailand	<i>Arada ROJANA-UDOMSART, Thailand</i>
Overview In Vietnam	<i>Tu Quoc Le TUAN, Vietnam</i>	
0940 - 0950	Strategies On Overcoming Barriers In Resource-Limited Settings	<i>Nortina SHAHRIZAILA, Malaysia</i>

DAY 2: PACTALS CONGRESS			
0950 - 1030	A World Free Of ALS - Global Perspective	<i>Calaneet BALAS (The ALS Association & Chair of the International Alliance of ALS/MND Associations)</i> <i>Jinsy ANDREWS (NEALS)</i> <i>José MATAMALA (ELATAM)</i> <i>Leonard VAN DEN BERG (ENCALS)</i> <i>Manish RAISINGHANI (Target ALS)</i> <i>Matthew KIERNAN (PACTALS)</i>	
1030 - 1100	BREAK		
1100 - 1230	PLENARY 2 - CURRENT KNOWLEDGE UPDATES Chairpersons: <i>Matthew KIERNAN, Australia & Emma SCOTTER, New Zealand</i>		
1100 - 1130	Update On Clinical Trials	<i>Angela GENGE, Canada</i>	
1130 - 1200	The Role Of Genetics In ALS	<i>Ammar AL-CHALABI, United Kingdom</i>	
1200 - 1230	Advancing ALS Clinical Trials: Integrating Data Platforms To Improve Design And Efficiency	<i>Ruben VAN EIJK, The Netherlands</i>	
1230 - 1300	BREAK		
INDUSTRY LUNCH SYMPOSIA by CorestemChemon Inc.  Chairperson: <i>Seung Hyun KIM, Korea</i>			
1300 - 1400	What Makes A Clinical Trial Successful In ALS	<i>Ammar AL-CHALABI, United Kingdom</i> <i>Angela GENGE, Canada</i> <i>Gen SOBUE, Japan</i> <i>Merit CUDKOWICZ, USA</i> <i>Nortina SHAHRIZAILA, Malaysia</i> <i>Matthew KIERNAN, Australia</i> <i>Ryung-A LEE (CorestemChemon Inc.)</i>	
HALL	GOLDFIELDS THEATRE	ROOM	EUREKA ROOMS
1400 - 1530	SESSION 3: SYMPOSIA 1A - NEUROPHYSIOLOGY AND CLINICAL TRIALS Chairpersons: <i>Ki-Wook OH, Korea</i> <i>Thanuja DHARMADASA, Australia</i>	1400 - 1530	SESSION 4: SYMPOSIA 1B - OMICS AND BIOMARKERS Chairpersons: <i>Allan MCRAE, Australia</i> <i>Atchayaram NALINI, India</i>
1400 - 1420	UMN Evaluation <i>Thanuja DHARMADASA, Australia</i>	1400 - 1420	The Genetic Landscape Of Indian Amyotrophic Lateral Sclerosis Patients: An Exome-Wide Investigation Of A Large Cohort <i>Atchayaram NALINI, India</i>

DAY 2: PACTALS CONGRESS

1420 - 1440	LMN Evaluation <i>Robert HENDERSON, Australia</i>	1420 - 1440	ALS Genetics And Therapy Development In New Zealand <i>Emma SCOTTER, New Zealand</i>
1440 - 1450	Oral Presentation 1: Diagnostic Value Of Threshold Tracking Transcranial Magnetic Stimulation Paradigms In Amyotrophic Lateral Sclerosis <i>Aicee CALMA, Australia</i>	1440 - 1450	Oral Presentation 1: Multi Omics Profiling Reveals Metabolic Reprogramming And Thermogenesis Impairment In Amyotrophic Lateral Sclerosis <i>Linjing ZHANG, China</i>
1450 - 1500	Oral Presentation 2: Longitudinal Assessment Of Cortical Motor Function In Amyotrophic Lateral Sclerosis <i>Dayna TALBOT, Australia</i>	1450 - 1500	Oral Presentation 2: Genetics Led Drug Repurposing Candidates For Amyotrophic Lateral Sclerosis <i>William REAY, Australia</i>
1500 - 1510	Oral Presentation 3: Clinical Trial Of Bosutinib For Amyotrophic Lateral Sclerosis: Idream Study <i>Haruhisa INOUE, Japan</i>	1500 - 1506	Oral Presentation 3: A Blood Based Biomarker To Monitor Autophagy Dysfunction In ALS <i>Bradley TURNER, Australia</i>
1510 - 1520	Oral Presentation 4: Phase 1 Open Label Extension Study Of An MTOR Inhibitor In Patients With Amyotrophic Lateral Sclerosis <i>Susan MATHERS, Australia</i>	1506 - 1512	Oral Presentation 4: Plasma Misfolded SOD1 In Amyotrophic Lateral Sclerosis <i>Li Kai TSAI, Taiwan</i>
		1512 - 1518	Oral Presentation 5: Plasma PDGFR Beta Levels : A Potential Indicator Of Disease Duration In ALS <i>Lu TANG, China</i>
1520 - 1530	Oral Presentation 5: PrimeC As A Promising Oral Therapy For ALS: Phase 2b Study Results And Biomarker Findings, And The Upcoming Phase 3 Study (PARAGON) <i>Jeremy SHEFNER, USA</i>	1518 - 1524	Oral Presentation 6: The Biomechanics Of Walking With MND: A Joint Level Perspective On The Lower Limb <i>James WILLIAMSON, Australia</i>
		1524 - 1530	Oral Presentation 7: Evaluating The Impact Of Weight Loss And Accuracy Of Predictive Energy Equations In Australians With Amyotrophic Lateral Sclerosis <i>Amber SEWELL-GREEN, Australia</i>

DAY 2: PACTALS CONGRESS			
HALL	GOLDFIELDS THEATRE		
1530 - 1600	TEA SYMPOSIA by TEVA <i>Chaiperson:</i> <i>Paul TALMAN, Australia</i>		teva
	ALS Treatment Update: RADICAVA®	<i>Matthew KIERNAN, Australia</i>	
HALL	EXHIBITION BAY (21B & 22B)	ROOM	COURTYARD ROOM 2
1600 - 1800	POSTER TOUR, POSTER JUDGING SESSION, WELCOME RECEPTION	1630 - 1800	INARC GATHERING
END OF DAY 2			

DAY 3: PACTALS CONGRESS			
0700 - 1830	REGISTRATION		
HALL	EUREKA ROOMS		
0700 - 0800	PACTALS AGM (<i>Closed Event</i>)		
HALL	GOLDFIELDS THEATRE		
0800 - 0830	MORNING SYMPOSIA by FightMND 		
	Developing A Global MND Research Initiative	<i>Bec SHEEAN, Australia</i>	
0830 - 1000	PLENARY 3 - PATHWAYS TO DISCOVERY <i>Chairpersons:</i> <i>Gen SOBUE, Japan & Julie ATKIN, Australia</i>		
0830 - 0900	Targeting TDP-43 Aggregation For ALS Treatment	<i>Seung Hyun KIM, Korea</i>	
0900 - 0930	Genomic Drug Discovery And Efficacy/Safety Assessment With Patient-derived iPS Cell/Motor Neuron For Sporadic ALS	<i>Gen SOBUE, Japan</i>	
0930 - 1000	Targeting Energy (Dys)homeostasis In ALS: From Mechanistic Insights To Clinical Translation	<i>Shyuan NGO, Australia</i>	
1000 - 1030	BREAK		
HALL	GOLDFIELDS THEATRE	ROOM	EUREKA ROOMS
1030 - 1245	SESSION 6: SYMPOSIA 2A - CLINICAL TRIALS, DISEASE STRATIFICATION, PALLIATIVE CARE <i>Chairpersons:</i> <i>Aicee CALMA, Australia</i> <i>Osamu KANO, Japan</i>	1030 - 1245	SESSION 7: SYMPOSIA 2B - MOLECULAR AND CELLULAR PATHOLOGY <i>Chairpersons:</i> <i>Frederik STEYN, Australia</i> <i>Shi-Yan NG, Singapore</i>
1030 - 1115	CLINICAL TRIALS IN PACTALS	1030 - 1050	Sporadic ALS-TDP Does Not Represent A Single Homogenous Neuropathology <i>Rachel TAN, Australia</i>
1030 - 1037	Clinical Trials In Australia <i>Matthew KIERNAN, Australia</i>		
1037 - 1044	Clinical Trials In China <i>Dongsheng FAN, China</i>	1050 - 1110	iPSC-Based Disease Modeling Reveals Cholesterol Biosynthesis As A Therapeutic Target In Sporadic ALS <i>Hideyuki OKANO, Japan</i>
1044 - 1051	Clinical Trials In Japan: Methylcobalamin Trial <i>Ryuji KAJI, Japan</i>		

DAY 3: PACTALS CONGRESS

1051 - 1058	Clinical Trials In Korea: A Double-blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Phase III Clinical Trial To Evaluate The Efficacy And Safety Of Lenzumestrocel (Neuronata-R® inj.) In Patients With ALS <i>Seung Hyun KIM, Korea</i>	1110 - 1130	Epitranscriptomic Code In ALS: Unraveling RNA Modifications As Key Disease Regulators <i>Jun-An CHEN, Taiwan</i>
1058 - 1105	Clinical Trials In Taiwan: Building Capacity And Welcoming Global Collaboration <i>Yi-Chung LEE, Taiwan</i>	1130 - 1150	Polystyrene Nanoplastics Promote Neurodegeneration By Catalysing TDP43 Hyperphosphorylation <i>Shi-Yan NG, Singapore</i>
1105 - 1115	Panel Discussion		
1115 - 1205	DISEASE STRATIFICATION AND CARE	1150 - 1200	Oral Presentation 1: Intramuscular Nerve Bundles Reflect TDP 43 Pathology In Medulla And Spinal Cord Of ALS Patients <i>Takashi KURASHIGE, Japan</i>
1115 - 1125	Sexual Dimorphism In Amyotrophic Lateral Sclerosis <i>Gerald PFEFFER, Canada</i>		
1125 - 1135	Respiratory Care In ALS <i>Emma GRAY, Australia</i>		
1135 - 1145	Nutrition In Amyotrophic Lateral Sclerosis (ALS) – An Overview <i>Elizabeth KAPUR, Australia</i>	1200 - 1206	Oral Presentation 2: Investigating The RPSA MOBP Risk Locus In ALS: An Integrative Genomic And Functional Approach <i>Allan MCRAE, Australia</i>
1145 - 1150	Oral Presentation 1: Enhancing The Lived Experience Of People With Amyotrophic Lateral Sclerosis: Best Practice Learnings From Patient Advisory Groups In The Asia Pacific Region <i>Oren LEVY, USA</i>	1206 - 1212	Oral Presentation 3: Multi Region Brain Transcriptomic Analysis Of Amyotrophic Lateral Sclerosis Reveals Widespread And TDP-43 Associated RNA Alterations <i>Natalie GRIMA, Australia</i>
1150 - 1155	Oral Presentation 2: Amplifying The Lived Experience Of MND Voice In Australia <i>Julie LABRA, Australia</i>		
1155 - 1205	Panel Discussion	1212 - 1218	Oral Presentation 4: Glial Cell Type Specific Immune And Metabolic Shifts Across The MND BVFTD Spectrum <i>Jeryn CHANG, Australia</i>

DAY 3: PACTALS CONGRESS			
1205 - 1245	PALLIATIVE CARE IN PACTALS	1218 - 1224	Oral Presentation 5: Exploring The Cell Biology Of Gene Environment Interactions In ALS Using Human iPSCs <i>Antony COOK, Australia</i>
1205 - 1215	Perspective From Australia <i>Susan MATHERS, Australia</i>	1224 - 1230	Oral Presentation 6: Divergent Neuronal Excitability Profiles On A Single Cell And Synaptic Network Level In iPSC Derived Motor Neurons From SALS Patients <i>DZUNG Do-Ha, Australia</i>
1215 - 1225	Perspective From Malaysia <i>Nortina SHAHRIZAILA, Malaysia</i>		
1225 - 1235	Perspective From Japan <i>Osamu KANO, Japan</i>	1230 - 1236	Oral Presentation 7: Assessing Intrinsic Oligodendrocyte Dysfunction In Amyotropic Lateral Sclerosis <i>Francois-Xavier BEAU, Australia</i>
1235 - 1245	Perspective From Indonesia <i>Sheila AGUSTINI, Indonesia</i>	1236 - 1242	Oral Presentation 8: RNA Binding Regulation Of TDP-43 Aggregation In Motor Neuron Disease <i>Adekunle BADEMOSI, Australia</i>
1245 - 1300	BREAK		
HALL	GOLDFIELDS THEATRE		
1300 - 1400	INDUSTRY LUNCH SYMPOSIA 1 by BIOGEN <i>Chairperson: Matthew KIERNAN, Australia</i> *HCP Attendance Only		
	Building On The Foundation Of VALOR OLE: A Global Account Of The SOD1-ALS Experience	<i>Gen SOBUE, Japan</i> <i>Seiichi NAGANO, Japan</i> <i>Steve VUCIC, Australia</i>	
HALL	GOLDFIELDS THEATRE	ROOM	EUREKA ROOMS
1400 - 1530	SESSION 8: SYMPOSIA 3A - IMAGING AND BIOMARKERS Chairpersons: <i>Jung-Joon SUNG, Korea</i> <i>Mary-Louise ROGERS, Australia</i>	1400 - 1530	SESSION 9: SYMPOSIA 3B - DISEASE MODELS AND THERAPEUTICS Chairpersons: <i>Azlina AHMAD-ANNUAR, Malaysia</i> <i>Bradley TURNER, Australia</i>
1400 - 1420	Imaging Network In ALS <i>Sicong TU, Australia</i>	1400 - 1420	iPSC Disease Modelling In ALS <i>Lezanne OOI, Australia</i>

DAY 3: PACTALS CONGRESS

1420 - 1440	Glymphatic Function Impairment in Amyotrophic Lateral Sclerosis Patients <i>Shuangwu LIU, China</i>	1420 - 1440	Deciphering The Glial Functions Of TDP-43 <i>Shuo-Chien LING, Singapore</i>
1440 - 1500	Fluid Biomarker In ALS <i>Jung-Joon SUNG, Korea</i>	1440 - 1450	Oral Presentation 1: Population Wide Drug Screening With Sporadic ALS Patient Derived Motor Neurons <i>Christopher BYE, Australia</i>
		1450 -1456	Oral Presentation 2: Ranolazine Rescue Mitochondrial Function And Dynamics In ALS Patient iPSC Lower Motor Neurons <i>Leanne JIANG, Australia</i>
1500 - 1510	Oral Presentation 1: Association Of Deep Learning Based Chest CT Derived Respiratory Parameters With Disease Progression In Amyotrophic Lateral Sclerosis <i>Seok Jin CHOI, Korea</i>	1456 -1502	Oral Presentation 3: C9orf72 Patient Derived Spinal Cord Organoids Reveal Key ALS Phenotypes <i>Samantha BARTON, Australia</i>
		1502 - 1508	Oral Presentation 4: Recapitulating Disease Progression In Amyotrophic Lateral Sclerosis (ALS) In Vivo <i>Chau Le Bao TRAN, Australia</i>
1510 - 1520	Oral Presentation 2: Geometric Deep Learning For Predicting ALS Diagnoses <i>Thomas SHAW, Australia</i>	1508 - 1514	Oral Presentation 5: Novel GABA Modulating Small Molecules Are Protective In Cellular, Zebrafish And Two Mouse Models Of ALS <i>Julie ATKIN, Australia</i>
		1514 - 1520	Oral Presentation 6: Developing A Peptide Treatment Strategy For Alleviating GGGGCC Induced C9ALS/FTD Neurodegeneration <i>Ho Yin Edwin CHAN, Hong Kong</i>
1520 - 1530	Oral Presentation 3: Association Between Clinical Features And Astrogliosis As Visualised By ¹⁸ F-THK5351 PET In Motor Neuron Disease <i>Mana HIGASHIHARA, Japan</i>	1520 - 1526	Oral Presentation 7: Novel Redox Regulated Gene Therapy Protective In Amyotrophic Lateral Sclerosis <i>Sonam PARAKH, Australia</i>

DAY 3: PACTALS CONGRESS		
HALL	GOLDFIELDS THEATRE	
1530 - 1600	TEA SYMPOSIA by QURALIS <i>Chairperson: Angela GENGE, Canada</i>	
	QurAlis' Pipeline And Development Updates For GRL-101 And GRL-201 In ALS <i>Emma BOWDEN (QurAlis)</i>	
1600 - 1730	PLENARY 4 - CLINICAL PROGRESS <i>Chairpersons:</i> José MATAMALA, Chile & Sheila AGUSTINI, Indonesia	
1600 - 1630	Fast-Tracking Discovery In ALS: Collaboration, Innovation And Open Science	<i>Merit CUDKOWICZ, USA</i>
1630 - 1700	<i>Stay tuned for the exciting update!</i>	<i>Dongsheng FAN, China</i>
1700 - 1730	Progress And Challenges In Spinal Muscular Atrophy	<i>Michelle FARRAR, Australia</i>
1730 - 1800	CLOSING CEREMONY <i>Chairpersons:</i> Nortina SHAHRIZAILA, Malaysia & Shyuan NGO, Australia	
1730 - 1735	International Alliance - Realising The Goal Of ALS/MND Beyond Borders	<i>Calaneet BALAS (Chair of The International Alliance of ALS/MND Associations)</i>
1735 - 1740	Global Funding Opportunities - FightMND And Longitude Prize	<i>Davor STANIC (FightMND)</i>
1740 - 1745	Awards Ceremony	
	Handover Of PACTALS Presidency	
1745 - 1750	PACTALS 2027	<i>Osamu KANO, Japan</i>
1750 - 1755	Closing Remarks by MND Australia	<i>Andrew DANSON, Australia</i>
1755 - 1800	Closing Remarks by Organising Chair	<i>Paul TALMAN, Australia</i>
END OF CONGRESS		

DAY 3: MNDA CARE FORUM		
0700 - 1800	REGISTRATION	
HALL	CLARENDON AUDITORIUM (LEVEL 1)	
0900 - 1700	MNDA CARE FORUM	
0900 - 1030	SESSION 1 - OPENING KEYNOTE <i>Chairpersons:</i> <i>Laura BIRKS, Australia</i> <i>Marnie GRACO, Australia</i>	
0900 - 0915	Welcome & Opening Remarks <i>Andrew DANSON (MND Australia)</i>	
0915 - 0945	How To Be Your Best Friend: The Power Of Resilience And Self-Compassion <i>Olivia ONG, Australia</i>	
0945 - 1015	Update On The Latest In MND Management <i>Steve VUCIC, Australia</i>	
1015 - 1030	Dare To Demand Better <i>Todd JOHNSON, Australia</i>	
1030 - 1100	BREAK	
1100 - 1230	SESSION 2 - WELLBEING AND COMMUNICATION <i>Chairpersons:</i> <i>Victoria TULL, Australia</i> <i>Nicole SHEERS, Australia</i>	
1100 - 1140	Re-imagining MND Care In Australia <i>David COX, Australia</i> <i>Gaye ALCORN, Australia</i> <i>Giulia VALENTE, Australia</i> <i>Hazmir MOHAMADAN, Australia</i> <i>Jean DOWNTON, Australia</i> <i>Karen HUTCHINSON, Australia</i> <i>Pete RUSSO, Australia</i> <i>Prue GRAY, Australia</i>	<i>This session focuses on enhancing wellbeing and communication for individuals living with motor neurone disease (MND) and those who support them. Emphasising a holistic and person-centred approach, the session explores strategies to promote wellbeing, empower carers, and support effective communication throughout the disease journey. Through shared experiences and research insights, the session highlights the emotional, psychological, and practical aspects of care—recognising the profound impact MND has not only on individuals, but also on families and communities.</i>
1140 - 1147	Tips And Tricks On Wellbeing And Communication To Not Just Survive But Thrive With MND <i>Leanne SKLAVENITIS, Australia</i>	
1147 - 1154	Exploring Preferences For Management Of Cognitive And Behavioural Changes In Motor Neurone Disease <i>Rebecca FRANCIS, Australia</i>	

DAY 3: MNDA CARE FORUM

1154 - 1201	'Invest' In Your Voice: How A Novel Co Designed Voice Banking Service Supports People With MND <i>Annalle ALELIGAY, Australia</i>	<i>This session focuses on enhancing wellbeing and communication for individuals living with motor neurone disease (MND) and those who support them. Emphasising a holistic and person-centred approach, the session explores strategies to promote wellbeing, empower carers, and support effective communication throughout the disease journey. Through shared experiences and research insights, the session highlights the emotional, psychological, and practical aspects of care—recognising the profound impact MND has not only on individuals, but also on families and communities.</i>
1201 - 1208	The All Encompassing Nature Of Care In MND <i>Sally NEVILLE, Australia</i>	
1208 - 1215	Sleep For People With Motor Neurone Disease And Their Families In New Zealand, A Questionnaire Study <i>Natalie GAULD, New Zealand</i>	
1215 - 1230	Question & Answer Time	
1230 - 1330	BREAK	
1330 - 1430	SESSION 3 - THE LATEST IN EVIDENCE-BASED CARE Chairpersons: <i>Jo WHITEHOUSE, Australia</i> <i>Rebecca FRANCIS, Australia</i>	
1330 - 1337	Developing The Australian Motor Neurone Disease Guideline: A Collaborative, Evidence Based Approach Using Grade Methodology <i>Zachary MUNN, Australia</i>	<i>This session explores the latest advances in evidence-based care for people living with motor neurone disease (MND) in Australia. Through a diverse range of research and practice-based insights, the session highlights collaborative approaches to improving clinical guidelines, innovative service models, and person-centred care. Presentations will examine challenges and opportunities in respiratory support, nutrition, multidisciplinary care, interventions, and workforce development—underscoring a commitment to translating evidence into impactful, compassionate care across the MND journey.</i>
1337 - 1344	Exploring The Narrative Behind The Numbers: Using Data To Improve Care And Support For Those Living With MND <i>Victoria TULL, Australia</i>	
1344 - 1351	Exploring The Uptake Of Non Invasive Ventilation By People With Motor Neurone Disease In Australia: A Qualitative Study <i>Marnie GRACO, Australia</i>	
1351 - 1358	Trial And Triumphs In Community Based Respiratory Care For Adults With Motor Neurone Disease (MND): West Australian Experience <i>Juliet TRAVLOS, Australia</i>	
1358 - 1405	Bridging Health Equity Gaps For Australians With MND: Co Designing Solutions With The MND Community <i>Karen HUTCHINSON, Australia</i>	
1405 - 1412	Dysphagia In Neurodegenerative Diseases: Implications For Swallowing, Dry Mouth, And Oral Health <i>Victoria PERCHYONOK, Australia</i>	

DAY 3: MNDA CARE FORUM		
1412 - 1419	Enhancing MND Care: Evaluating The Effectiveness Of In Person MND Upskill Workshops <i>Savannah JEWELL, Australia</i>	<i>This session explores the latest advances in evidence-based care for people living with motor neurone disease (MND) in Australia. Through a diverse range of research and practice-based insights, the session highlights collaborative approaches to improving clinical guidelines, innovative service models, and person-centred care. Presentations will examine challenges and opportunities in respiratory support, nutrition, multidisciplinary care, interventions, and workforce development—underscoring a commitment to translating evidence into impactful, compassionate care across the MND journey.</i>
1419 - 1430	Question & Answer Time	
1430 - 1505	SESSION 4 - INTERNATIONAL PERSPECTIVES IN CARE AND SUPPORT <i>Chairpersons:</i> <i>Alicia EDWARDS, Australia</i> <i>Savannah JEWELL, Australia</i>	
1430 - 1445	Insights From Lived Experience <i>Paula TREFIAK, Canada</i>	<i>This session offers an international perspective on care and support for people living with motor neurone disease (MND), highlighting insights from diverse healthcare settings. It explores how tailored, resource-sensitive approaches—such as the early integration of neuropalliative care—can address the complex clinical needs of individuals with MND, even in environments with limited resources. The session underscores the importance of global knowledge-sharing to improve equity, access, and quality of care across varied health systems.</i>
1445 - 1455	International Network For ALS Research And Care (INARC) <i>Corey STRAUB, Canada</i> <i>Tommy BUNTE, The Netherlands</i>	
1455 - 1505	International Alliance Of ALS / MND Associations <i>Catherine CUMMINGS, Canada</i>	
1505 - 1530	AFTERNOON TEA	

DAY 3: MNDA CARE FORUM		
1530 - 1615	<p align="center">SESSION 5 - INNOVATIONS AND NEW HORIZONS</p> <p align="center"><i>Chairpersons:</i> Marnie GRACO, Australia Jessica AUDINO, Australia</p>	
1530 - 1537	<p>Amplifying The Lived Experience Of MND Voice In Australia <i>Julie LABRA, Australia</i> <i>Phil CAMDEN, Australia</i></p>	<p><i>This session showcases cutting-edge innovations and forwardthinking approaches aimed at enhancing the lives of people living with motor neurone disease (MND). From harnessing technology and creative problem-solving to expanding global education and advocacy, the presentations explore how new tools, ideas, and voices are shaping the future of MND care and support. With a strong focus on independence, accessibility, and the lived experience, the session highlights the transformative potential of innovation in improving quality of life and fostering inclusive participation.</i></p>
1537 - 1544	<p>Developing A Motor Neurone Disease Massive Open Online Course (MND MOOC) To Increase Global Knowledge, Understanding And Awareness Of MND <i>Sharn PERRY, Australia</i></p>	
1544 - 1551	<p>Continuing The Game In Spite Of The Beast: Supporting Gaming Accessibility For People With MND <i>Alicia EDWARDS, Australia</i></p>	
1551 - 1558	<p>Occupational Therapy Meets Mcgyver – Solving Functional Challenges With Creativity And Innovation <i>Sarah SOLOMON, Australia</i></p>	
1558 - 1605	<p>Meeting The Assistive Technology Needs Of People With MND – NSW And VIC Collaborative Model <i>Alicia GIBB, Australia</i> <i>Amy SCHNEIDER, Australia</i></p>	
1605 - 1615	Question & Answer Time	
1615 - 1700	<p align="center">SESSION 6 - CLOSING KEYNOTE</p> <p align="center"><i>Chairpersons:</i> Andrew COLLINS, Australia Julie LABRA, Australia</p>	
1615 - 1645	Keynote Presentation	<i>Paul TALMAN, Australia</i>
1645 - 1700	Insights From Lived Experience	<i>Emma VULLIN</i>
1700	<p align="center">Closing Remarks <i>Clare SULLIVAN (MND Australia)</i></p>	
HALL	GOLDFIELDS THEATRE	
1730 - 1800	CLOSING CEREMONY	
END OF CONGRESS		

PACTALS 2025

BASIC SCIENCE ORAL PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
BIOMARKERS	BS-O-B001	<p>GEOMETRIC DEEP LEARNING FOR PREDICTING ALS DIAGNOSES</p> <p>THOMAS B SHAW^{1,2,3†*}, AKSHIT BENIWAL^{1*}, ROBERT D HENDERSON^{3,4}, MATTHEW C KIERNAN^{5,6}, SHYUAN T NGO^{3,7}, FREDERIK J STEYN^{3,8}, SICONG TU^{5,9}, MARKUS BARTH^{1,2,10}, FERNANDA L RIBEIRO^{1,11}</p> <p>¹SCHOOL OF ELECTRICAL ENGINEERING AND COMPUTER SCIENCE, THE UNIVERSITY OF QUEENSLAND, ST LUCIA, QLD, AUSTRALIA ²CENTRE FOR ADVANCED IMAGING, AIBN, THE UNIVERSITY OF QUEENSLAND, ST LUCIA, QLD, AUSTRALIA ³DEPARTMENT OF NEUROLOGY, ROYAL BRISBANE AND WOMEN'S HOSPITAL, HERSTON, QLD, AUSTRALIA ⁴UQ CENTRE FOR CLINICAL RESEARCH, HERSTON QUEENSLAND, AUSTRALIA ⁵BRAIN AND MIND CENTRE, THE UNIVERSITY OF SYDNEY, SYDNEY, NSW, AUSTRALIA ⁶NEUROSCIENCE RESEARCH AUSTRALIA, RANDWICK, NSW, AUSTRALIA ⁷AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, UQ, QLD, AUSTRALIA ⁸SCHOOL OF BIOMEDICAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, ST LUCIA, QLD, AUSTRALIA ⁹SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT, RANDWICK, NSW, AUSTRALIA ¹⁰ARC TRAINING CENTRE FOR INNOVATION IN BIOMEDICAL IMAGING AND TECHNOLOGY (CIBIT), CENTRE FOR ADVANCED IMAGING, THE UNIVERSITY OF QUEENSLAND, QLD, AUSTRALIA ¹¹JUSTUS-LIEBIG UNIVERSITY GIESSEN</p>
	BS-O-B002	<p>A BLOOD BASED BIOMARKER TO MONITOR AUTOPHAGY DYSFUNCTION IN ALS</p> <p>¹PERERA, N; ²NIJAGAL, B; ¹TOMAS, D; ¹CUIC, B; ¹LUIKINGA, S, ¹TURNER, BJ</p> <p>¹FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH, UNIVERSITY OF MELBOURNE, PARKVILLE, VIC 3052, AUSTRALIA, ²METABOLOMICS AUSTRALIA, BIO21 INSTITUTE, THE UNIVERSITY OF MELBOURNE, PARKVILLE VIC 3010, AUSTRALIA</p>

PACTALS 2025

BASIC SCIENCE ORAL PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
BIOMARKERS	BS-O-B003	<p>THE BIOMECHANICS OF WALKING WITH MND: A JOINT LEVEL PERSPECTIVE ON THE LOWER LIMB</p> <p><i>¹JAMES L. WILLIAMSON, ²CORY J. HOLDOM, ¹GEORGIA O'REILLY, ^{3,4}ROBERT D. HENDERSON, ¹SALLY NEVILLE, ^{2,4}SHYUAN T. NGO, AND ^{1,4}FREDERIK J. STEYN, ¹TAYLOR J. M. DICK</i></p> <p>*EQUAL CONTRIBUTION ¹SCHOOL OF BIOMEDICAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, BUILDING 64, ST LUCIA, QLD, 4072, AUSTRALIA, ²AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, THE UNIVERSITY OF QUEENSLAND, BUILDING 75, ST LUCIA, QLD, 4072, AUSTRALIA, ³CENTRE FOR CLINICAL RESEARCH, THE UNIVERSITY OF QUEENSLAND, BUILDING 71, HERSTON, QLD, 4029, AUSTRALIA, ⁴DEPARTMENT OF NEUROLOGY, ROYAL BRISBANE AND WOMEN'S HOSPITAL, NED HANLON BUILDING, HERSTON, QLD, 4029, AUSTRALIA</p>
DISEASE SPECTRUM/ STRATIFICATION	BS-O-DS/S001	<p>INTRAMUSCULAR NERVE BUNDLES REFLECT TDP 43 PATHOLOGY IN MEDULLA AND SPINAL CORD OF ALS PATIENTS</p> <p><i>¹KURASHIGE, TAKASHI; ¹MURAO T; ¹KANAYA Y; ¹DODO Y; ¹SUGIURA T; ²KURAIKA K; ¹OHSHITA T</i></p> <p>¹DEPARTMENT OF NEUROLOGY, NHO KURE MEDICAL CENTER AND CHUGOKU CANCER CENTER, AOYAMACHO 3-1, KURE, JAPAN, ²DEPARTMENT OF DIAGNOSTIC PATHOLOGY, NHO KURE MEDICAL CENTER AND CHUGOKU CANCER CENTER, AOYAMACHO 3-1, KURE, JAPAN</p>
	BS-O-DS/S002	<p>POPULATION WIDE DRUG SCREENING WITH SPORADIC ALS PATIENT DERIVED MOTOR NEURONS</p> <p><i>¹QIAN, E; ¹LIM, K; ¹TRẦN, -LÊ BC; ¹DHARMADASA, T; ²KIERNAN, MC; ³TALBOT, K; ¹TURNER, BJ; ¹BYE, CR.</i></p> <p>¹THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH, THE UNIVERSITY OF MELBOURNE, MELBOURNE, AUSTRALIA. ²NEUROSCIENCE RESEARCH AUSTRALIA; UNIVERSITY OF NEW SOUTH WALES, SYDNEY, AUSTRALIA; ³NUFFIELD DEPARTMENT OF CLINICAL NEUROSCIENCES, UNIVERSITY OF OXFORD, OXFORD, UK</p>

PACTALS 2025

BASIC SCIENCE ORAL PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
GENOMICS	BS-O-G001	<p>GENETICS LED DRUG REPURPOSING CANDIDATES FOR AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>^{1,2,3}GERRING, ZACHARY, ^{1,4}BHALALA, ONEIL, ^{1,2}FEARNLEY, LIAM, ³OIKARI, LOTTA, WHITE, ANTHONY³, ³DERKS, ESKE, ^{1,4}WATSON, ROSIE, YASSI, NAWAF^{1,4}, BAHLO, MELANIE^{1,2}, REAY, WILLIAM⁵</i></p> <p>¹POPULATION HEALTH AND IMMUNITY DIVISION, WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH, PARKVILLE, VICTORIA, 3052, AUSTRALIA, ²THE ROYAL MELBOURNE HOSPITAL, UNIVERSITY OF MELBOURNE, PARKVILLE, VICTORIA, 3052, AUSTRALIA, ³QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE, HERSTON, QUEENSLAND, 4006, AUSTRALIA, ⁴DEPARTMENT OF MEDICAL BIOLOGY, UNIVERSITY OF MELBOURNE, PARKVILLE, VICTORIA, 3052, AUSTRALIA, ⁵MENZIES INSTITUTE FOR MEDICAL RESEARCH, UNIVERSITY OF TASMANIA, HOBART, TASMANIA, 7000, AUSTRALIA</p>
	BS-O-G002	<p>INVESTIGATING THE RPSA MOBP RISK LOCUS IN ALS: AN INTEGRATIVE GENOMIC AND FUNCTIONAL APPROACH</p> <p><i>GARTON, FLEUR¹; GIACOMOTTO, JEAN^{2, 3}, STRINGER, BRETT²; WONG, CHEONG¹; ZISER, LAURA¹; THOMPSON, MIKE J. ⁴; LI, ANG^{1,5}; CHENG, FEI-FEI¹; WRAY, NAOMI^{1,3,5}; HENDERS, ANJALI¹; MCRAE, ALLAN¹;</i></p> <p>¹INSTITUTE FOR MOLECULAR BIOSCIENCE, UNIVERSITY OF QUEENSLAND, BRISBANE, 4072, QLD AUSTRALIA ²GRIFFITH INSTITUTE FOR DRUG DISCOVERY (GRIDD), GRIFFITH UNIVERSITY, BRISBANE, 4122, QLD AUSTRALIA, ³QUEENSLAND BRAIN INSTITUTE, UNIVERSITY OF QUEENSLAND, BRISBANE, 4072, QLD AUSTRALIA ⁴DEPARTMENT OF COMPUTER SCIENCE, UNIVERSITY OF CALIFORNIA LOS ANGELES, LA, CA, USA, ⁵OXFORD BIG DATA INSTITUTE, UNIVERSITY OF OXFORD, OXFORD, UK</p>

PACTALS 2025

BASIC SCIENCE ORAL PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
MOLECULAR PATHOGENESIS	BS-O-MP001	<p>MULTI REGION BRAIN TRANSCRIPTOMIC ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS REVEALS WIDESPREAD AND TDP 43 ASSOCIATED RNA ALTERATIONS</p> <p><i>¹GRIMA, N; ¹SMITH AN; ²SHEPHERD CE; ¹HENDEN L; ³ZAW T; ³CARROLL L; ¹ROWE DB; ^{2,4,5}KIERNAN MC; ¹BLAIR IP;</i></p> <p>¹WILLIAMS KL 1MACQUARIE UNIVERSITY MOTOR NEURON DISEASE RESEARCH CENTRE, FACULTY OF MEDICINE, HEALTH AND HUMAN SCIENCES, MACQUARIE UNIVERSITY, SYDNEY, NSW 2109 AUSTRALIA. ²NEUROSCIENCE RESEARCH AUSTRALIA, RANDWICK, NSW 2031, AUSTRALIA. ³AUSTRALIAN PROTEOME RESEARCH FACILITY, MACQUARIE UNIVERSITY, SYDNEY, NSW 2109, AUSTRALIA. ⁴BRAIN AND MIND CENTRE, THE UNIVERSITY OF SYDNEY, SYDNEY, NSW 2050, AUSTRALIA. ⁵DEPARTMENT OF NEUROLOGY, ROYAL PRINCE ALFRED HOSPITAL, SYDNEY, NSW 2050, AUSTRALIA</p>
	BS-O-MP002	<p>RECAPITULATING DISEASE PROGRESSION IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN VIVO</p> <p><i>¹CHAU-BAO TRAN-LE, ¹VALERIA RYTOVA, ¹DORIS TOMAS, ¹BRITTANY CUIC, ¹ELIZABETH QUIAN, ¹KATHERINE LIM, ¹AZIN AMIN, ¹MOUNA HAIDAR, ¹BRADLEY TURNER, ¹CHRIS BYE</i></p> <p>¹FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH, UNIVERSITY OF MELBOURNE, PARKVILLE, VIC, AUSTRALIA</p>
	BS-O-MP003	<p>RANOLAZINE RESCUE MITOCHONDRIAL FUNCTION AND DYNAMICS IN ALS PATIENT IPSC LOWER MOTOR NEURONS</p> <p><i>^{1,2}JIANG, LEANNE; ³GILL, MK; ¹HOWE, SL; ⁴DUNLOP, F; ¹TRACEY, TJ; ⁴RUSSELL, A; ³STEYN, FJ; ¹NGO, ST</i></p> <p>¹AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, UNIVERSITY OF QUEENSLAND, BRISBANE, AUSTRALIA, ²PERRON INSTITUTE FOR NEUROLOGICAL AND TRANSLATIONAL SCIENCES, UNIVERSITY OF WESTERN AUSTRALIA, PERTH, AUSTRALIA, ³SCHOOL OF BIOMEDICAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, BRISBANE, AUSTRALIA, ⁴SCHOOL OF EXERCISE AND NUTRITION SCIENCES, DEAKIN UNIVERSITY, GEELONG, AUSTRALIA</p>

PACTALS 2025

BASIC SCIENCE ORAL PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
MOLECULAR PATHOGENESIS	BS-O-MP004	<p>NOVEL GABA MODULATING SMALL MOLECULES ARE PROTECTIVE IN CELLULAR, ZEBRAFISH AND TWO MOUSE MODELS OF ALS</p> <p><i>¹CYRIL JONES JAGARAJ; ¹SINA SHADFAR; ¹PRACHI MEHTA; ¹JULIE HUNTER; ¹SONAM PARAKH; ¹JULIE D ATKIN</i></p> <p>¹MND RESEARCH CENTRE, MACQUARIE UNIVERSITY, SYDNEY, AUSTRALIA</p>
	BS-O-MP005	<p>DEVELOPING A PEPTIDE TREATMENT STRATEGY FOR ALLEVIATING GGGGCC INDUCED C9 ALS/FTD NEURODEGENERATION</p> <p><i>¹CHAN, HO YIN EDWIN; ¹CHEN HUIZHEN; ¹LEONG LOK I MAGGIE; ¹NGO CHI KEI JACKY</i></p> <p>¹SCHOOL OF LIFE SCIENCES, THE CHINESE UNIVERSITY OF HONG KONG, ROOM 509B MONG MAN WAI BUILDING, HONG KONG, CHINA</p>
	BS-O-MP006	<p>EXPLORING THE CELL BIOLOGY OF GENE ENVIRONMENT INTERACTIONS IN ALS USING HUMAN IPSCS</p> <p><i>¹THORNE, BRYONY; ¹TALBOT J; ¹BINDOFF A; ¹PHIPPS A; ¹ATKINSON R; ¹KING A; ¹PERRY S; ¹COOK A</i></p> <p>¹WICKING DEMENTIA RESEARCH AND EDUCATION CENTRE, UNIVERSITY OF TASMANIA, 17 LIVERPOOL ST, HOBART, AUSTRALIA</p>
	BS-O-MP007	<p>DIVERGENT NEURONAL EXCITABILITY PROFILES ON A SINGLE CELL AND SYNAPTIC NETWORK LEVEL IN IPSC DERIVED MOTOR NEURONS FROM SALS PATIENTS</p> <p><i>^{1,2}DO-HA D; ^{1,2}ISSAC A; ¹MAKSOUR S; ^{1,2}MCALARY L; ^{1,2}OOI L</i></p> <p>¹SCHOOL OF SCIENCE, AND MOLECULAR HORIZONS, UNIVERSITY OF WOLLONGONG, NSW, AUSTRALIA, ²ARC CENTRE OF EXCELLENCE IN QUANTUM BIOTECHNOLOGY, AUSTRALIA</p>
	BS-O-MP008	<p>C9 ORF72 PATIENT DERIVED SPINAL CORD ORGANOID REVEAL KEY ALS PHENOTYPES</p> <p><i>LI JUN LOH¹, JOEL MASON¹, YIFAN WANG², YUPEI YOU³, HEEJUNG SHIM², FOROUGH HABIBOLLAHI⁴, BRETT KAGAN⁴, BRADLEY TURNER^{1*}, SAMANTHA BARTON^{1*}</i></p> <p>¹FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH, MELBOURNE VIC ²SCHOOL OF MATHEMATICS AND STATISTICS/MELBOURNE INTEGRATIVE GENOMICS, UNIVERSITY OF MELBOURNE VIC ²WALTER AND ELIZA HALL INSTITUTE, MELBOURNE VIC ⁴CORTICAL LABS, MELBOURNE VIC</p>

PACTALS 2025

BASIC SCIENCE ORAL PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
MOLECULAR PATHOGENESIS	BS-O-MP009	<p>RNA BINDING REGULATION OF TDP 43 AGGREGATION IN MOTOR NEURON DISEASE</p> <p><i>BADEMOSI AT¹, CHYE YJ¹, ELLIS S¹, KELLET E¹, MEUNIER FA^{1,2}, WALKER AK^{1,3}</i></p> <p>¹CLEM JONES CENTRE FOR AGEING DEMENTIA RESEARCH, QUEENSLAND BRAIN INSTITUTE, THE UNIVERSITY OF QUEENSLAND, BRISBANE, QLD, AUSTRALIA, 4072 ²SCHOOL OF BIOMEDICAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, BRISBANE, QLD, AUSTRALIA, 4072 ³SYDNEY PHARMACY SCHOOL, FACULTY OF MEDICINE AND HEALTH, THE UNIVERSITY OF SYDNEY, 2006</p>
OTHERS	BS-O-O001	<p>NOVEL REDOX REGULATED GENE THERAPY PROTECTIVE IN AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>¹PARAKH S; ¹SHADFAR S; ¹HUNTER J; ¹MUMTAZ N, ¹PRACHI M, ¹ATKIN JD</i></p> <p>¹MOTOR NEURON DISEASE (MND) RESEARCH CENTRE, MACQUARIE MEDICAL SCHOOL (MMS), MACQUARIE UNIVERSITY, SYDNEY, AUSTRALIA</p>
	BS-O-O002	<p>ASSESSING INTRINSIC OLIGODENDROCYTE DYSFUNCTION IN AMYOTROPIC LATERAL SCLEROSIS</p> <p><i>^{1,2}BEAU, FRANCOIS-XAVIER; ¹MASON J; ¹ANDRES A; ³GONSALVEZ D; ¹TURNER B; ³BARTON S</i></p> <p>¹THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH, THE UNIVERSITY OF MELBOURNE, MELBOURNE, AUSTRALIA. ²DEPARTMENT OF ANATOMY AND PHYSIOLOGY, THE UNIVERSITY OF MELBOURNE, MELBOURNE, AUSTRALIA ³DEPARTMENT OF ANATOMY AND DEVELOPMENTAL BIOLOGY, MONASH UNIVERSITY, MELBOURNE, AUSTRALIA</p>

PACTALS 2025

BASIC SCIENCE POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
ASSISTIVE TECHNOLOGY	BS-P-AT001	<p>IMOVE MND: IMPROVING MOBILITY VIA EXOSKELETONS IN PEOPLE LIVING WITH MND</p> <p><i>¹JAMES L. WILLIAMSON, ^{1,2}DINA WICKREMERATNE, ³ZACHARY F. LERNER, ⁴, ⁵ROBERT D. HENDERSON, ^{2,4}SHYUAN T. NGO, ^{1,4}FREDERIK J. STEYN, ¹TAYLOR J. M. DICK</i></p> <p>¹SCHOOL OF BIOMEDICAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, BUILDING 64, ST LUCIA, QLD, 4072, AUSTRALIA, ²AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, THE UNIVERSITY OF QUEENSLAND, BUILDING 75, ST LUCIA, QLD, 4072, AUSTRALIA, ³DEPARTMENT OF MECHANICAL ENGINEERING AND ORTHOPEDIC SURGERY, NORTHERN ARIZONA UNIVERSITY, BUILDING 69, FLAGSTAFF, AZ, 86011, UNITED STATES, ⁴DEPARTMENT OF NEUROLOGY, ROYAL BRISBANE AND WOMEN'S HOSPITAL, NED HANLON BUILDING, HERSTON, QLD, 4029, AUSTRALIA, ⁵CENTRE FOR CLINICAL RESEARCH, THE UNIVERSITY OF QUEENSLAND, BUILDING 71, HERSTON, QLD, 4029, AUSTRALIA</p>
BIOMARKERS	BS-P-B001	<p>EPIGENETIC REGULATION IN MOTOR NEURONE DISEASE: INSIGHTS FROM GENE EXPRESSION AND NEXT GENERATION SEQUENCING</p> <p><i>MILLAR, DOUG; MELKI, JR</i></p> <p>MIND BIOSCIENCES, RANDWICK, NSW, 2031</p>
	BS-P-B002	<p>MONITORING NEURODEGENERATION WITHIN CORE MOTOR PATHWAYS IN AMYOTROPHIC LATERAL SCLEROSIS USING DIFFUSION MRI</p> <p><i>^{1,2}HANNES ALMGREN, ⁴COLIN J. MAHONEY, ^{1,3}WILLIAM HUYNH, ¹ARKIEV D'SOUZA, ¹SIENNA BERTE, ^{1,2}JINGLEI LV, ^{1,5}CHENYU WANG, ⁶MATTHEW C KIERNAN, ^{1,2*}FERNANDO CALAMANTE, ^{1,3*}SICONG TU</i></p> <p>¹BRAIN & MIND CENTRE, THE UNIVERSITY OF SYDNEY, SYDNEY, AUSTRALIA, ²SCHOOL OF BIOMEDICAL ENGINEERING, FACULTY OF ENGINEERING, THE UNIVERSITY OF SYDNEY, SYDNEY, AUSTRALIA, ³SYDNEY MEDICAL SCHOOL, FACULTY OF MEDICINE AND HEALTH, THE UNIVERSITY OF SYDNEY, SYDNEY, AUSTRALIA, ⁴DEPARTMENT OF NEUROLOGY, LIVERPOOL HOSPITAL, NSW, AUSTRALIA, ⁵SYDNEY NEUROIMAGING ANALYSIS CENTRE, SYDNEY, AUSTRALIA, ⁶NEUROSCIENCE RESEARCH AUSTRALIA; SCIENTIA PROFESSOR OF NEUROSCIENCE, UNIVERSITY OF NSW, SYDNEY, AUSTRALIA. *EQUAL CONTRIBUTION</p>

PACTALS 2025

BASIC SCIENCE POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
BIOMARKERS	BS-P-B003	<p>MOTOR UNIT TRACKING USING HIGH DENSITY SURFACE ELECTROMYOGRAPHY IN PEOPLE DIAGNOSED WITH MOTOR NEURON DISEASE</p> <p><i>¹BAYER PA; ²DEL VECCHIO A; ¹THOMAS HJ; ³PERJU-DUMBRAVA L; ¹FERRI A</i></p> <p>¹INSTITUTE FOR HEALTH AND SPORT, VICTORIA UNIVERSITY, FOOTSCRAY, AUSTRALIA, ²DEPARTMENT OF ARTIFICIAL INTELLIGENCE IN BIOMEDICAL ENGINEERING, FRIEDRICH-ALEXANDER-UNIVERSITY, ERLANGEN, GERMANY, ³CALVARY HEALTH CARE BETHLEHEM, CAULFIELD SOUTH, AUSTRALIA</p>
	BS-P-B004	<p>INVESTIGATING DNA DAMAGE IN AMYOTROPHIC LATERAL SCLEROSIS (ALS): UNVEILING PROSPECTIVE ALS BIOMARKERS</p> <p><i>¹SHASHI GAUTAM, ¹SAYANTHOORAN SARAVANABAVAN, ¹EDWIN LIM, ^{1,2}JULIE D ATKIN</i></p> <p>¹MACQUARIE MEDICAL SCHOOL, MACQUARIE UNIVERSITY CENTRE FOR MND RESEARCH, FACULTY OF MEDICINE AND HEALTH SCIENCES, MACQUARIE UNIVERSITY, SYDNEY, NSW, AUSTRALIA, ²LA TROBE INSTITUTE FOR MOLECULAR SCIENCE, LA TROBE UNIVERSITY, BUNDOORA, VIC, AUSTRALIA</p>
	BS-P-B005	<p>DOWNREGULATION OF MIR 423 3 P EXACERBATES STRESS GRANULE PATHOLOGY IN CELL MODEL OF AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>SHIFFALI KHURANA^{1,2}, VANSHIKA AHUJA¹, BANDANA KUMARI SAHU¹, SAGAR VERMA^{1,§}, MANDAVILLE GOURIE-DEV^{3,4**}, NIRMAL KUMAR GANGULY¹, UMA DHAWAN^{2**}, VIBHA TANEJA^{1*}</i></p> <p>¹DEPARTMENT OF BIOTECHNOLOGY AND RESEARCH, SIR GANGA RAM HOSPITAL, DELHI, INDIA ²DEPARTMENT OF BIOMEDICAL SCIENCE, BHASKARACHARYA COLLEGE OF APPLIED SCIENCES, UNIVERSITY OF DELHI, INDIA ³DEPARTMENT OF NEUROPHYSIOLOGY, SIR GANGA RAM HOSPITAL, DELHI, INDIA ⁴DEPARTMENT OF NEUROLOGY, SIR GANGA RAM HOSPITAL, DELHI, INDIA [*]CURRENT AFFILIATION: DEPARTMENT OF CELL AND MOLECULAR BIOLOGY, KAROLINSKA INSTITUTET, STOCKHOLM, SWEDEN</p>

PACTALS 2025

BASIC SCIENCE POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
BIOMARKERS	BS-P-B006	<p>MACHINE LEARNING TO UNCOVER UNIQUE LIPID BIOMARKERS FOR MND</p> <p><i>^{1,2}LUIKINGA SJ, ¹THAROONPHANSAK C, ³NARAYANA V, ⁴EISNER A, ¹LIN V, ¹TOMAS D, ¹CUIC B, ¹TURNER BJ</i></p> <p>¹MOTOR NEURON DISEASE LABORATORY, THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH, PARKVILLE, MELBOURNE, AUSTRALIA, ²AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, ST LUCIA, BRISBANE, AUSTRALIA, ³METABOLOMICS AUSTRALIA, PARKVILLE, MELBOURNE AUSTRALIA, ⁴UNIVERSITY OF MELBOURNE, PARKVILLE, MELBOURNE, AUSTRALIA</p>
	BS-P-B007	<p>TONGUE MUSCLE ABNORMALITIES AND SURVIVAL OUTCOMES IN MND</p> <p><i>THOMAS B SHAW^{1,2,3*} PATRICK AIKEN⁴ JERYN CHANG⁵ FERNANDA L RIBEIRO¹ XIANGYUN ZHU^{1,6,7} ROBERT D HENDERSON^{3,7} MATTHEW C KIERNAN^{8,9} PAMELA A MCCOMBE³ SHYUAN T NGO^{3,10} SHANA T TAUBERT⁷ FREDERIK J STEYN^{3,5} SICONG TU^{11,12} MARKUS BARTH^{1,2,10} BROOKE-MAI WHELAN^{4†}</i></p> <p>¹SCHOOL OF ELECTRICAL ENGINEERING AND COMPUTER SCIENCE, THE UNIVERSITY OF QUEENSLAND, ST LUCIA, QLD, AUSTRALIA ²CENTRE FOR ADVANCED IMAGING, THE UNIVERSITY OF QUEENSLAND, ST LUCIA, QLD, AUSTRALIA ³DEPARTMENT OF NEUROLOGY, ROYAL BRISBANE AND WOMEN'S HOSPITAL, HERSTON, QLD, AUSTRALIA ⁴SCHOOL OF HEALTH AND REHABILITATION SCIENCES, THE UNIVERSITY OF QUEENSLAND, ST LUCIA, QLD, AUSTRALIA ⁵SCHOOL OF BIOMEDICAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, ST LUCIA, QLD, AUSTRALIA ⁶SCHOOL OF MEDICINE AND DENTISTRY, GRIFFITH UNIVERSITY, GOLD COAST, QLD, AUSTRALIA ⁷QUEENSLAND HEALTH, QUEENSLAND, AUSTRALIA ⁸BRAIN AND MIND CENTRE, THE UNIVERSITY OF SYDNEY, SYDNEY, NSW, AUSTRALIA ⁹NEUROSCIENCE RESEARCH AUSTRALIA, RANDWICK, NSW, AUSTRALIA ¹⁰AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, THE UNIVERSITY OF QUEENSLAND, ST LUCIA, QLD, AUSTRALIA ¹¹SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT, RANDWICK, NSW, AUSTRALIA ¹²ARC TRAINING CENTRE FOR INNOVATION IN BIOMEDICAL IMAGING AND TECHNOLOGY (CIBIT), CENTRE FOR ADVANCED IMAGING, THE UNIVERSITY OF QUEENSLAND, ST LUCIA, QLD, AUSTRALIA</p>

PACTALS 2025

BASIC SCIENCE POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
BIOMARKERS	BS-P-B008	<p>THE AUSTRALIAN SPORADIC ALS TRANSCRIPTOMIC RESOURCE: INSIGHTS INTO DISEASE PROGRESSION AND SPLICING FROM LONG AND SHORT READ RNA SEQUENCING</p> <p>WAI CHEONG¹, LAURA ZISER¹, LACHLAN SPARKE¹, ROBERT HENDERSON², LEANNE WALLACE¹, NAOMI WRAY^{1,3}, ANJALI HENDERS¹, PAMELA MCCOMBE⁴, ALLAN MCRAE¹, FLEUR GARTON¹</p> <p>¹INSTITUTE FOR MOLECULAR BIOSCIENCE - UNIVERSITY OF QUEENSLAND ²ROYAL BRISBANE AND WOMEN'S HOSPITAL, QUEENSLAND ³THE BIG DATA INSTITUTE - UNIVERSITY OF OXFORD ⁴CENTRE FOR CLINICAL RESEARCH - UNIVERSITY OF QUEENSLAND</p>
CLINICAL MANAGEMENT	BS-P-CM001	<p>THE NOTORIOUS SUSPECTED ALS: TO BE OR NOT TO BE?</p> <p>¹MERKULOV YA; ²PLIEVA EL; ²LEZINA DS; ³PYATKOV AA; ²MERKULOVA DM</p> <p>¹INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY, 8 BALTIYSKAYA ST., MOSCOW, RUSSIA, ²BM GUEKHT NEUROLOGY CENTER, CENTRAL CLINICAL HOSPITAL «RZD-MEDICINE», 2 BUDAYSKAYA ST., MOSCOW, RUSSIA, ³SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY, 11-1 ROSSOLIMO ST., MOSCOW, RUSSIA</p>
CLINICAL TRIAL AND PLATFORMS	BS-P-CT&P001	<p>THE CHALLENGES OF RUNNING ALS INVESTIGATOR INITIATED TRIALS AND OPPORTUNITIES TO IMPROVE</p> <p>¹RAMSEY, ELEANOR; ¹TIMMINS, HANNAH C; ¹MAZUMDER, SRESTHA; ¹TALBOT, DAYNA-LEE; ¹MURPHY, PARIS M; ¹ASHHURST, JASMINE F; ^{1,2}KIERNAN, MATTHEW C.</p> <p>¹NEUROSCIENCE RESEARCH AUSTRALIA, 139 BARKER ST, RANDWICK, AUSTRALIA, ²UNIVERSITY OF NEW SOUTH WALES, SYDNEY, AUSTRALIA</p>
EPIDEMIOLOGY	BS-P-E001	<p>LIPID LOWERING DRUGS AND AMYOTROPHIC LATERAL SCLEROSIS: A MENDELIAN RANDOMIZATION STUDY</p> <p>¹KAILIN XIA, ²NINGHAO HUANG, ¹YAJUN WANG, ¹GAN ZHANG, ¹LU TANG, ¹LINJING ZHANG, ²TAO HUANG, ¹DONGSHENG FAN</p> <p>¹DEPARTMENT OF NEUROLOGY, PEKING UNIVERSITY THIRD HOSPITAL, 49 NORTH GARDEN ROAD, BEIJING, CHINA ²DEPARTMENT OF EPIDEMIOLOGY AND BIostatISTICS, SCHOOL OF PUBLIC HEALTH, PEKING UNIVERSITY, 38 XUEYUAN ROAD, BEIJING, CHINA</p>

PACTALS 2025

BASIC SCIENCE POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
EPIDEMIOLOGY	BS-P-E002	<p>RELATIONSHIP BETWEEN PRIOR EXPOSURE TO ARTHROPOD VIRUSES AND AMYOTROPIC LATERAL SCLEROSIS IN MALAYSIAN PATIENTS</p> <p><i>^{1,2}ZULHAIRY-LIONG, NA; ¹LEE CLL; ¹TAN MP; ¹CAPELLE DP; ^{1,2}EDGAR S; ¹SOO CI; ²AHMAD-ANNUAR A; ¹SHAHRIZAILA N; ³SAM IC</i></p> <p>¹DEPARTMENT OF MEDICINE, FACULTY OF MEDICINE, UNIVERSITY OF MALAYA, 50603, KUALA LUMPUR, MALAYSIA, ²DEPARTMENT OF BIOMEDICAL SCIENCE, FACULTY OF MEDICINE, UNIVERSITY OF MALAYA, 50603, KUALA LUMPUR, MALAYSIA, ³DEPARTMENT OF MEDICAL MICROBIOLOGY, FACULTY OF MEDICINE, UNIVERSITY OF MALAYA, 50603, KUALA LUMPUR, MALAYSIA</p>
GENOMICS	BS-P-G001	<p>STRATEGIC ALS AUSTRALIA SYSTEMS GENOMICS CONSORTIUM: SALSA SGC</p> <p><i>ANJALI K HENDERS¹, LAURA ZISER¹, FLEUR GARTON¹, ALLAN MCRAE¹, SHYUAN T. NGO¹, MATTHEW KIERNAN², NIGEL LAING³, SUSAN MATHERS⁴, MERRILEE NEEDHAM⁵, DOMINIC ROWE⁶, DAVID SCHULTZ⁷, STEVE VUCIC⁸, PAMELA MCCOMBE⁹, ROBERT HENDERSON⁹, IAN P BLAIR⁶, NAOMI R WRAY¹, AND THE SALSA-SYSTEM GENOMICS CONSORTIUM</i></p> <p>¹THE UNIVERSITY OF QUEENSLAND, QUEENSLAND; ²THE UNIVERSITY OF NEW SOUTH WALES, NEW SOUTH WALES; ³HARRY PERKINS INSTITUTE, WESTERN AUSTRALIA; ⁴CALVARY HEALTH CARE BETHLEHEM, VICTORIA; ⁵FIONA STANLEY HOSPITAL, WESTERN AUSTRALIA; ⁶MACQUARIE UNIVERSITY, NEW SOUTH WALES; ⁷FLINDERS MEDICAL CENTRE, SOUTH AUSTRALIA; ⁸THE UNIVERSITY OF SYDNEY, NEW SOUTH WALES; ⁹ROYAL BRISBANE AND WOMEN'S HOSPITAL, QUEENSLAND</p>
	BS-P-G002	<p>INTEGRATED MULTI OMICS ANALYSIS IDENTIFIES NOVEL RISK LOCI FOR AMYOTROPHI</p> <p><i>¹Ji, HE; ¹DONGSHENG, FAN</i></p> <p>¹NEUROLOGY DEPARTMENT, PEKING UNIVERSITY THIRD HOSPITAL, BEIJING, CHINA</p>

PACTALS 2025

BASIC SCIENCE POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
GENOMICS	BS-P-G003	<p>MUTATION IN NEK1 CAUSES CILIARY DYSFUNCTION AS A NOVEL PATHOGENETIC MECHANISM IN ALS</p> <p><i>¹MIN-YOUNG NOH; ²SEOUNG-IL OH;¹SUGYEONG AHN; ¹MI-HYEON KANG; ³SUN JOO CHA; ³MINYEOP NAHM; ¹SEUNG HYUN KIM*</i></p> <p>¹DEPARTMENT OF NEUROLOGY, COLLEGE OF MEDICINE, HANYANG UNIVERSITY, SEOUL, REPUBLIC OF KOREA ²DEPARTMENT OF NEUROLOGY, KYUNG HEE UNIVERSITY MEDICAL CENTER, SEOUL, REPUBLIC OF KOREA ³DEMENTIA RESEARCH GROUP, KOREA BRAIN RESEARCH INSTITUTE, DAEGU, REPUBLIC OF KOREA</p>
	BS-P-G004	<p>COMPREHENSIVE GENETIC TESTING EXPANDS THE NUMBER OF CLINICALLY RELEVANT MUTATIONS IN ALS GENES IN A MULTI ETHNIC MALAYSIAN COHORT</p> <p><i>^{1,2}ZULHAIRY-LIONG, NA; ^{1,2}EDGAR S; ^{3,4}ELLIS M; ¹CAPELLE DP; ^{3,4,5}KENNERSON ML; ¹SHAHRIZAILA N; ²AHMAD-ANNUAR A</i></p> <p>¹DEPARTMENT OF MEDICINE, FACULTY OF MEDICINE, UNIVERSITY OF MALAYA, 50603, KUALA LUMPUR, MALAYSIA, ²DEPARTMENT OF BIOMEDICAL SCIENCE, FACULTY OF MEDICINE, UNIVERSITY OF MALAYA, 50603, KUALA LUMPUR, MALAYSIA, ³NORTHCOTT NEUROSCIENCE LABORATORY, ANZAC RESEARCH INSTITUTE, SYDNEY LOCAL HEALTH DISTRICT, CONCORD, NSW, AUSTRALIA, ⁴FACULTY OF MEDICINE AND HEALTH, UNIVERSITY OF SYDNEY, SYDNEY, NSW, AUSTRALIA, ⁵MOLECULAR MEDICINE LABORATORY, CONCORD HOSPITAL, CONCORD, NSW, AUSTRALIA</p>

PACTALS 2025

BASIC SCIENCE POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
GENOMICS	BS-P-G005	<p>A GENOME WIDE ASSOCIATION STUDY IDENTIFIES ADAM25 GPM6 A LOCUS ASSOCIATED WITH AGE AT ONSET IN JAPANESE PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS</p> <p>¹NAKAMURA RYOICHI; ¹TOHNAI G; ¹ATSUTA N; ²MATSUDA Y; ^{3,4}MORIMOTO S; ²ITO D; ²KATSUNO M; ⁵IZUMI Y; ⁶MORITA M; ⁷IWATA I; ⁷YABE I; ⁸NAKAZATO T; ⁸HATTORI N; ⁹HIRAYAMA T; ⁹KANO O; ¹⁰TAMURA A; ¹¹SUZUKI N; ¹¹AOKI M; ¹²SHIBUYA K; ¹²KUWABARA S; ¹³ODA M; ¹⁴HASHIMOTO R; ¹⁴AIBA I; ¹⁵ISHIHARA T; ¹⁵ONODERA O; ¹⁶YAMASHITA T; ¹⁶ISHIURA H; ¹⁷BOKUDA K; ¹⁷SHIMIZU T; ¹⁸IKEDA Y; ¹⁹HASEGAWA K; ²⁰TANAKA F; ²¹YOKOTA T; ²²KANAI K; ²³NOTO Y; ⁵KAJIR; ¹NIWA J; ¹DOYUM; ¹⁰KADA Y; ^{3,4}OKANO H; ²NAKATOCHI M; ¹SOBUE G; ON BEHALF OF THE JAPANESE CONSORTIUM FOR AMYOTROPHIC LATERAL SCLEROSIS RESEARCH (JACALS) STUDY GROUP</p> <p>¹AICHI MEDICAL UNIVERSITY, NAGAKUTE, JAPAN; ²NAGOYA UNIVERSITY, NAGOYA, JAPAN; ³KEIO UNIVERSITY, KAWASAKI, JAPAN; ⁴TOKYO METROPOLITAN INSTITUTE FOR GERIATRICS AND GERONTOLOGY, TOKYO, JAPAN; ⁵TOKUSHIMA UNIVERSITY, TOKUSHIMA, JAPAN; ⁶JICHI MEDICAL UNIVERSITY, SHIMOTSUKE, JAPAN; ⁷HOKKAIDO UNIVERSITY, SAPPORO, JAPAN; ⁸JUNTENDO UNIVERSITY, TOKYO, JAPAN; ⁹TOHO UNIVERSITY, TOKYO, JAPAN; ¹⁰MIE UNIVERSITY, TSU, JAPAN; ¹¹TOHOKU UNIVERSITY, SENDAI, JAPAN; ¹²CHIBA UNIVERSITY, CHIBA, JAPAN; ¹³VIHARA HANANOSATO HOSPITAL, MIYOSHI, JAPAN; ¹⁴NHO HIGASHINAGOYA NATIONAL HOSPITAL, NAGOYA, JAPAN; ¹⁵NIIGATA UNIVERSITY, NIIGATA, JAPAN; ¹⁶OKAYAMA UNIVERSITY, OKAYAMA, JAPAN; ¹⁷TOKYO METROPOLITAN NEUROLOGICAL HOSPITAL, TOKYO, JAPAN; ¹⁸GUNMA UNIVERSITY, MAEBASHI, JAPAN; ¹⁹NHO SAGAMIHARA NATIONAL HOSPITAL, SAGAMIHARA, JAPAN; ²⁰YOKOHAMA CITY UNIVERSITY, YOKOHAMA, JAPAN; ²¹TOKYO MEDICAL AND DENTAL UNIVERSITY, TOKYO, JAPAN; ²²FUKUSHIMA MEDICAL UNIVERSITY, FUKUSHIMA, JAPAN; ²³KYOTO PREFECTURAL UNIVERSITY, KYOTO, JAPAN</p>

PACTALS 2025

BASIC SCIENCE POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
GENOMICS	BS-P-G006	<p>GLYCOLYSIS INHIBITION DOWNREGULATES DNA REPAIR PATHWAYS IN NEURONS</p> <p><i>THAIS SOBANSKI¹, DEREK J. RICHARD², FREDERIK J. STEYN³, SHYUAN T NGO¹</i></p> <p>¹THE AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, UNIVERSITY OF QUEENSLAND, SAINT LUCIA, QUEENSLAND, AUSTRALIA. ²CANCER AND AGEING RESEARCH PROGRAM, CENTRE FOR GENOMICS AND PERSONALISED HEALTH, QUEENSLAND UNIVERSITY OF TECHNOLOGY, BRISBANE, QLD, AUSTRALIA. ³SCHOOL OF BIOMEDICAL SCIENCES, UNIVERSITY OF QUEENSLAND, SAINT LUCIA, QUEENSLAND, AUSTRALIA</p>
MOLECULAR PATHOGENESIS	BS-P-MP001	<p>INTERROGATING THE ANATOMICAL ORIGINS OF AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>^{1,2}VIDEN, AIDA; ^{1,2}BYE, CHRISTOPHER; ^{1,2}TURNER, BRADLEY J; ^{1,2}Haidar, MOUNA</i></p> <p>¹FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH, 30 ROYAL PARADE, PARKVILLE, VIC, 3052, AUSTRALIA, ²UNIVERSITY OF MELBOURNE, PARKVILLE, VIC, 3010, AUSTRALIA</p>
	BS-P-MP002	<p>IN VIVO AXONAL TRANSPORT OF MITOCHONDRIA AND SIGNALLING ENDOSOMES IS IMPAIRED IN FAST ALPHA MOTOR NEURONS IN MND MICE</p> <p><i>TOSOLINI, ANDREW P.^{1,2,3}; NGO , SHYUAN T.?²; SCHIAVO, GIAMPIETRO ^{3,4}</i></p> <p>¹SCHOOL OF BIOMEDICAL SCIENCES, FACULTY OF MEDICINE, THE UNIVERSITY OF QUEENSLAND, ST LUCIA, AUSTRALIA ²AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, THE UNIVERSITY OF QUEENSLAND, ST LUCIA, AUSTRALIA ³DEPARTMENT OF NEUROMUSCULAR DISEASES AND UCL QUEEN SQUARE MOTOR NEURON DISEASE CENTRE, QUEEN SQUARE INSTITUTE OF NEUROLOGY, UNIVERSITY COLLEGE LONDON, UNITED KINGDOM ⁴UK DEMENTIA RESEARCH INSTITUTE, UNIVERSITY COLLEGE LONDON, UNITED KINGDOM</p>

PACTALS 2025

BASIC SCIENCE POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
MOLECULAR PATHOGENESIS	BS-P-MP003	<p>DISCOVERING CORE MECHANISMS OF ALS USING PHENOTYPIC SCREENING</p> <p><i>ANTHONY BASILONE¹, CHRISTIAN MAKHOUL¹, KAYLENE J. SIMPSON², MICHAEL P. MENDEN¹, DANNY M. HATTERS¹</i></p> <p>¹DEPARTMENT OF BIOCHEMISTRY AND PHARMACOLOGY, BIO21 MOLECULAR SCIENCE AND BIOTECHNOLOGY INSTITUTE, UNIVERSITY OF MELBOURNE, PARKVILLE, VICTORIA, AUSTRALIA. ²VICTORIAN CENTRE FOR FUNCTIONAL GENOMICS, PETER MACCALLUM CANCER CENTRE, PARKVILLE, VICTORIA, AUSTRALIA</p>
	BS-P-MP004	<p>INVESTIGATING THE ROLE OF ASTROCYTE AUTOPHAGY IN AMYOTROPHIC LATERAL SCLEROSIS (ALS)</p> <p><i>¹DUSHANA ALAGIYAWANNA, ¹DORIS TOMAS, ¹BRITTANY CUIC, ¹BRADLEY TURNER, ¹NIRMA PERERA</i></p> <p>¹DEPARTMENT OF ANATOMY AND PHYSIOLOGY, THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH, 30 ROYAL PARADE PARKVILLE, MELBOURNE, AUSTRALIA</p>
	BS-P-MP005	<p>NOVEL STRATEGIES TO PREVENT DNA DAMAGE AND ENHANCE DNA REPAIR IN AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>FABIHA FARZANA¹, SINA SHADFAR¹, CYRIL JONES JAGARAJ¹, PRACHI MEHTA¹, JULIE D. ATKIN^{1,2}</i></p> <p>¹MOTOR NEURON DISEASE RESEARCH CENTRE, MACQUARIE MEDICAL SCHOOL, FACULTY OF MEDICINE, HEALTH AND HUMAN SCIENCES, MACQUARIE UNIVERSITY, SYDNEY, NSW 2109, AUSTRALIA. ²DEPARTMENT OF BIOCHEMISTRY AND GENETICS, LA TROBE INSTITUTE FOR MOLECULAR SCIENCE, LA TROBE UNIVERSITY, BUNDOORA, MELBOURNE, VIC 3086, AUSTRALIA</p>

PACTALS 2025

BASIC SCIENCE POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
MOLECULAR PATHOGENESIS	BS-P-MP006	<p>ENHANCING SKELETAL MUSCLE REGENERATION IN ALS VIA INTRAMUSCULAR ALLOSTERIC ACTIVATION OF THE P2 X7 RECEPTOR</p> <p>CASSANDRA MARGOTTA¹, P. FABBRIZIO¹, S. CARAVITA¹, A. PASSONI², A. LANNO², A. M. SICILIANO², N. INNOCENTI³, C. NASTASI⁴, A. TOSOLINI⁵, F. J STEYN⁶, E. DAVOLI², E. BIASINI³, S. T NGO⁵ AND G. NARDO¹</p> <p>¹RESEARCH CENTER FOR ALS, DEPARTMENT OF NEUROSCIENCE, MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH IRCCS, MILAN, ITALY. ²MASS SPECTROMETRY CENTRE FOR HEALTH AND ENVIRONMENT, MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH IRCCS, MILAN, ITALY. ³DEPARTMENT OF CELLULAR, COMPUTATIONAL AND INTEGRATIVE BIOLOGY, UNIVERSITY OF TRENTO, TRENTO, ITALY, ⁴LABORATORY OF CANCER PHARMACOLOGY, DEPARTMENT OF ONCOLOGY, MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH IRCCS, MILAN, ITALY. ⁵THE AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, THE UNIVERSITY OF QUEENSLAND, BRISBANE QLD, AUSTRALIA. ⁶SCHOOL OF BIOMEDICAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, BRISBANE, QLD, AUSTRALIA</p>
	BS-P-MP007	<p>VISUALIZING THE DYNAMICS OF THE PROTEIN INTERACTION NETWORK OF FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS</p> <p>¹HANIEH BEYRAMPOUR-BASMENJ; ¹CHRISTIAN MAKHOUL; ¹DANNY M. HATTERS</p> <p>¹DEPARTMENT OF BIOCHEMISTRY AND PHARMACOLOGY, BIO21 MOLECULAR SCIENCE AND BIOTECHNOLOGY INSTITUTE, UNIVERSITY OF MELBOURNE, PARKVILLE, VICTORIA, AUSTRALIA</p>
	BS-P-MP008	<p>MITOCHONDRIAL RESPIRATION IN SKELETAL MUSCLE OF HUMANS WITH MOTOR NEURON DISEASE: A PILOT STUDY</p> <p>HANNAH J THOMAS¹, NAVABEH ZARE¹, PATRICIA BAYER¹, DALE TAYLOR¹, JAMES BROATCH¹, ITAMAR LEVINGER¹, ANDREW GARAHAM¹, DAVID BISHOP¹, ALESSANDRA FERRI¹</p> <p>¹INSTITUTE FOR HEALTH AND SPORT, VICTORIA UNIVERSITY, MELBOURNE, VICTORIA, AUSTRALIA</p>

PACTALS 2025

BASIC SCIENCE POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
MOLECULAR PATHOGENESIS	BS-P-MP009	<p>HIGH THROUGHPUT COMPOUND SCREENING UNRAVELS PATHOGENESIS OF C9 ORF72 ALS/FTD</p> <p><i>KEIKO IMAMURA^{1,2,3,4}, MAKOTO FURUSAWA², KEISUKE SHIBATA², HARUHISA INOUE^{1,2,3,4}</i></p> <p>¹CENTER FOR IPS CELL RESEARCH AND APPLICATION (CIRA), KYOTO UNIVERSITY, KYOTO, JAPAN ²TAKEDA-CIRA (T-CIRA) JOINT PROGRAM, FUJISAWA, JAPAN. ³IPSC-BASED DRUG DISCOVERY AND DEVELOPMENT TEAM, RIKEN BIORESOURCE RESEARCH CENTER (BRC), KYOTO, JAPAN ⁴MEDICAL-RISK AVOIDANCE BASED ON IPS CELLS TEAM, RIKEN CENTER FOR ADVANCED INTELLIGENCE PROJECT (AIP), KYOTO, JAPAN</p>
	BS-P-MP010	<p>DECIPHERING THE MECHANISMS OF C9 ORF72 REPEAT EXPANSION IN MOTOR NEURON DISEASE: DIPEPTIDE REPEAT PROTEIN PRODUCTION, STALLING, AND CYTOTOXICITY</p> <p><i>¹CASTILLO, KEVIN; ¹HATTERS, DANNY; ²FURIC, LUC</i></p> <p>¹DEPARTMENT OF BIOCHEMISTRY AND PHARMACOLOGY AND BIO21 MOLECULAR SCIENCE AND BIOTECHNOLOGY INSTITUTE, THE UNIVERSITY OF MELBOURNE, MELBOURNE, 3052 VICTORIA, AUSTRALIA, ²TRANSLATIONAL PROSTATE CANCER RESEARCH LABORATORY, PETER MACCALLUM CANCER CENTRE, MELBOURNE, 3052 VICTORIA, AUSTRALIA, ³SIR PETER MACCALLUM DEPARTMENT OF ONCOLOGY, UNIVERSITY OF MELBOURNE, PARKVILLE, 3052 VICTORIA, AUSTRALIA</p>
	BS-P-MP011	<p>CELL FUSION: A NOVEL THERAPEUTIC STRATEGY TO INHIBIT CELL DEATH AND ALLEVIATE NEURODEGENERATION IN ALS</p> <p><i>¹DO-YEON LEE, PHD, ¹JUNG-JOON SUNG, MD, PHD*</i></p> <p>¹DEPARTMENT OF NEUROLOGY, SEOUL NATIONAL UNIVERSITY HOSPITAL, SEOUL 03080, SOUTH KOREA</p>
	BS-P-MP012	<p>INVESTIGATING SPINAL CORD MOTOR CIRCUITRY VULNERABILITY AND DEGENERATION IN THE TDP 43 Q331 K MOUSE MODEL OF ALS</p> <p><i>¹MATTHEWS, LYZETTE; ¹JOHNSTONE, OLIVER; ²CRANE, JAMES; ¹KING, ANNA; ¹PERRY, SHARN</i></p> <p>¹WICKING DEMENTIA RESEARCH AND EDUCATION CENTRE, UNIVERSITY OF TASMANIA, 17 LIVERPOOL STREET, HOBART, AUSTRALIA. ²SCHOOL OF MEDICINE, UNIVERSITY OF TASMANIA, 17 LIVERPOOL STREET, HOBART, AUSTRALIA</p>

PACTALS 2025

BASIC SCIENCE POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
MOLECULAR PATHOGENESIS	BS-P-MP013	<p>MURINE ARYLAMINE N ACETYLTRANSFERASE 2 AS A MODULATOR OF SKELETAL MUSCLE RESPONSES IN MND: IMPLICATIONS FOR DISEASE PROGRESSION AND MYOGENESIS</p> <p><i>¹MELINDER K. GILL; ²STEPHANIE L. HOWE; ¹NEVILLE BUTCHER; ^{2,3}SHYUAN NGO; ¹RODNEY F. MINCHIN; ^{1,3}FREDERIK STEYN</i></p> <p>¹SCHOOL OF BIOMEDICAL SCIENCES, FACULTY OF MEDICINE, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA ²AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA ³ROYAL BRISBANE AND WOMEN'S HOSPITAL, HERSTON, BRISBANE, AUSTRALIA</p>
	BS-P-MP014	<p>WILL REDUCING ABNORMAL CORTICAL ACTIVITY IN MND HAVE A THERAPEUTIC EFFECT?</p> <p><i>MOUNA HAIDAR, AIDA VIDEN, CHRISTIN DANIEL, BRADLEY TURNER</i></p>
	BS-P-MP015	<p>LRP4 OVEREXPRESSION IN MUSCLE HELPS STABILIZE NEUROMUSCULAR SYNAPSES IN SOD1 G83 A ALS MODEL MICE</p> <p><i>¹NOAKES. PG; ¹AGRAWAL, U; ¹VINCENT CHEN V; ²CHAND K; ³NGO ST; ^{4,5}MEI L; ⁵XIONG W-C; ¹LAVIDIS NA</i></p> <p>¹SCHOOL OF BIOMEDICAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, ST LUCIA, QLD AUSTRALIA. ²PERINATAL RESEARCH CENTER, CENTRE FOR CLINICAL RESEARCH, THE UNIVERSITY OF QUEENSLAND, ST LUCIA, QLD AUSTRALIA. ³AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, THE UNIVERSITY OF QUEENSLAND, ST LUCIA, QLD AUSTRALIA. ⁴CHINESE INSTITUTE FOR MEDICAL RESEARCH BEIJING, CHINA. ⁵DEPARTMENT OF NEUROSCIENCES, SCHOOL OF MEDICINE CASE WESTERN UNIVERSITY, OH, USA</p>
	BS-P-MP016	<p>CAN WE HARNESS HYPOTHERMIA TO TREAT MOTOR NEURON DISEASE?</p> <p><i>¹ATKINSON, RACHEL; ¹COOK, ANTHONY; ¹KING, ANNA</i></p> <p>¹WICKING DEMENTIA RESEARCH AND EDUCATION CENTRE, UNIVERSITY OF TASMANIA, 17 LIVERPOOL STREET, HOBART, AUSTRALIA</p>

PACTALS 2025

BASIC SCIENCE POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
MOLECULAR PATHOGENESIS	BS-P-MP017	<p>IDENTIFYING THE DISRUPTED PATHWAY OF INSULIN LIKE GROWTH FACTOR 1 MEDIATED SIGNALLING IN MOUSE NEUROBLASTOMA CELLS EXPRESSING FUS MUTATION</p> <p><i>YOUSUN (SUNNY) AN, KATHERINE ROBINSON, ANGELA LAIRD</i></p> <p>NEURODEGENERATION TREATMENT TEAM, MOTOR NEURON DISEASE RESEARCH CENTRE, MACQUARIE UNIVERSITY</p>
NEUROINFLAMMATION	BS-P-N001	<p>PROFILING MITOCHONDRIAL DERIVED VESICLES TO INFORM THERAPEUTIC STRATEGIES FOR IMMUNE MEDIATED NEURODEGENERATION IN MND</p> <p><i>¹HANSEN, AGGIE; ^{1,2}VELLA, LAURA; ^{1,2}TURNER, BRADLEY</i></p> <p>¹FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH, PARKVILLE VIC 3052, AUSTRALIA ²FLOREY DEPARTMENT OF NEUROSCIENCE AND MENTAL HEALTH, UNIVERSITY OF MELBOURNE, PARKVILLE VIC 3052, AUSTRALIA</p>
	BS-P-N002	<p>EXPRESSION OF FATTY ACID BINDING PROTEIN 4 AND POTASSIUM CHANNEL KV1.3 IN MICROGLIA ISOLATED FROM SOD1 G93 A MOUSE BRAIN AND SPINAL CORD</p> <p><i>AMELIA MIKLAVEC¹, LIAM KOEHN¹ AND JOSEPH A NICOLAZZO²</i></p> <p>¹DRUG DELIVERY, DISPOSITION AND DYNAMICS, MONASH INSTITUTE OF PHARMACEUTICAL SCIENCES, MONASH UNIVERSITY, MELBOURNE, VIC, AUSTRALIA. ²CENTRE FOR DRUG CANDIDATE OPTIMISATION, MONASH INSTITUTE OF PHARMACEUTICAL SCIENCES, MONASH UNIVERSITY, MELBOURNE, VIC, AUSTRALIA</p>
	BS-P-N003	<p>A PATHOGENIC ROLE OF C5 AR2 ACTIVATION IN AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>JOHN D. LEE¹, JENNY N. FUNG¹, ALANA JULIANISYA¹, AUSTIN READ¹, AND TRENT M. WOODRUFF¹</i></p> <p>1 SCHOOL OF BIOMEDICAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, QLD, AUSTRALIA</p>

PACTALS 2025

BASIC SCIENCE POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
OTHERS	BS-P-0001	<p>FLUID DYNAMICS PROMOTE THE INDUCTION OF SPINAL CORD ORGANOIDS FOR TRANSPLANTATION</p> <p><i>SUONG NGOC ANH DANG^{1,2}, KEIKO IMAMURA^{1,2,3}, HARUHISA INOUE^{1,2,3}</i></p> <p>¹IPSC-BASED DRUG DISCOVERY AND DEVELOPMENT TEAM, RIKEN BIORESOURCE RESEARCH CENTER (BRC), KYOTO, JAPAN ²CENTER FOR IPS CELL RESEARCH AND APPLICATION (CIRA), KYOTO UNIVERSITY, KYOTO, JAPAN ³MEDICAL-RISK AVOIDANCE BASED ON IPS CELLS TEAM, RIKEN CENTER FOR ADVANCED INTELLIGENCE PROJECT (AIP), KYOTO, JAPAN</p>
	BS-P-0002	<p>DEVELOPING A MICROFLUIDIC MODEL OF THE CORTICOMOTOR SYSTEM</p> <p><i>KATHRYN MASKELL, YIING YAP, JYOTI CHUCKOWREE, TRACEY DICKSON, CATHERINE BLIZZARD</i></p> <p>MENZIES INSTITUTE FOR MEDICAL RESEARCH, TASMANIA, AUSTRALIA</p>
	BS-P-0003	<p>THE IMPACT OF RESCUING SCHWANN CELLS ON LOWER MOTOR NEURON FUNCTION IN ALS</p> <p><i>KATHERINE LEWIS¹, GEORGINA CRAIG², ROBIN MCALLEN¹, ANDREW TOSOLINI^{3,4}, DAVID GONSALVEZ⁵, BRADLEY TURNER¹ & SAMANTHA BARTON¹</i></p> <p>¹THE FLOREY INSTITUTE, THE UNIVERSITY OF MELBOURNE, MELBOURNE VIC ²LI KA SHING KNOWLEDGE INSTITUTE, UNITY HEALTH, ST MICHAEL'S HOSPITAL, TORONTO, CANADA ³SCHOOL OF BIOMEDICAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, BRISBANE QLD ⁴AUSTRALIAN INSTITUTE OF BIOTECHNOLOGY AND NANOTECHNOLOGY, BRISBANE, QLD ⁵DEPARTMENT OF ANATOMY AND DEVELOPMENTAL BIOLOGY, MONASH UNIVERSITY, MELBOURNE VIC</p>
	BS-P-0004	<p>SARM1 INHIBITION LIMITS AXONAL DEGENERATION CAUSED BY KAINIC ACID INDUCED EXCITOTOXICITY</p> <p><i>¹LENG CHENG, JAN; ¹THORNE, B; ¹TALBOT J; ¹ATKINSON R; ¹PERRY S; ¹KING A; ¹COOK A</i></p> <p>¹WICKING DEMENTIA RESEARCH AND EDUCATION CENTRE, UNIVERSITY OF TASMANIA, 17 LIVERPOOL ST, HOBART, AUSTRALIA</p>

PACTALS 2025

BASIC SCIENCE POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
OTHERS	BS-P-0005	<p>VISUALIZATION OF DYSREGULATED PROTEINS INVOLVED IN MOTOR NEURON DISEASE USING ELECTRON CRYOTOMOGRAPHY</p> <p><i>ALEMU GEBRIE CHEKOL, DEBNATH GHOSAL, ARCOT ANIL KUMAR MANASI, DANNY M. HATTERS</i></p> <p>DEPARTMENT OF BIOCHEMISTRY AND PHARMACOLOGY, BIO21 MOLECULAR SCIENCE AND BIOTECHNOLOGY INSTITUTE, THE UNIVERSITY OF MELBOURNE, PARKVILLE, VICTORIA 3052, AUSTRALIA</p>
	BS-P-0006	<p>DEVELOPMENT OF ANTISENSE OLIGONUCLEOTIDES TO RESTORE AXONAL HEALTH IN SPORADIC AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>JESSICA MANTEGNA^{1,2}, STEVE WILTON^{2,3}, BRADLEY TURNER^{1,4}, ANTHONY AKKARI^{1,2,3,5}, FRANCES THEUNISSEN^{1,2,3,5}</i></p> <p>¹SCHOOL OF HEALTH SCIENCE, THE UNIVERSITY OF NOTRE DAME AUSTRALIA, FREMANTLE, WA, AUSTRALIA ²PERRONINSTITUTEFORNEUROLOGICALANDTRANSLATIONAL SCIENCE, NEDLANDS, WA, AUSTRALIA ³PRECISION MEDICINE CENTRE, MURDOCH UNIVERSITY, MURDOCH, WA, AUSTRALIA ⁴FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH, MELBOURNE ⁵BLACK SWAN BIOTECH, PERTH, WA, AUSTRALIA</p>
	BS-P-0007	<p>SELECTIVE MODULATION OF VOLTAGE GATED SODIUM CHANNELS ON MOTOR NEURONS AS A THERAPEUTIC STRATEGY FOR AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>JESSICA AI MULLER¹, REFIK KANJHAN¹, VAN TRAN¹, CHARAN KOTAPATI¹, MARK BELLINGHAM², JEAN GIACOMOTTO³ AND FERNANDA C CARDOSO¹</i></p> <p>¹INSTITUTE FOR MOLECULAR BIOSCIENCE, THE UNIVERSITY OF QUEENSLAND, BRISBANE, AUSTRALIA ²SCHOOL OF BIOMEDICAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, BRISBANE, AUSTRALIA ³GRIFFITH INSTITUTE FOR DRUG DISCOVERY, GRIFFITH UNIVERSITY, BRISBANE, AUSTRALIA</p>

PACTALS 2025

BASIC SCIENCE POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
OTHERS	BS-P-0008	<p>REBALANCING EXCITABILITY WITH GENE THERAPY</p> <p><i>JOSHUA R CURSON¹, EBONY S. BAX¹, PETRA L. SEDLAK¹, LI XU¹, PANKAJ SAH^{1,3}, MARGREET C. RIDDER^{1,2}</i></p> <p>¹THE QUEENSLAND BRAIN INSTITUTE, THE UNIVERSITY OF QUEENSLAND, ST LUCIA 4072, AUSTRALIA ²THE SCHOOL OF BIOMEDICAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, ST LUCIA 4072, AUSTRALIA ³JOINT CENTER FOR NEUROSCIENCE AND NEURAL ENGINEERING, AND DEPARTMENT OF BIOLOGY, SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY, SHENZHEN, GUANGDONG PROVINCE, P. R. CHINA, 518055</p>
	BS-P-0009	<p>DEVELOPING A CNS PENETRATING ANTISENSE THERAPY APPROACH FOR SOD1 MEDIATED ALS</p> <p><i>^{1,2}PITTERI, MATTEO; ¹SHABANPOOR F; ¹TURNER BJ</i></p> <p>¹THE FLOREY INSTITUTE OF NEUROSCIENCE & MENTAL HEALTH, THE UNIVERSITY OF MELBOURNE, AUSTRALIA, ²DEPARTMENT OF ANATOMY & PHYSIOLOGY, THE UNIVERSITY OF MELBOURNE, AUSTRALIA</p>
	BS-P-0010	<p>INVESTIGATING TDP 43 MODULATION AND THERAPEUTIC POTENTIAL OF AMORPHOLINO ANTISENSE OLIGONUCLEOTIDE TARGETING TARDBP IN A HUMANISED ALS MOUSE MODEL</p> <p><i>TAORO-GONZÁLEZ, LUCAS¹; MUÑOZ DE BUSTILLO-ALFARO, RAMÓN A.¹; MEJZINI, RITA^{2,3,4}; LOREN FLYNN, LEZANNE OOI⁶, DZUNG DO-HA⁶, CHLOE SLIGAR⁶, ADAM WALKER⁸, BRADLEY TURNER⁷, FRANCESSE THEUNISSEN AKKARI, PATRICK A.^{2,3,4,5}; ACEVEDO-AROZENA, ABRAHAM¹</i></p> <p>¹U. HOSPITAL OF THE CANARY ISLANDS; ITB-ULL, FIISC AND CIBERNED (SPAIN). ²PERSONALIZED MEDICINE CENTRE, MURDOCH U. (AUSTRALIA). ³THE PERRON INSTITUTE FOR NEUROLOGICAL AND TRANSLATIONAL SCIENCE, (AUSTRALIA). ⁴DEPARTMENT OF NEUROLOGY, DUKE U. (USA). ⁵THE U. OF WESTERN AUSTRALIA (AUSTRALIA). ⁶SCHOOL OF SCIENCE, MOLECULAR HORIZONS, UNIVERSITY OF WOLLONGONG ⁷FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH, MELBOURNE ⁸UNIVERSITY OF SYDNEY</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
BIOMARKERS	C-O-B001	<p>DIAGNOSTIC VALUE OF THRESHOLD TRACKING TRANSCRANIAL MAGNETIC STIMULATION PARADIGMS IN AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>AICEE DAWN CALMA^{1,2}, NATHAN PAVEY^{1,2}, CLÁUDIA SANTOS SILVA^{1,3,4}, MEHDI A.J. VAN DEN BOS¹, CON YIANNIKAS², MICHELLE A. FARRAR^{6,7}, MATTHEW C KIERNAN^{8,9}, PARVATHI MENON^{1,2}, STEVE VUCIC^{1,2}</i></p> <p>¹BRAIN AND NERVE RESEARCH CENTRE, CONCORD CLINICAL SCHOOL, UNIVERSITY OF SYDNEY, CONCORD HOSPITAL, SYDNEY, AUSTRALIA. ²DEPARTMENT OF NEUROLOGY, CONCORD REPATRIATION GENERAL HOSPITAL, SYDNEY, AUSTRALIA ³DEPARTMENT OF NEUROSCIENCES AND MENTAL HEALTH, UNIDADE LOCAL DE SAÚDE DE SANTA MARIA, LISBON, PORTUGAL ⁴FACULDADE DE MEDICINA-INSTITUTO DE MEDICINA MOLECULAR, CENTRO DE ESTUDOS EGAS MONIZ, UNIVERSIDADE DE LISBOA, LISBON, PORTUGAL. ⁵DISCIPLINE OF PAEDIATRICS AND CHILD HEALTH, SCHOOL OF CLINICAL MEDICINE, UNSW MEDICINE AND HEALTH, THE UNIVERSITY OF NEW SOUTH WALES, SYDNEY, AUSTRALIA. ⁶NEUROSCIENCE RESEARCH AUSTRALIA, SYDNEY, AUSTRALIA. ⁷SCIENTIA PROFESSOR OF NEUROSCIENCE, UNIVERSITY OF NSW; AND DEPARTMENT OF NEUROLOGY, SOUTHEASTERN SYDNEY LOCAL HEALTH DISTRICT, SYDNEY, AUSTRALIA</p>
	C-O-B002	<p>MULTI OMICS PROFILING REVEALS METABOLIC REPROGRAMMING AND THERMOGENESIS IMPAIRMENT IN AMYOTROPHIC LATERAL SCLEROSIS</p> <p>¹LINJING,ZHANG; ¹DONGSHENG FAN</p> <p>¹DEPARTMENT OF NEUROLOGY, PEKING UNIVERSITY THIRD HOSPITAL, GARDEN ROAD CODE 49, HAIDIAN DISTRICT, BEIJING 100191, CHINA</p>
	C-O-B003	<p>PLASMA MISFOLDED SOD1 IN AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>¹ TSAI, LI-KAI; ¹ KUO, YIH-CHIH; ² TING, CHEN-HUNG; ² CHANG, HSIANG-YU; ² WANG, I-FAN</i></p> <p>¹DEPARTMENT OF NEUROLOGY, NATIONAL TAIWAN UNIVERSITY HOSPITAL, CHUNG-SHAN SOUTH ROAD, TAIPEI CITY, TAIWAN. ²GARAGE BRAIN SCIENCE, CENTRAL TAIWAN INNOVATION CAMPUS, MINISTRY OF ECONOMIC AFFAIRS, NANTOU CITY, TAIWAN</p>

PACTALS 2025

CLINICAL ORAL PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
BIOMARKERS	C-O-B004	<p>PLASMA PDGFR BETA LEVELS : A POTENTIAL INDICATOR OF DISEASE DURATION IN ALS</p> <p><i>LU TANG; GAN ZHANG; LU CHEN; XIAOLU LIU; DONGSHENG FAN</i></p> <p>DEPARTMENT OF NEUROLOGY, PEKING UNIVERSITY THIRD HOSPITAL, BEIJING, CHINA</p>
CLINICAL MANAGEMENT	C-O-CM001	<p>ENHANCING THE LIVED EXPERIENCE OF PEOPLE WITH AMYOTROPHIC LATERAL SCLEROSIS: BEST PRACTICE LEARNINGS FROM PATIENT ADVISORY GROUPS IN THE ASIA PACIFIC REGION</p> <p><i>¹SELLATI R; ¹ALI T; ¹HARARI O; ¹LEVY O</i></p> <p>¹REGENERON PHARMACEUTICALS, INC., TARRYTOWN, NY, USA</p>
CLINICAL NEUROPHYSIOLOGY AND IMAGING	C-O-CN&I001	<p>ASSOCIATION BETWEEN CLINICAL FEATURES AND ASTROGLIOSIS AS VISUALISED BY 18 F THK5351 PET IN MOTOR NEURON DISEASE</p> <p><i>¹HIGASHIHARA M; ²ISHIBASHI K; ³HATANAKA Y; ¹KURIHARA M; ¹KOMORI Y; ¹TAKAHASHI K; ¹FUNAKAWA K; ⁴MATSUBARA T; ¹IHARA R; ³SONOO M; ⁵KATO T; ⁶MURAYAMA S; ⁷TOKUMARU AM; ²ISHII K; ¹IWATA A</i></p> <p>¹DEPARTMENT OF NEUROLOGY, TOKYO METROPOLITAN INSTITUTE FOR GERIATRICS AND GERONTOLOGY, ITABASHI-KU, TOKYO, JAPAN, ²RESEARCHTEAMFORNEUROIMAGING, TOKYOMETROPOLITAN INSTITUTE FOR GERIATRICS AND GERONTOLOGY, ITABASHI-KU, TOKYO, JAPAN, ³DEPARTMENT OF NEUROLOGY, TEIKYO UNIVERSITY, ITABASHI-KU, TOKYO, JAPAN, ⁴DEPARTMENT OF NEUROLOGY, TOKUSHIMA UNIVERSITY, TOKUSHIMA CITY, TOKUSHIMA, JAPAN, ⁵DEPARTMENT OF REHABILITATION, TOKYO METROPOLITAN INSTITUTE FOR GERIATRICS AND GERONTOLOGY, ITABASHI-KU, TOKYO, JAPAN, ⁶BRAIN BANK FOR AGING RESEARCH, TOKYO METROPOLITAN INSTITUTE FOR GERIATRICS AND GERONTOLOGY, ITABASHI-KU, TOKYO, JAPAN, ⁷DEPARTMENT OF RADIOLOGY, TOKYO METROPOLITAN INSTITUTE FOR GERIATRICS AND GERONTOLOGY, ITABASHI-KU, TOKYO, JAPAN</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL NEUROPHYSIOLOGY AND IMAGING	C-O-CN&I002	<p>LONGITUDINAL ASSESSMENT OF CORTICAL MOTOR FUNCTION IN AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>DAYNA-LEE TALBOT¹, DHAYALEN KRISHNAN^{1,2}, JASMINE F. ASHHURST^{1,2}, SUSANNA B. PARK³, STEVE VUCIC⁴, HANNAH C. TIMMINS¹, MATTHEW C. KIERNAN^{1,2,5}</i></p> <p>¹NEUROSCIENCE RESEARCH AUSTRALIA, SYDNEY, AUSTRALIA. ²INSTITUTE OF CLINICAL NEUROSCIENCES, ROYAL PRINCE ALFRED HOSPITAL, SYDNEY, AUSTRALIA. ³SCHOOL OF MEDICAL SCIENCES, UNIVERSITY OF SYDNEY, AUSTRALIA ⁴BRAIN AND NERVE CENTRE, CONCORD HOSPITAL, SYDNEY, AUSTRALIA. ⁵UNIVERSITY OF NEW SOUTH WALES, SYDNEY, AUSTRALIA</p>
CLINICAL TRIAL AND PLATFORMS	C-O-CT&P001	<p>PRIMEC AS A PROMISING ORAL THERAPY FOR ALS: PHASE 2 B STUDY RESULTS AND BIOMARKER FINDINGS, AND THE UPCOMING PHASE 3 STUDY (PARAGON)</p> <p><i>SHEFNER JM¹, DRORY VE², CHIO A³, LUNETTA C⁴, SHOESMITH C⁵, ZIMRI S⁶, RUSSEK-BLUM N⁶, SHTOSSEL D⁶, KEREM N⁶, VAN EIJK RPA⁷, SHAPIRA G⁸, SHOMRON N⁸, TRACIK F⁶, ROSENFELD J⁹ & CUDKOWICZ ME¹⁰</i></p> <p>¹BARROW NEUROLOGICAL INSTITUTE, PHOENIX, AZ, USA; ²NEUROMUSCULAR DISEASES UNIT, DEPARTMENT OF NEUROLOGY, TEL AVIV SOURASKY MEDICAL CENTER, TEL AVIV, ISRAEL; ³UNIVERSITY OF TURIN, TURIN, ITALY; ⁴ISTITUTI CLINICI SCIENTIFICI MAUGERI IRCCS, DEPARTMENT OF NEUROREHABILITATION, INSTITUTE OF MILAN, ITALY; ⁵DEPARTMENT OF CLINICAL NEUROLOGICAL SCIENCES, DIVISION OF NEUROLOGY, LONDON HEALTH SCIENCES CENTRE, LONDON, ON, CANADA; ⁶NEUROSENSE THERAPEUTICS, LTD, HERZLIYA, ISRAEL; ⁷DEPARTMENT OF NEUROLOGY, UMC UTRECHT BRAIN CENTER, UNIVERSITY MEDICAL CENTER UTRECHT, UTRECHT, THE NETHERLANDS; ⁸FACULTY OF MEDICAL AND HEALTH SCIENCE, TEL AVIV UNIVERSITY, TEL AVIV, ISRAEL; ⁹DEPARTMENT OF NEUROLOGY, LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE & ¹⁰MASS GENERAL BRIGHAM NEUROSCIENCE INSTITUTE, HEALEY & AMG CENTER FOR ALS, DEPARTMENT OF NEUROLOGY, MGH, HARVARD MEDICAL SCHOOL, BOSTON, MA, USA</p>

PACTALS 2025

CLINICAL ORAL PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL TRIAL AND PLATFORMS	C-O-CT&P002	<p>PHASE 1 OPEN LABEL EXTENSION STUDY OF AN MTOR INHIBITOR IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>SUSAN MATHERS^{1,2}, DOMINIC ROWE³, PHILIP WHITE⁴, MELANIE QUINTANA⁴, JOHN CLARK⁵ AND MICHAEL THURN⁵.</i></p> <p>¹CALVARY HEALTH CARE BETHLEHEM, CAULFIELD SOUTH, VIC 3162, AUSTRALIA ²SCHOOL OF CLINICAL SCIENCES, MONASH UNIVERSITY, CLAYTON, VIC 3800, AUSTRALIA ³CENTRE FOR MND RESEARCH, FACULTY OF MEDICINE AND HEALTH RESEARCH, MACQUARIE UNIVERSITY, SYDNEY, NSW 2109, AUSTRALIA ⁴BERRY CONSULTANTS, AUSTIN, TEXAS, 78746, USA ⁵NEURIZON THERAPEUTICS LTD, SOUTH MELBOURNE, VIC 3205, AUSTRALIA</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL TRIAL AND PLATFORMS	C-O-CT&P003	<p>CLINICAL TRIAL OF BOSUTINIB FOR AMYOTROPHIC LATERAL SCLEROSIS: IDREAM STUDY</p> <p><i>HARUHISA INOUE¹, KEIKO IMAMURA¹, NAOHIRO EGAWA², TAKASHI AYAKI², MAKIKO NAGAI³, KAZUTOSHI NISHIYAMA³, YASUHIRO WATANABE⁴, TAKENOBU MURAKAMI⁴, RITSUKO HANAJIMA⁴, HIROSHI KATAOKA⁵, TAKAO KIRIYAMA⁵, HITOKI NANAURA⁵, KAZUMA SUGIE⁵, TAKEHISA HIRAYAMA⁶, OSAMU KANO⁶, MASAHIRO NAKAMORI⁷, HIROFUMI MARUYAMA⁷, SHOTARO HAJI⁸, KOJI FUJITA⁸, NAOKI ATSUTA⁹, NAOTO TAKAHASHI¹⁰, SATOSHI MORITA¹¹, GEN SOBUE⁹, RYOSUKE TAKAHASHI³, YUISHIN IZUMI⁸</i></p> <p>¹CENTER FOR IPS CELL RESEARCH AND APPLICATION (CIRA), KYOTO UNIVERSITY, KYOTO, JAPAN ²DEPARTMENT OF NEUROLOGY, GRADUATE SCHOOL OF MEDICINE, KYOTO UNIVERSITY, KYOTO, JAPAN ³DEPARTMENT OF NEUROLOGY, KITASATO UNIVERSITY SCHOOL OF MEDICINE, SAGAMIHARA, JAPAN ⁴DIVISION OF NEUROLOGY, DEPARTMENT OF BRAIN AND NEUROSCIENCES, FACULTY OF MEDICINE, TOTTORI UNIVERSITY, YONAGO, JAPAN ⁵DEPARTMENT OF NEUROLOGY, NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE, KASHIHARA, JAPAN ⁶DEPARTMENT OF NEUROLOGY, TOHO UNIVERSITY FACULTY OF MEDICINE, TOKYO, JAPAN ⁷DEPARTMENT OF CLINICAL NEUROSCIENCE AND THERAPEUTICS, GRADUATE SCHOOL OF BIOMEDICAL AND HEALTH SCIENCES, HIROSHIMA UNIVERSITY, HIROSHIMA, JAPAN ⁸DEPARTMENT OF NEUROLOGY, TOKUSHIMA UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, TOKUSHIMA, JAPAN ⁹DEPARTMENT OF NEUROLOGY, AICHI MEDICAL UNIVERSITY, NAGAKUTE, JAPAN ¹⁰DEPARTMENT OF HEMATOLOGY, NEPHROLOGY, AND RHEUMATOLOGY, AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE, AKITA, JAPAN ¹¹DEPARTMENT OF BIOMEDICAL STATISTICS AND BIOINFORMATICS, KYOTO UNIVERSITY, KYOTO, JAPAN</p>
MOLECULAR PATHOGENESIS	C-O-MP001	<p>GLIAL CELL TYPE SPECIFIC IMMUNE AND METABOLIC SHIFTS ACROSS THE MND BVFTD SPECTRUM</p> <p><i>¹JERYN CHANG, ²STEPHANIE HOWE; ³ZHERUI XIONG; ³QUAN NGUYEN; ²SHYUAN NGO; ¹FREDERIK STEYN</i></p> <p>¹SCHOOL OF BIOMEDICAL SCIENCES, FACULTY OF HEALTH, MEDICINE AND BEHAVIOURAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA ²AUSTRALIAN INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA ³QUEENSLAND INSTITUTE OF MEDICAL RESEARCH, HERSTON, QUEENSLAND, AUSTRALIA</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
NUTRITIONAL MANAGEMENT	C-O-NM001	<p>EVALUATING THE IMPACT OF WEIGHT LOSS AND ACCURACY OF PREDICTIVE ENERGY EQUATIONS IN AUSTRALIANS WITH AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>^{1,2}SEWELL-GREEN, AMBER; ¹CAPSTICK R; ^{2,3}MATTHEWS-RENSCH KL; ⁴HENDERSON R; ^{4,5}NGO ST; ^{1,4}STEYN FJ</i></p> <p>¹SCHOOL OF BIOMEDICAL SCIENCES, FACULTY OF MEDICINE, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA, ²DIETETICS AND FOODSERVICES, ROYAL BRISBANE AND WOMEN'S HOSPITAL, AUSTRALIA, ³QUEENSLAND CENTRE FOR MENTAL HEALTH RESEARCH, THE PARK CENTRE FOR MENTAL HEALTH TREATMENT, RESEARCH AND EDUCATION, WACOL, AUSTRALIA, ⁴DEPARTMENT OF NEUROLOGY, ROYAL BRISBANE AND WOMEN'S HOSPITAL, AUSTRALIA, ⁵AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA</p>
RESPIRATORY MANAGEMENT	C-O-RM001	<p>ASSOCIATION OF DEEP LEARNING BASED CHEST CT DERIVED RESPIRATORY PARAMETERS WITH DISEASE PROGRESSION IN AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>¹SEOK-JIN CHOI; ¹JONG-SU KIM; ¹JUNG-JOON SUNG; ²KYU SUNG CHOI</i></p> <p>¹DEPARTMENT OF NEUROLOGY, SEOUL NATIONAL UNIVERSITY HOSPITAL, SEOUL, REPUBLIC OF KOREA ¹DEPARTMENT OF RADIOLOGY, SEOUL NATIONAL UNIVERSITY HOSPITAL, SEOUL, REPUBLIC OF KOREA</p>
OTHERS	C-O-O001	<p>AMPLIFYING THE LIVED EXPERIENCE OF MND VOICE IN AUSTRALIA</p> <p><i>¹LABRA J; CAMDEN P; MALPRESS K; ²YAP MY; SKLAVENITIS L; SIMPSON J.</i></p> <p>¹MND AUSTRALIA, 20 BRADLEY ST, WODEN, AUSTRALIAN CAPITAL TERRITORY, AUSTRALIA, ²FIGHTMND, PO BOX 3073 BURNLEY NORTH, VICTORIA, AUSTRALIA</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
ASSISTIVE TECHNOLOGY	C-P-AT001	<p>GLOBAL ACCESS TO VOICE PRESERVATION IN ALS/MND POPULATIONS: A PILOT PROJECT</p> <p><i>¹CHUDGE JARNAIL, ¹MABE JESSICA, ¹SIMON JULIA, ¹DE MAJO MARTINA, ¹CUMMINGS CATHY</i></p> <p>¹INTERNATIONAL ALLIANCE OF ALS/MND ASSOCIATION, FRANCIS CRICK HOUSE, 6 SUMMERHOUSE ROAD, MOULTON PARK, NORTHAMPTON NN3 6BJ. UK</p>
	C-P-AT002	<p>ASSISTIVE TECHNOLOGY FOR PEOPLE WITH MOTOR NEURON DISEASE IN NEW ZEALAND, A QUESTIONNAIRE STUDY OF USE, CHALLENGES AND PERSPECTIVES</p> <p><i>^{1,2}GAULD, N; ²HIKAKA, J; ³BUCHANAN, S; ⁴FALETAU, J; ⁵CLELAND, J. ⁶BUETOW, S.</i></p> <p>¹MOTOR NEURONE DISEASE NEW ZEALAND, 14 ERSON ST, ROYAL OAK, AUCKLAND, NEW ZEALAND, ²DSCHOOL OF PHARMACY, THE UNIVERSITY OF AUCKLAND, PARK RD, GRAFTON, AUCKLAND, NEW ZEALAND; ³UNIVERSITY OF OTAGO, LEITH ST, DUNEDIN. NEW ZEALAND; ⁴PACIFIC PUBLIC HEALTH DIRECTORATE, NATIONAL PUBLIC HEALTH SERVICE, TE WHATU ORA, CLAUDE RD, GREENLANE, AUCKLAND, NEW ZEALAND; ⁵TE WHATU ORA BAY OF PLENTY, CAMERON RD, TAURANGA, NEW ZEALAND; ⁶DEPARTMENT OF GENERAL PRACTICE AND PRIMARY HEALTH CARE, UNIVERSITY OF AUCKLAND, PARK RD, GRAFTON, AUCKLAND, NEW ZEALAND</p>
BIOMARKERS	C-P-B001	<p>SERUM GFAP AS A SURVIVAL PREDICTOR IN ADVANCED ALS: A MULTICENTER ANALYSIS</p> <p><i>¹HEE-JAE JUNG, ²WOO-SEUNG JEONG, ³MINSUNG KANG, ¹EUN-JAE LEE, ¹YOUNG-MIN LIM, ³JIN-SUNG PARK, ¹HYUNJIN KIM</i></p> <p>¹DEPARTMENT OF NEUROLOGY, ASAN MEDICAL CENTER, UNIVERSITY OF ULSAN, COLLEGE OF MEDICINE, SEOUL, REPUBLIC OF KOREA, ²UNIVERSITY OF ULSAN, COLLEGE OF MEDICINE, SEOUL, REPUBLIC OF KOREA, ³DEPARTMENT OF NEUROLOGY, KYUNGPOOK NATIONAL UNIVERSITY CHILGOK HOSPITAL, DAEGU, REPUBLIC OF KOREA</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
BIOMARKERS	C-P-B002	<p>TELOMERE LENGTH AND BIOLOGICAL AGE IN ALS: EVIDENCE FOR ACCELERATED AGING?</p> <p><i>SANE HEMANGI*^{2,4}; GOKULCHANDRAN NANDINI¹; KULKARNI POOJA²; SHARMA PRIYANKA³; GEORGE VINNIT²; SHARMA ALOK^{1,4}</i></p> <p>¹DEPARTMENT OF MEDICAL SERVICES, NEUROGEN BRAIN AND SPINE INSTITUTE, PLOT NO.: 19, SECTOR-40, SEAWOODS, NAVI MUMBAI – 400706, INDIA ²DEPARTMENT OF RESEARCH AND DEVELOPMENT, NEUROGEN BRAIN AND SPINE INSTITUTE, PLOT NO.: 19, SECTOR-40, SEAWOODS, NAVI MUMBAI – 400706, INDIA ³DEPARTMENT OF NEUROREHABILITATION, NEUROGEN BRAIN AND SPINE INSTITUTE, PLOT NO.: 19, SECTOR-40, SEAWOODS, NAVI MUMBAI – 400706, INDIA ⁴ASHA EK HOPE FOUNDATION FOR MND/ALS, INDIA</p>
	C-P-B003	<p>CXCR4 EXPRESSION IN CD4+T CELLS: POTENTIAL BIOMARKERS FOR ALS PROGRESSION</p> <p><i>¹KE, SHUPEI; ¹XU, CHUNZUAN; ¹LU, YINGQIAN; ¹LIU, CHANGYUN; ¹ZOU, ZHANGYU; ¹CHEN, SHENG</i></p> <p>¹DEPARTMENT OF NEUROLOGY, UNION HOSPITAL, FUJIAN MEDICAL UNIVERSITY, NO.29 XINQUAN ROAD, GULOU DISTRICT, FUZHOU, FUJIAN PROVINCE, CHINA</p>
	C-P-B004	<p>SPHINGOSINE 1 PHOSPHATE AS A PREDICTOR OF NEUROLOGICAL DETERIORATION IN SPINAL BULBAR MUSCULAR ATROPHY</p> <p><i>PARK JINSUNG</i></p> <p>KYUNGPOOK NATIONAL UNIVERSITY CHILGOK HOSPITAL</p>
	C-P-B005	<p>USE OF ELECTRONIC NOSE TECHNOLOGY IN DIAGNOSIS AND PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>PRINCIPAL INVESTIGATORS:</i> ROBERT NONA. PHD CANDIDATE UQCCR – ROBERT.NONA@UQCONNECT.EDU.AU PROF PAMELA MCCOMBE UQCCR, NEUROLOGIST THE ROYAL BRISBANE & WOMEN’S HOSPITAL, QUEENSLAND</p> <p><i>CO-INVESTIGATORS</i> A/PROF ROBERT HENDERSON NEUROLOGIST, RBWH DR DAVID FIELDING – HEAD OF RESPIRATORY MEDICINE, RBWH PROF XUE LI – SCHOOL OF IT & ENGINEERING, UQ DR TONY CHEN – FACULTY OF SCIENCES, ENGINEERING AND IT, UNIVERSITY OF ADELAIDE</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
BIOMARKERS	C-P-B006	<p>SERUM TRANSTHYRETIN IN ALS: INSIGHTS FROM A CROSS SECTIONAL AND LONGITUDINAL STUDY</p> <p><i>^{1,2,3}ZHANG, YIXUAN*, ^{1,2,3}HUANG, XIN*; ^{1,2,3}ZHU, DENGGE; ^{1,2,3}CHEN, LU; ^{1,2,3}HE, JI#; ^{1,2,3}FAN, DONGSHENG#</i></p> <p>¹DEPARTMENT OF NEUROLOGY, PEKING UNIVERSITY THIRD HOSPITAL, BEIJING, CHINA, ²BEIJING KEY LABORATORY OF BIOMARKER AND TRANSLATIONAL RESEARCH IN NEURODEGENERATIVE DISEASES, BEIJING, CHINA, ³KEY LABORATORY FOR NEUROSCIENCE, NATIONAL HEALTH COMMISSION/MINISTRY OF EDUCATION, PEKING UNIVERSITY, BEIJING, CHINA</p>
CLINICAL MANAGEMENT	C-P-CM001	<p>THE EXPERIENCE OF SUFFERING IN ALS: A CASE REPORT</p> <p><i>¹ANG CM, ⁵RASYID M, ⁵KRISHNAN P, ¹ZAINUDDIN S, ¹LAM CL, ⁴PEK EW, ³SOO CI, ²SHAHORIZAILA N, ¹CAPELLE D</i></p> <p>¹PALLIATIVE DEPARTMENT, UNIVERSITI MALAYA MEDICAL CENTRE, LEMBAH PANTAI, KUALA LUMPUR, MALAYSIA, ²NEUROLOGY DEPARTMENT, UNIVERSITI MALAYA MEDICAL CENTRE, LEMBAH PANTAI, KUALA LUMPUR, MALAYSIA, ³RESPIRATORY DEPARTMENT, UNIVERSITI MALAYA MEDICAL CENTRE, LEMBAH PANTAI, KUALA LUMPUR, MALAYSIA, ⁴REHABILITATION DEPARTMENT, UNIVERSITI MALAYA MEDICAL CENTRE, LEMBAH PANTAI, KUALA LUMPUR, MALAYSIA, ⁵HOSPIS MALAYSIA, CHERAS, KUALA LUMPUR, MALAYSIA</p>
	C-P-CM002	<p>SURVEY OF CONSTIPATION IN AUSTRALIANS WITH MND USING THE LIVED EXPERIENCE NETWORK</p> <p><i>¹WERTH, BARRY; ¹FISHER, MURRAY</i></p> <p>¹SUSAN WAKIL SCHOOL OF NURSING AND MIDWIFERY, FACULTY OF MEDICINE AND HEALTH, UNIVERSITY OF SYDNEY, SYDNEY, AUSTRALIA.</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL MANAGEMENT	C-P-CM003	<p>BEYOND TRADITIONAL BULBAR FUNCTION MEASURES: AUTOMATED SPEECH ANALYSIS AND PATIENT EXPERIENCE OF COMMUNICATION CHANGE AS INTEGRATED CLINICAL MARKERS IN ALS</p> <p><i>BROOKE-MAI WHELAN¹, ELAINE KEARNEY^{1,7}, ADAM P. VOGEL², ROBERT HENDERSON^{3,4}, SHANA TAUBERT⁴, PATRICK AIKEN¹, ANTHONY ANGWIN¹, REBECCA PACKER¹, ADRIANA PENMAN¹, DAVID COPLAND^{1,5}, SALMA CHARANIA⁶</i></p> <p>¹SCHOOL OF HEALTH AND REHABILITATION SCIENCES, THE UNIVERSITY OF QUEENSLAND ²SPEECH PATHOLOGY, THE UNIVERSITY OF MELBOURNE AND REDENLAB, MELBOURNE ³UNIVERSITY OF QUEENSLAND CENTRE FOR CLINICAL RESEARCH, FACULTY OF MEDICINE THE UNIVERSITY OF QUEENSLAND ⁴METRO NORTH HOSPITAL AND HEALTH SERVICE ⁵QUEENSLAND APHASIA RESEARCH CENTRE ⁶SCHOOL OF HEALTH, MEDICAL AND APPLIED SCIENCES, CENTRAL QUEENSLAND UNIVERSITY ⁷METRO SOUTH HOSPITAL AND HEALTH SERVICE</p>
	C-P-CM004	<p>WITHDRAWAL OF NON INVASIVE ASSISTED VENTILATION IN PATIENTS WITH MOTOR NEURONE DISEASE</p> <p>1 DR COREY LAU, 2TANYA MUNN</p> <p>1 ROYAL PRINCE ALFRED HOSPITAL, SYDNEY LOCAL HEALTH DISTRICT 2CONCORD CENTRE FOR PALLIATIVE CARE, SLHD</p>
	C-P-CM005	<p>AN EVALUATION OF THE ALSSQOL SF IN THE MALAYSIAN CONTEXT THROUGH COGNITIVE INTERVIEWING</p> <p><i>Wafa Sabirin¹, Fazlina Ahmad², Saiful Adni Abd Latif², Sheriza Izwa Zainuddin¹, Chee-Loong Lam¹, Chun-Ian Soo¹, Kee-Huat Chuah¹, Sakinah Sabirin¹, Nortina Shahrizaila¹, David Paul Capelle¹</i></p> <p>¹DEPARTMENT OF MEDICINE, FACULTY OF MEDICINE, UNIVERSITY OF MALAYA, 50603, KUALA LUMPUR, MALAYSIA. ²DEPARTMENT OF BIOMEDICAL SCIENCE, FACULTY OF MEDICINE, UNIVERSITY OF MALAYA, 50603, KUALA LUMPUR, MALAYSIA</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL MANAGEMENT	C-P-CM006	<p>EFFECT OF A BRIEF MINDFULNESS INTERVENTION ON THE EMOTION AND QUALITY OF LIFE OF PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>¹XIN HUANG[†],¹GUANGHAO HOU[†], ²HUI LI, ¹TIELUN YIN, ¹HONG LIU, ¹YANJING YANG, ¹LINNA BAI,¹WENXIA BAN, ¹JIAYING ZHANG, ¹RUIXUE ZHANG, ^{1,3,4#}DONGSHENG FAN, ^{1,3,4#}SHAN YE</i></p> <p>¹DEPARTMENT OF NEUROLOGY, PEKING UNIVERSITY THIRD HOSPITAL, BEIJING, CHINA. ²DEPARTMENT OF PSYCHIATRY, PEKING UNIVERSITY SIXTH HOSPITAL, BEIJING, CHINA. ³KEY LABORATORY FOR NEUROSCIENCE, NATIONAL HEALTH COMMISSION/MINISTRY OF EDUCATION, PEKING UNIVERSITY, BEIJING, CHINA. ⁴BEIJING KEY LABORATORY OF BIOMARKER AND TRANSLATIONAL RESEARCH IN NEURODEGENERATIVE DISEASES, BEIJING, CHINA</p>
	C-P-CM007	<p>TDP 43 PROTEINOPATHIES AS A DISEASE SPECTRUM: LIMBIC PREDOMINANT AGE RELATED TDP 43 ENCEPHALOPATHY</p> <p><i>¹ASHHURST, JASMINE F, ¹KIERNAN, MATTHEW C</i></p> <p>¹NEUROSCIENCE RESEARCH AUSTRALIA, MARGARETE AINSWORTH BUILDING, 139 BARKER ST, RANDWICK, AUSTRALIA</p>
	C-P-CM008	<p>PARANEOPLASTIC AMYOTROPHIC LATERAL SCLEROSIS ASSOCIATED WITH ANTI SOX1 ANTIBODIES</p> <p><i>¹ASHHURST, JASMINE F, ²GRANOT, RON, ¹KIERNAN, MATTHEW C.</i></p> <p>¹NEUROSCIENCE RESEARCH AUSTRALIA, MARGARETE AINSWORTH BUILDING, 139 BARKER ST, RANDWICK, AUSTRALIA. ²EAST NEUROLOGY, 403/251 OXFORD ST, BONDI JUNCTION, AUSTRALIA</p>
	C-P-CM009	<p>ELEVATED PYRIDOXINE DUE TO VITAMIN SUPPLEMENTATION WORSENE FASCICULATIONS IN MND</p> <p><i>¹ASHHURST, JASMINE F, ¹THOMPSON, ALEXANDRA, ¹KIERNAN, MATTHEW C.</i></p> <p>¹NEUROSCIENCE RESEARCH AUSTRALIA, MARGARETE AINSWORTH BUILDING, 139 BARKER ST, RANDWICK, AUSTRALIA.</p>

PACTALS 2025

CLINICAL POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL MANAGEMENT	C-P-CM010	<p>THE DEVELOPMENT OF A SYSTEMICALLY DELIVERABLE ANTISENSE THERAPY FOR THE TREATMENT OF MOTOR NEURON DISEASES</p> <p><i>¹MCCARTHY, LOUISE; ²TURNER BRADLEY; ²SHABANPOOR, FAZEL</i></p> <p>¹DEPARTMENT OF ANATOMY AND PHYSIOLOGY, UNIVERSITY OF MELBOURNE, 30 ROYAL PARADE, PARKVILLE, AUSTRALIA, ²MOTOR NEURON DISEASE, FLOREY INSTITUTE, 30 ROYAL PARADE, PARKVILLE, AUSTRALIA</p>
	C-P-CM011	<p>SHORT TERM SAFETY AND EFFICACY OF INTRAVENOUS EDARAVONE IN MOTOR NEURON DISEASE: A CASE SERIES</p> <p><i>¹MOHD NOH, MIMI NASHRA; ²TAN JK; ³RATHIKA RAJAH; ²REMLI, RABANI</i></p> <p>¹DEPARTMENT OF MEDICINE, HOSPITAL AL-SULTAN ABDULLAH UNIVERSITI TEKNOLOGI MARA (UITM) PUNCAK ALAM, SELANGOR, MALAYSIA, ²DEPARTMENT OF MEDICINE, FACULTY OF MEDICINE, NATIONAL UNIVERSITY OF MALAYSIA, KUALA LUMPUR, MALAYSIA, ³DEPARTMENT OF MEDICINE, HOSPITAL CANSELOR TUANKU MUHRIZ, NATIONAL UNIVERSITY OF MALAYSIA, KUALA LUMPUR, MALAYSIA</p>
	C-P-CM012	<p>NECK FLEXION WEAKNESS PREDICTS RESPIRATORY DYSFUNCTION IN AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>NATHAN PAVEY¹, ALYSSA TIEPPO, ANDREW HANNAFORD¹, PARVATHI MENON¹, MATTHEW SILSBY, STEVE VUCIC¹</i></p> <p>¹BRAIN AND NERVE RESEARCH CENTRE, CONCORD CLINICAL SCHOOL, UNIVERSITY OF SYDNEY, CONCORD HOSPITAL, SYDNEY NSW AUSTRALIA</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL MANAGEMENT	C-P-CM013	<p>THE NECESSITY TO RAISE AWARENESS OF ACCESSIBILITY FEATURES AND IMPROVE SUPPORT SYSTEMS AMONG PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS AND THEIR CAREGIVERS</p> <p><i>TAKEHISA HIRAYAMA¹, JUNPEI NAGASAWA¹, MARI SHIBUKAWA¹, HARUMI MORIOKA¹, TATSUHIRO YOKOYAMA¹, HIROSHI TSUDA¹, KOTA BOKUDA², MIEKO OGINO³, HIROYUKI TAKAO⁴, MITSUYA MORITA⁵, YOSHIAKI TAKAHASHI⁶, RYOICHI NAKAMURA⁷, NAOKI ATSUTA⁷, MAKOTO URUSHITANI⁸, KOJI YAMANAKA⁹, YUISHIN IZUMI¹⁰, OSAMU KANO¹</i></p> <p>¹DEPARTMENT OF NEUROLOGY, TOHO UNIVERSITY FACULTY OF MEDICINE, ²DEPARTMENT OF NEUROLOGY, TOKYO METROPOLITAN NEUROLOGICAL HOSPITAL, ³DEPARTMENT OF NEUROLOGY, OFFICE OF MEDICAL EDUCATION, INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE, SCHOOL OF MEDICINE, ⁴DEPARTMENT OF NEUROSURGERY, JIKEI UNIVERSITY SCHOOL OF MEDICINE, ⁵DIVISION OF NEUROLOGY, DEPARTMENT OF INTERNAL MEDICINE, JICHI MEDICAL UNIVERSITY, ⁶YUI LIFE COMMUNICATION LABORATORY, ⁷DEPARTMENT OF NEUROLOGY, AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE, ⁸DEPARTMENT OF NEUROLOGY, SHIGA UNIVERSITY OF MEDICAL SCIENCE, ⁹DEPARTMENT OF NEUROSCIENCE AND PATHOBIOLOGY, RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE, NAGOYA UNIVERSITY, ¹⁰DEPARTMENT OF NEUROLOGY, TOKUSHIMA UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES</p>
	C-P-CM014	<p>CARE AUGMENTATION BY LOCATION LINKED MESSAGING (CALL ME) A PILOT RANDOMISED CONTROL TRIAL OF CARE AUGMENTATION BY LOCATION LINKED MESSAGING IN AMYOTROPHIC LATERAL SCLEROSIS WITH RESPIRATORY IMPAIRMENT</p> <p><i>^{1,3}CHIWER A T; ^{1,2}MUZAFAR I; ¹TUCK R; ¹SAIDU K; ^{1,3}AL-CHALABI A</i></p> <p>¹DEPARTMENT OF NEUROLOGY, MOTOR NERVE CLINIC, KING'S COLLEGE HOSPITAL LONDON, DENMARK HILL, LONDON, UNITED KINGDOM, ²GUY'S, KING'S COLLEGE, AND ST THOMAS' HOSPITAL (GKT) SCHOOL OF MEDICAL EDUCATION, KING'S COLLEGE LONDON, LONDON, UNITED KINGDOM, ³DEPARTMENT OF BASIC AND CLINICAL NEUROSCIENCE, KING'S COLLEGE LONDON, MAURICE WOHL CLINICAL NEUROSCIENCE INSTITUTE, LONDON, UNITED KINGDOM</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL MANAGEMENT	C-P-CM015	<p>A CASE OF PROBABLE MMN TO ALS PROGRESSION: UNFORTUNATE MISDIAGNOSIS OR INCOMPREHENSIBLE OVERLAP?</p> <p><i>¹MERKULOV YA; ²FEDOROVA AN; ²LEZINA DS; ²GAMBURG AM; ²MERKULOVA DM</i></p> <p>¹INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY, 8 BALTIYSKAYA ST., MOSCOW, RUSSIA, ²BM GUEKHT NEUROLOGY CENTER, CENTRAL CLINICAL HOSPITAL «RZD-MEDICINE», 2 BUDAYSKAYA ST., MOSCOW, RUSSIA</p>
	C-P-CM016	<p>DEVELOPING THE AUSTRALIAN MOTOR NEURONE DISEASE GUIDELINE: A COLLABORATIVE, EVIDENCE BASED APPROACH USING GRADE METHODOLOGY</p> <p><i>ZACHARY MUNN¹, CINDY STERN¹, DANIELLE POLLOCK¹, TIMOTHY BARKER¹, STEVE VUCIC² FOR THE AUSTRALIAN MND GUIDELINE DEVELOPMENT GROUP</i></p> <p>¹HEALTH EVIDENCE SYNTHESIS, RESEARCH, AND IMPACT (HESRI), UNIVERSITY OF ADELAIDE, AUSTRALIA ²BRAIN AND NERVE RESEARCH CENTRE, CONCORD CLINICAL SCHOOL, THE UNIVERSITY OF SYDNEY, SYDNEY, AUSTRALIA</p>
CLINICAL NEUROPHYSIOLOGY AND IMAGING	C-P-CN&I001	<p>IDENTIFICATION OF SENSORY INVOLVEMENT IN SPINAL BULBAR MUSCULAR ATROPHY (SBMA): NEUROPHYSIOLOGICAL AND FUNCTIONAL EVIDENCE OF SENSORY DYSFUNCTION</p> <p><i>¹LIN, CINDY (SHIN-YI); ²PARK SB; ¹TU S; ²LI T; ³CARROLL A; ⁴HENDERSON R; ⁵SILSBY M; ⁶VUCIC S, ⁷KIERNAN MC</i></p> <p>¹CENTRAL CLINICAL SCHOOL, FACULTY OF MEDICINE AND HEALTH, BRAIN AND MIND CENTRE, THE UNIVERSITY OF SYDNEY, AUSTRALIA ²SCHOOL OF MEDICAL SCIENCES, FACULTY OF MEDICINE AND HEALTH, BRAIN AND MIND CENTRE, THE UNIVERSITY OF SYDNEY, AUSTRALIA ³DEPARTMENT OF NEUROLOGY AND NEUROPHYSIOLOGY, ST VINCENT'S HOSPITAL, SYDNEY, AUSTRALIA ⁴DEPARTMENT OF NEUROLOGY, ROYAL BRISBANE & WOMEN'S HOSPITAL (RBWH), QUEENSLAND, AUSTRALIA ⁵DEPARTMENT OF NEUROLOGY, WESTMEAD HOSPITAL, SYDNEY, AUSTRALIA ⁶BRAIN AND NERVE RESEARCH CENTRE, CONCORD CLINICAL SCHOOL, THE UNIVERSITY OF SYDNEY, NEW SOUTH WALES, AUSTRALIA ⁷NEUROSCIENCE RESEARCH AUSTRALIA (NEURA), UNSW, SYDNEY, AUSTRALIA</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL NEUROPHYSIOLOGY AND IMAGING	C-P-CN&I002	<p>SLEEP PARAMETER DURING REM SLEEP PERIOD PREDICT RESPIRATORY FAILURE IN AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>SEUNG-AH LEE¹, JEE HYUN KIM¹, SUK-WON AHN², YOON-HO HONG³, JUNG-JOON SUNG³, JEE-EUN KIM^{4*}</i></p> <p>¹DEPARTMENT OF NEUROLOGY, EWHA WOMANS UNIVERSITY COLLEGE OF MEDICINE, SEOUL, KOREA ²DEPARTMENT OF NEUROLOGY, CHUNG ANG UNIVERSITY, COLLEGE OF MEDICINE, SEOUL, KOREA ³DEPARTMENT OF NEUROLOGY, SEOUL NATIONAL UNIVERSITY, COLLEGE OF MEDICINE, SEOUL, KOREA ⁴DEPARTMENT OF NEUROLOGY, SEOUL MEDICAL CENTER, SEOUL, KOREA</p>
	C-P-CN&I003	<p>FUNCTIONAL AND MICROSTRUCTURAL CHANGES IN APPETITE CONTROL BRAIN REGIONS IN PATIENTS LIVING WITH MND</p> <p><i>¹JERYN, CHANG; ^{2,3}JINGLEI, LV; ^{4,5,6}PAMELA, A MCCOMBE; ^{4,5,6}ROBERT, D HENDERSON; ⁷DIANA, LUCIA; ⁸CHRISTINE, C GUO; ⁹SASKIA, BOLLMANN; ¹⁰KELLY, GARNER; ^{4,5,6,7}SHYUAN, T NGO; ^{1,4,5,6}FREDERIK, J STEYN, ^{4,9,11}THOMAS, B SHAW</i></p> <p>¹SCHOOL OF BIOMEDICAL SCIENCES, FACULTY OF HEALTH, MEDICINE AND BEHAVIOURAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA ²SCHOOL OF BIOMEDICAL ENGINEERING, FACULTY OF ENGINEERING, THE UNIVERSITY OF SYDNEY, AUSTRALIA ³BRAIN AND MIND CENTRE, THE UNIVERSITY OF SYDNEY, AUSTRALIA ⁴DEPARTMENT OF NEUROLOGY, ROYAL BRISBANE AND WOMEN'S HOSPITAL, AUSTRALIA ⁵UQ CENTRE FOR CLINICAL RESEARCH, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA ⁶WESLEY MEDICAL RESEARCH, THE WESLEY HOSPITAL, AUSTRALIA ⁷AUSTRALIAN INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA ⁸ACTIGRAPH, LLC, PENSACOLA, FL, USA ⁹SCHOOL OF INFORMATION TECHNOLOGY AND ELECTRICAL ENGINEERING, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA ¹⁰SCHOOL OF PSYCHOLOGY, UNIVERSITY OF NEW SOUTH WALES, AUSTRALIA ¹¹CENTRE FOR ADVANCED IMAGING AIBN, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA</p>
	C-P-CN&I004	<p>PROPOSED PROTOCOL FOR FASCICULATION DETECTION BY MUSCLE ULTRASOUND IN AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>MINGSHENG LIU, LIYING CUI</i></p> <p>PEKING UNION MEDICAL COLLEGE HOSPITAL</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL NEUROPHYSIOLOGY AND IMAGING	C-P-CN&I005	<p>VARIANCE AND RELIABILITY OF METHODS FOR MEASURING THE CORTICAL SILENT PERIOD IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>^{1,2}KUROIWA R; ²SHIBUYA K; ^{1,2}NARA T; ¹MORITA M; ¹MURATA A; ²KUWABARA S</i></p> <p>¹DEPARTMENT OF REHABILITATION MEDICINE, CHIBA UNIVERSITY HOSPITAL, 1-8-1 INOHANA, CHUO-KU, CHIBA, JAPAN. ²DEPARTMENT OF NEUROLOGY, GRADUATE SCHOOL OF MEDICINE, CHIBA UNIVERSITY, 1-8-1 INOHANA, CHUO-KU, CHIBA, JAPAN</p>
	C-P-CN&I006	<p>AMYOTROPHIC LATERAL SCLEROSIS: ULTRASONOGRAPHIC ASSESSMENT OF TONGUE AND VAGUS NERVE AND CORRELATION WITH SPEECH</p> <p><i>SEENA VENGALIL¹, ARJUN CHANDRASHEKAR¹, YAMINI BK², KARTHIK KULANTHAIVELU³, KEERTHIPRIYA MS¹, SARASWATI NASHI¹, DEEPAK MENON¹, ATCHAYARAM NALINI¹</i></p> <p>¹DEPARTMENT OF NEUROLOGY, NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES, BANGALORE, INDIA-560029 ²DEPARTMENT OF SPEECH PATHOLOGY AND AUDIOLOGY, NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES, BANGALORE, INDIA-560029 ³DEPARTMENT OF NEUROIMAGING AND INTERVENTIONAL RADIOLOGY, NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES, BANGALORE, INDIA-560029</p>
	C-P-CN&I007	<p>ENLARGED PERIVASCULAR SPACES (EPVS) IN AMYOTROPHIC LATERAL SCLEROSIS AND ITS CLINICAL IMPLICATIONS</p> <p><i>^{1,2}HSUEH SJ, ²CHAO CC</i></p> <p>¹DEPARTMENT OF NEUROLOGY, NATIONAL TAIWAN UNIVERSITY HOSPITAL BEI-HU BRANCH, 37 NEIJIANG ST, TAIPEI, TAIWAN ²DEPARTMENT OF NEUROLOGY, NATIONAL TAIWAN UNIVERSITY HOSPITAL, 7 ZHONGSHAN S. RD, TAIPEI, TAIWAN</p>

PACTALS 2025

CLINICAL POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL NEUROPHYSIOLOGY AND IMAGING	C-P-CN&I008	<p>DIFFERENT PATTERNS OF FASCICULATION IN SPINAL AND BULBAR MUSCULAR ATROPHY AND AMYOTROPHIC LATERAL SCLEROSIS: A MUSCLE ULTRASONOGRAPHIC STUDY</p> <p><i>^{1,2}NARA T; ²SHIBUYA K; ³IKEDA S; ^{1,2}KUROIWA R; ²OTANI R; ²OGUSHI M; ²SUICHI T; ^{4,5}SHIKO Y; ⁵TAKAHASHI K; ²MISAWA S; ¹MURATA A; ²KUWABARA S</i></p> <p>¹DEPARTMENT OF REHABILITATION MEDICINE, CHIBA UNIVERSITY HOSPITAL, 1-8-1 INOHANA, CHUO-KU, CHIBA, JAPAN ²DEPARTMENT OF NEUROLOGY, GRADUATE SCHOOL OF MEDICINE, CHIBA UNIVERSITY, 1-8-1 INOHANA, CHUO-KU, CHIBA, JAPAN ³DEPARTMENT OF LABORATORY MEDICINE, CHIBA UNIVERSITY HOSPITAL, 1-8-1 INOHANA, CHUO-KU, CHIBA, JAPAN. ⁴DEPARTMENT OF BIostatISTICS, GRADUATE SCHOOL OF MEDICINE, SAITAMA MEDICAL UNIVERSITY, 38 MOROHONGOU, IRUMAGUN, JAPAN ⁵BIostatISTICS SECTION, CLINICAL RESEARCH CENTER, CHIBA UNIVERSITY HOSPITAL, 1-8-1 INOHANA, CHUO-KU, CHIBA, JAPAN</p>
	C-P-CN&I009	<p>THE ROLE OF THE PERIPHERAL IMMUNE SYSTEM IN MEDIATING AXONAL DYSFUNCTION IN EARLY STAGE AMYOTROPHIC LATERAL SCLEROSIS: AN AGE AND SEX BASED ANALYSIS</p> <p><i>¹WANG ZHUOYA, ¹CAO WEN, ¹CHEN LU, ¹ZHANG SHUO, ¹TANG LU, ¹CUI WENJUAN, ¹KONG MINGJUN, ¹YU LING. ¹FAN DONGSHENG, ¹ZHENG WEI</i></p> <p>¹DEPARTMENT OF NEUROLOGY, PEKING UNIVERSITY THIRD HOSPITAL, BEIJING, CHINA</p>

PACTALS 2025

CLINICAL POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL NEUROPHYSIOLOGY AND IMAGING	C-P-CN&I010	<p>VOXEL MIRRORED HOMOTOPIC CONNECTIVITY IN UPPER MOTOR NEURON DOMINANT AMYOTROPHIC LATERAL SCLEROSIS IS ASSOCIATED WITH DIFFERENT SPREAD DIRECTIONS</p> <p><i>JIEYING WU^{1,5}, YINGSHENG XU¹, TIELUN YIN¹, NAN ZHANG¹, JIANQIAO GE⁴, DONGSHENG FAN^{1,2,3*}, SHAN YE^{1,2,3*}</i></p> <p>¹DEPARTMENT OF NEUROLOGY, PEKING UNIVERSITY THIRD HOSPITAL, BEIJING, CHINA ²BEIJING KEY LABORATORY OF BIOMARKER AND TRANSLATIONAL RESEARCH IN NEURODEGENERATIVE DISEASES, BEIJING, CHINA ³KEY LABORATORY FOR NEUROSCIENCE, NATIONAL HEALTH COMMISSION/MINISTRY OF EDUCATION, PEKING UNIVERSITY, BEIJING, CHINA ⁴CENTER FOR MRI RESEARCH, ACADEMY FOR ADVANCED INTERDISCIPLINARY STUDIES, PEKING UNIVERSITY, BEIJING, CHINA ⁵DEPARTMENT OF NEUROLOGY, XUANWU HOSPITAL OF CAPITAL MEDICAL UNIVERSITY, BEIJING, CHINA *CONTRIBUTE EQUALLY AS A CO-CORRESPONDING AUTHOR</p>
	C-P-CN&I011	<p>UNVEILING STRUCTURAL DAMAGE OF THE CORPUS CALLOSUM IN AMYOTROPHIC LATERAL SCLEROSIS THROUGH DIFFUSION TENSOR IMAGING AND SPREAD DIRECTION PERSPECTIVES</p> <p><i>JIEYING WU, MD^{1,4}, YINGSHENG XU, MD¹, TIELUN YIN, MS¹, NAN ZHANG, BSC¹, DONGSHENG FAN, PHD^{1,2,3*}, SHAN YE, MD^{1,2,3*}</i></p> <p>¹DEPARTMENT OF NEUROLOGY, PEKING UNIVERSITY THIRD HOSPITAL, BEIJING, CHINA ²BEIJING KEY LABORATORY OF BIOMARKER AND TRANSLATIONAL RESEARCH IN NEURODEGENERATIVE DISEASES, BEIJING, CHINA ³KEY LABORATORY FOR NEUROSCIENCE, NATIONAL HEALTH COMMISSION/MINISTRY OF EDUCATION, PEKING UNIVERSITY, BEIJING, CHINA ⁴DEPARTMENT OF NEUROLOGY, XUANWU HOSPITAL OF CAPITAL MEDICAL UNIVERSITY, BEIJING, CHINA *CONTRIBUTE EQUALLY AS A CO-CORRESPONDING AUTHOR</p>

PACTALS 2025

CLINICAL POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL NEUROPHYSIOLOGY AND IMAGING	C-P-CN&I012	<p>THE CONTRALATERAL CO MOVEMENT TEST IN A CHINESE POPULATION WITH AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>JIEYING WUA,^B CAN SUN^A, YINGSHENG XU^A, DONGSHENG FANA,^{C,D,*} SHAN YEA,^{C,D,*}</i></p> <p>^ADEPARTMENT OF NEUROLOGY, PEKING UNIVERSITY THIRD HOSPITAL, BEIJING 100191, CHINA ^BDEPARTMENT OF NEUROLOGY, XUANWU HOSPITAL, CAPITAL MEDICAL UNIVERSITY, BEIJING, 100053, CHINA ^CBEIJING KEY LABORATORY OF BIOMARKER AND TRANSLATIONAL RESEARCH IN NEURODEGENERATIVE DISEASES, BEIJING 100191, CHINA ^DKEY LABORATORY FOR NEUROSCIENCE, NATIONAL HEALTH COMMISSION/MINISTRY OF EDUCATION, PEKING UNIVERSITY, BEIJING 100091, CHINA *CONTRIBUTED EQUALLY AS A CO-CORRESPONDING AUTHOR</p>
	C-P-CN&I013	<p>CORNEAL CONFOCAL MICROSCOPY CHANGES PREDICT DISEASE PROGRESSION OF ALS</p> <p><i>¹ZOU, ZHANGYU; ¹WEN, YUNQIN; ¹CHEN, SHENG; ¹LIU, CHANGYUN</i></p> <p>¹DEPARTMENT OF NEUROLOGY, FUJIAN MEDICAL UNIVERSITY UNION HOSPITAL, NO. 29, XINQUAN ROAD, FUZHOU, CHINA</p>
CLINICAL TRIAL AND PLATFORMS	C-P-CT&P001	<p>QRL 101 – PHASE 1 STUDIES EVALUATING SAFETY AND PHARMACODYNAMICS OF A KCNQ2/3 MODULATOR IN HEALTHY VOLUNTEERS & NEXT STEPS FOR DEVELOPMENT IN ALS</p> <p><i>ANGELA GENGE¹, THOMAS S BOWMAN¹, HANNAH KANEB¹, SAMANTHA RUBINO¹, TAYLOR GRAY ¹, SHARON LU¹, AMIT JAIN¹, GUZIDE ADHIKARI¹, SANDY HINCKLEY¹, DANIEL ELBAUM¹, EMMA BOWDEN¹</i></p> <p>¹QURALIS, CAMBRIDGE MASSACHUSETTS, UNITED STATES</p>

PACTALS 2025

CLINICAL POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL TRIAL AND PLATFORMS	C-P-CT&P002	<p>PACTALS CLINICAL TRIAL READINESS – A SURVEY ON THE CURRENT STATE OF PLAY IN MEMBER COUNTRIES</p> <p><i>¹FUNG WY, ²AGUSTINI S, ³NALINI A, ⁴OHNMAR O, ⁵FAN DS, ⁶HOANG NTT, ⁷HU CJ, ⁸KANO O, ⁹KULKANTRAKORN K, ¹⁰NG K, ¹¹PRADO M, ¹²REMLI R, ¹³SON BG, ¹⁴SUNG JJ, ¹⁵VUCIC S, ¹⁶NGO S, ¹⁷TALMAN P, ¹⁸KIERNAN M, ¹³KIM SH, ¹⁹SOBUE G, ²⁰SHAHRIZAILA N ON BEHALF OF PACTALS</i></p> <p>¹PACTALS, ²DEPARTMENT OF NEUROLOGY, MAYAPADA HOSPITAL, INDONESIA, ³NATIONAL INSTITUTE OF MENTAL HEALTH AND NEURO SCIENCE, ⁴YANGON GENERAL HOSPITAL, ⁵PEKING UNIVERSITY THIRD HOSPITAL, ⁶DEPARTMENT OF NEUROLOGY, MILITARY HOSPITAL 175, ⁷TAIPEI MEDICAL UNIVERSITY, ⁸TOHO UNIVERSITY, ⁹THAMMASAT UNIVERSITY, ¹⁰NATIONAL UNIVERSITY HOSPITAL, SINGAPORE, ¹¹COLLEGE OF MEDICINE, UNIVERSITY OF THE PHILIPPINES MANILA, ¹²UNIVERSITI KEBANGSAAN MALAYSIA, ¹³HANYANG UNIVERSITY HOSPITAL, ¹⁴SEOUL NATIONAL UNIVERSITY HOSPITAL, ¹⁵UNIVERSITY OF SYDNEY, ¹⁶UNIVERSITY OF QUEENSLAND, ¹⁷DEAKIN UNIVERSITY, ¹⁸NEUROSCIENCE RESEARCH AUSTRALIA, ¹⁹AICHI MEDICAL UNIVERSITY, ²⁰UNIVERSITI MALAYA</p>
	C-P-CT&P003	<p>CLINICAL TRIAL INVOLVEMENT AS A POTENTIAL SURVIVAL MODIFIER IN MOTOR NEURONE DISEASE</p> <p><i>HANNAH C. TIMMINS¹, SRESTHA MAZUMDER¹, DAYNA-LEE TALBOT¹, PARIS M. MURPHY¹, JASMINE F. ASHHURST¹, ELEANOR RAMSEY¹, MATTHEW C. KIERNAN</i></p> <p>¹NEUROSCIENCE RESEARCH AUSTRALIA, SYDNEY, AUSTRALIA ²UNIVERSITY OF NEW SOUTH WALES, SYDNEY, AUSTRALIA</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL TRIAL AND PLATFORMS	C-P-CT&P004	<p>TETRAMETHYLPYRAZINE NITRONE IN AMYOTROPHIC LATERAL SCLEROSIS: A RANDOMIZED CLINICAL TRIAL</p> <p>XIAOLU LIU, MD^{1,2,3}; HUIFANG SHANG, MD⁴; QIANQIAN WEI, MD⁴; XIAOLI YAO, MD, PHD⁵; LING LIAN, MD⁵; JINGXIA DANG, MD⁶; RUI JIA, MD⁶; ZHIYING WU, MD, PHD⁷; HONGFU LI, MD, PHD⁷; QI NIU, MD⁸; XI CHENG, MD⁸; ZHANGYU ZOU, MD, PHD⁹; SHENG CHEN, MD, PHD⁹; MIN ZHANG, MD, PHD¹⁰; YANG LIU, MD, PHD¹⁰; YALING LIU, MD¹¹; QI LIU, MD¹¹; XUSHENG HUANG, MD, PHD¹²; HONGFEN WANG, MD¹²; HONGLIN FENG, MD¹³; SHUYU WANG, MD¹³; DONGSHENG FAN, MD, PHD^{1,2,3}</p> <p>¹DEPARTMENT OF NEUROLOGY, PEKING UNIVERSITY THIRD HOSPITAL, BEIJING, CHINA; ²BEIJING KEY LABORATORY OF BIOMARKER AND TRANSLATIONAL RESEARCH IN NEURODEGENERATIVE DISEASES, BEIJING, CHINA; ³KEY LABORATORY FOR NEUROSCIENCE, NATIONAL HEALTH COMMISSION/MINISTRY OF EDUCATION, PEKING UNIVERSITY, BEIJING, CHINA; ⁴DEPARTMENT OF NEUROLOGY, WEST CHINA HOSPITAL, SICHUAN UNIVERSITY, SICHUAN, CHINA; ⁵DEPARTMENT OF NEUROLOGY, THE FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY, GUANGZHOU, CHINA; ⁶DEPARTMENT OF NEUROLOGY, THE FIRST AFFILIATED HOSPITAL OF XI'AN JIAOTONG UNIVERSITY, XI'AN, CHINA; ⁷DEPARTMENT OF NEUROLOGY, THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE, HANGZHOU, CHINA; ⁸DEPARTMENT OF NEUROLOGY, JIANGSU PROVINCE HOSPITAL, NANJING, CHINA; ⁹DEPARTMENT OF NEUROLOGY, FUJIAN MEDICAL UNIVERSITY UNION HOSPITAL, FUZHOU, CHINA; ¹⁰DEPARTMENT OF NEUROLOGY, TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE OF HUST, WUHAN, CHINA; ¹¹DEPARTMENT OF NEUROLOGY, THE SECOND HOSPITAL OF HEBEI MEDICAL UNIVERSITY, SHIJIAZHUANG, CHINA; ¹²DEPARTMENT OF NEUROLOGY, CHINESE PLA GENERAL HOSPITAL, BEIJING, CHINA; ¹³DEPARTMENT OF NEUROLOGY, THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY, HARBIN, CHINA</p>

PACTALS 2025

CLINICAL POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL TRIAL AND PLATFORMS	C-P-CT&P005	<p>TASKFORCE LED GLOBAL EFFORT: OPTIMIZING ALS/MND CLINICAL TRIAL ENDPOINTS</p> <p><i>¹DE MAJO MARTINA, ²VAN DAMME PHILIP, ³DAVE KULDIP, ⁴VAN EIJK RUBEN, ⁵SHEEAN BEC, ⁶FOURNIER CHRISTINA NICOLE, ¹KAYA ALPER, ¹ROBINSON MICHAEL, ¹OCAMPO FELIPE, ⁷GENGE ANGELA, ¹GREEN PHIL, ¹CUMMINGS CATHY</i></p> <p>¹INTERNATIONAL ALLIANCE OF ALS/MND ASSOCIATION, FRANCIS CRICK HOUSE, 6 SUMMERHOUSE ROAD, MOULTON PARK, NORTHAMPTON NN3 6BJ. UK. ²EXPERIMENTAL NEUROLOGY AND LEUVEN INSTITUTE FOR NEURODEGENERATIVE DISORDERS (LIND), UNIVERSITY OF LEUVEN, LEUVEN, BELGIUM. ³THE ALS ASSOCIATION, ARLINGTON, VA, USA. ⁴DEPARTMENT OF NEUROLOGY, BRAIN CENTER RUDOLF MAGNUS, UNIVERSITY MEDICAL CENTER UTRECHT, UTRECHT, THE NETHERLANDS. ⁵FIGHTMND, MELBOURNE, AUSTRALIA. ⁶DEPARTMENT OF NEUROLOGY, EMORY UNIVERSITY, ATLANTA, GA, USA. ⁷CLINICAL RESEARCH AND ALS CLINIC, MONTREAL NEUROLOGICAL INSTITUTE AND HOSPITAL, MONTREAL, CANADA</p>
	C-P-CT&P006	<p>EVALUATION OF NUN 004, A NOVEL ENGINEERED EPHRIN ANTAGONIST, IN HEALTHY VOLUNTEERS AND PATIENTS WITH ALS: A PHASE I/IB, OPEN LABEL, ESCALATING DOSE AND EXTENDED ACCESS STUDY</p> <p><i>MICHAEL GEROMETTA¹ · ROBERT D. HENDERSON² · RICHARD FRIEND³ · LEANNE T. COOPER¹ · JING ZHAO¹ · ANDREW W. BOYD⁴ · PERRY F. BARTLETT¹</i></p> <p>¹QUEENSLAND BRAIN INSTITUTE, UNIVERSITY OF QUEENSLAND, ST LUCIA, BRISBANE, QLD 4072, AUSTRALIA ²UQ CENTRE FOR CLINICAL RESEARCH, ROYAL BRISBANE AND WOMEN'S HOSPITAL CAMPUS, HERSTON, QLD 4029, AUSTRALIA ³NUCLEUS NETWORK, CLIVE BERGHOFER CANCER RESEARCH CENTRE, HERSTON, QLD 4006, AUSTRALIA ⁴SCHOOL OF MEDICINE, UNIVERSITY OF QUEENSLAND, ST LUCIA, BRISBANE, QLD 4072, AUSTRALIA</p>
	C-P-CT&P007	<p>THE IMPACT OF DIAGNOSTIC DELAYS ON CLINICAL TRIAL ELIGIBILITY IN AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>PARIS M. MURPHY¹, HANNAH C. TIMMINS¹, SRESTHA MAZUMDER¹, DAYNA-LEE TALBOT¹, JASMINE F. ASHHURST¹, ELEANOR RAMSEY¹, MATTHEW C. KIERNAN^{1,2}</i></p> <p>¹NEUROSCIENCE RESEARCH AUSTRALIA, SYDNEY, AUSTRALIA, ²UNIVERSITY OF NEW SOUTH WALES, SYDNEY, AUSTRALIA</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL TRIAL AND PLATFORMS	C-P-CT&P008	<p>INVESTIGATION OF THE EFFECT OF TOFERSEN IN A JAPANESE FAMILIAL ALS PATIENT WITH SOD1 MUTATION</p> <p><i>^{1,2}NAGANO S; ¹NAGASHIMA N; ¹FUJIOKA T; ¹KIHARA K; ¹OGAWA K; ¹OKUNO T; ¹MOCHIZUKI H</i></p> <p>¹DEPARTMENT OF NEUROLOGY, GRADUATE SCHOOL OF MEDICINE, OSAKA UNIVERSITY, 2-2 YAMADAOKA, SUITA, OSAKA, JAPAN, ²DEPARTMENT OF NEURO-DEVELOPMENTAL AND -DEGENERATIVE DISEASE RESEARCH, UNITED GRADUATE SCHOOL OF CHILD DEVELOPMENT, OSAKA UNIVERSITY, 2-2 YAMADAOKA, SUITA, OSAKA, JAPAN</p>
	C-P-CT&P009	<p>FINAL RESULTS FROM THE PHASE 3 VALOR TRIAL AND OPEN LABEL EXTENSION EVALUATING EFFICACY AND SAFETY OF TOFERSEN IN ADULTS WITH SOD1 ALS</p> <p><i>¹MILLER, TM; ^{2,3}SOBUE G; ⁴CUDKOWICZ ME; ^{5,6}SHAW PJ; ⁷GENGE A; ⁸GRAHAM D; ⁸SUN P; ⁹MCNEILL M; ⁸MALEK S; ⁸INRA J; ⁸GARAFALO S; ⁸FRADETTE S, ON BEHALF OF THE VALOR AND OLE WORKING GROUP</i></p> <p>¹DEPARTMENT OF NEUROLOGY, NEUROMUSCULAR MEDICINE, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE, SAINT LOUIS, MO, USA; ²DEPARTMENT OF NEUROLOGY, NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE, NAGOYA, JAPAN; ³AICHI MEDICAL UNIVERSITY, AICHI, JAPAN; ⁴DEPARTMENT OF NEUROLOGY, MASSACHUSETTS GENERAL HOSPITAL, HARVARD MEDICAL SCHOOL, BOSTON, MA, USA; ⁵SHEFFIELD INSTITUTE FOR TRANSLATIONAL NEUROSCIENCE, UNIVERSITY OF SHEFFIELD, SHEFFIELD, UK; ⁶NATIONAL INSTITUTE FOR HEALTH AND CARE RESEARCH (NIHR) SHEFFIELD BIOMEDICAL RESEARCH CENTRE AND NIHR CLINICAL RESEARCH FACILITY, UNIVERSITY OF SHEFFIELD AND SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST, SHEFFIELD, UK; ⁷DEPARTMENT OF NEUROLOGY AND NEUROSURGERY, FACULTY OF MEDICINE AND HEALTH SCIENCES, MCGILL UNIVERSITY, MONTREAL, CANADA; ⁸BIOGEN, CAMBRIDGE, MA, USA; ⁹BIOGEN, MAIDENHEAD, UK</p>

PACTALS 2025

CLINICAL POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
CLINICAL TRIAL AND PLATFORMS	C-P-CT&P010	<p>FIRST IN HUMAN STUDY DESIGN TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ASCENDING DOSES OF ALN SOD IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS AND SOD1 VARIANTS</p> <p><i>¹LEE, YI-CHUNG; ²LEVY, OREN; ²PHAM, LY; ²MILLER, JUTTA; ³SOSTELLY, ALEXANDRE; ²BANERJEE, POULABI; ²TONG, ZHENTAO; ²ROSARIO, MARIA; ²MAHMOOD, ADNAN; ²HARARI, OLIVIER</i></p> <p>¹TAIPEI VETERANS GENERAL HOSPITAL, TAIPEI CITY, TAIWAN, ²REGENERON PHARMACEUTICALS, INC., TARRYTOWN, NY, USA, ³ALNYLAM PHARMACEUTICALS, CAMBRIDGE, MA, USA.</p>
DISEASE SPECTRUM/ STRATIFICATION	C-P-DS/S001	<p>PROGNOSTIC FACTORS IN PATIENTS WITH MOTOR NEURON DISEASE: A SINGLE CENTRE STUDY</p> <p><i>MEI LIAN GOH¹, SU RONG FAM¹, SI YAN LEO¹, CARLYNE LI³, IAN XU⁴, MAVIS ANG², JOSIAH CHAI²</i></p> <p>¹DEPARTMENT OF NURSING, NATIONAL NEUROSCIENCE INSTITUTE, SINGAPORE. ²DEPARTMENT OF NEUROLOGY, NATIONAL NEUROSCIENCE INSTITUTE, SINGAPORE. ³LEE KONG CHIAN SCHOOL OF MEDICINE, NATIONAL TECHNOLOGICAL UNIVERSITY, SINGAPORE. ⁴DUKE-NUS MEDICAL SCHOOL, SINGAPORE</p>
	C-P-DS/S002	<p>ALS WITH AND WITHOUT UPPER MOTOR NEURON SIGNS: A COMPARATIVE STUDY SUPPORTING THE GOLD COAST CRITERIA</p> <p><i>^{††}HEE-JAE JUNG, ^{2†}E-NAE CHEONG, ^{1,3}JUNGMIN SO, ²YANGSEAN CHOI, ¹EUN-JAE LEE, ¹HYUNJIN KIM, ¹YOUNG-MIN LIM</i></p> <p>¹DEPARTMENT OF NEUROLOGY, ASAN MEDICAL CENTER, UNIVERSITY OF ULSAN, COLLEGE OF MEDICINE, SEOUL, REPUBLIC OF KOREA ²DEPARTMENT OF RADIOLOGY AND RESEARCH INSTITUTE OF RADIOLOGY, ASAN MEDICAL CENTER, UNIVERSITY OF ULSAN COLLEGE OF MEDICINE, SEOUL, REPUBLIC OF KOREA ³DEPARTMENT OF NEUROLOGY, KOREA UNIVERSITY ANSAN HOSPITAL, ANSAN, REPUBLIC OF KOREA [†]THESE AUTHORS CONTRIBUTED EQUALLY TO THIS WORK</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
DISEASE SPECTRUM/ STRATIFICATION	C-P-DS/S003	<p>MONOCLONAL GAMMOPATHY IN AMYOTROPHIC LATERAL SCLEROSIS: NO IMPACT ON CLINICAL PROGRESSION AND IMMUNOTHERAPY OUTCOMES</p> <p><i>HYUNKEE KIMA^B, JI-EUN UHM^C, JINSEOK PARK^B, YOUNG SUNG KIM^{A,B}, WONJAE SUNG^{A,B}, SANGGON LEED, SEUNG HYUN KIM^{A,B}, KI-WOOK OH^{A,B}</i></p> <p>^ADEPARTMENT OF NEUROLOGY, HANYANG UNIVERSITY COLLEGE OF MEDICINE, SEOUL, REPUBLIC OF KOREA. ^BCELL THERAPY CENTRE, HANYANG UNIVERSITY HOSPITAL, SEOUL, REPUBLIC OF KOREA ^CDIVISION OF HEMATOLOGY-ONCOLOGY, DEPARTMENT OF INTERNAL MEDICINE, HANYANG UNIVERSITY COLLEGE OF MEDICINE, HANYANG UNIVERSITY SEOUL HOSPITAL, SEOUL 04763, KOREA ^DDEPARTMENT OF NEUROLOGY, CHUNG-ANG UNIVERSITY GWANGMYEONG HOSPITAL, 110 DEOKAN-RO, GWANGMYEONG 14353, KOREA</p>
	C-P-DS/S004	<p>OVERVIEW OF ADULT SPINAL MUSCULAR ATROPHY (SMA) PATIENTS IN A TERTIARY NEUROSCIENCE CENTRE IN SINGAPORE</p> <p><i>SI YAN LEO¹, SU RONG FAM¹, MEI LIAN GOH¹, RACHEL YZELMAN², HUI XIN HUANG³, XING TONG YONG⁴, MAVIS ANG⁵, JOSIAH CHAI⁵</i></p> <p>¹DEPARTMENT OF NURSING, NATIONAL NEUROSCIENCE INSTITUTE, SINGAPORE. ²DEPARTMENT OF PHYSIOTHERAPY, TAN TOCK SENG HOSPITAL, SINGAPORE. ³DEPARTMENT OF OCCUPATIONAL THERAPIST, TAN TOCK SENG HOSPITAL, SINGAPORE ⁴DEPARTMENT OF SPEECH THERAPIST, TAN TOCK SENG HOSPITAL, SINGAPORE ⁵DEPARTMENT OF NEUROLOGY, NATIONAL NEUROSCIENCE INSTITUTE, SINGAPORE</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
DISEASE SPECTRUM/ STRATIFICATION	C-P-DS/S005	<p>TARGET ALS GLOBAL RESEARCH INITIATIVE (AGRI)</p> <p>AMY EASTON¹, LAURA DUGOM¹, JUDITH CHAVIRA², LIZZI NEYLON¹⁰, KAYCIE OPIYO³, MICHAEL WEISS³, ARLEEN MATOS⁴, SENDA AJROUD-DRISS⁴, JINGQI ZHU⁵, JAMES BERRY⁵, HUY TRAN⁶, BJORN OSKARSSON⁶, NATHAN BUDDEN⁷, CINDY LY⁷, GILBERT GUTIERREZ⁸, JOHN RAVITS⁸, BENJAMIN HOOVER⁹, SARAH GRIFFEN⁹, MATTHEW HARMS⁹, NEIL SHNEIDER⁹, WHITNEY DAILEY¹⁰, SHAFEEQ LADHA¹⁰, CASSANDRA HOLMES¹¹, NICHOLAS STREICHER¹¹, BRENT HARRIS¹¹, SARAH BERTH¹², FRANCES APONTE¹³, BRENDA DELIZ¹³, VALERIE WOJNA¹³, MANUELA QUIROGA CARILLO¹⁴, MARTHA PEÑA¹⁴, MARC GOTKINE¹⁵, NORTINASHAHRIZAILA¹⁶, VISHNU V VENUGOPALAN¹⁷, NALINI ATCHAYARAM¹⁸, SEOK-JIN CHOI¹⁹, JEANNINE HECKMAN²⁰, MARCONDES C FRANCA²¹, MANISH RAISINGHANI¹, ROBERT BOWSER^{2, 10}</p> <p>¹TARGET ALS, NEW YORK, NEW YORK, USA. ²DEPARTMENT OF TRANSLATIONAL NEUROSCIENCE, BARROW NEUROLOGICAL INSTITUTE, PHOENIX, AZ, USA. ³DEPARTMENT OF NEUROLOGY, UNIVERSITY OF WASHINGTON, WA, USA. ⁴DEPARTMENT OF NEUROLOGY, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA. ⁵DEPARTMENT OF NEUROLOGY, MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MA, USA. ⁶DEPARTMENT OF NEUROLOGY, MAYO CLINIC JACKSONVILLE, JACKSONVILLE, FL, USA. ⁷DEPARTMENT OF NEUROLOGY, WASHINGTON UNIVERSITY ST. LOUIS, ST. LOUIS, MO. USA. ⁸DEPARTMENT OF NEUROSCIENCES, UNIVERSITY OF CALIFORNIA, SAN DIEGO, SAN DIEGO, CA, USA. ⁹DEPARTMENT OF NEUROLOGY, COLUMBIA UNIVERSITY MEDICAL CENTER, NEW YORK NY, USA. ¹⁰DEPARTMENT OF NEUROLOGY, BARROW NEUROLOGICAL INSTITUTE, PHOENIX, AZ, USA. ¹¹DEPARTMENT OF NEUROLOGY AND PATHOLOGY, GEORGETOWN UNIVERSITY, WASHINGTON, DC, USA. 12 BAYLOR ¹²COLLEGE OF MEDICINE, WACO, TX, USA. ¹³UNIVERSITY OF PUERTO RICO, SAN JUAN, PUERTO RICO. ¹⁴INSTITUTO ROOSEVELT, BOGOTÁ, COLOMBIA. ¹⁵HEBREW UNIVERSITY, JERUSALEM, ISRAEL. ¹⁶UNIVERSITY OF MALAYA MEDICAL CENTRE (UMMC), KUALA LUMPUR, MALAYSIA ¹⁷ALL INDIA INSTITUTE OF MEDICAL SCIENCES (AIIMS), NEW DELHI, INDIA ¹⁸NATIONAL INSTITUTE OF MENTAL HEALTH AND NEURO SCIENCES (NIMHANS), BENGALURU, INDIA ¹⁹EOUL NATIONAL UNIVERSITY HOSPITAL, SEOUL, SOUTH KOREA ²⁰UNIVERSITY OF CAPE TOWN, SOUTH AFRICA ²¹UNIVERSITY OF CAMPINAS, CAMPINAS, BRAZIL</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
DISEASE SPECTRUM/ STRATIFICATION	C-P-DS/S006	<p>MINDAUS REGISTRY: A PATIENT DATA PLATFORM SUPPORTING MOTOR NEURONE DISEASE CLINICAL CARE, POLICY DEVELOPMENT AND RESEARCH</p> <p><i>STEVE VUCIC¹, MATTHEW KIERNAN^{1,2}, SUSAN MATHERS³, LAURA PERJU-DUMBRAVA³, DAVID SCHULTZ⁴, ANTONY WINKEL⁵, ROBERT HENDERSON⁶, MERRILEE NEEDHAM⁷, JESSIE CHEN⁸, LAUREN GILES⁹, TOM JENKINS¹⁰, DEV NATHAN⁷, MATTHEW BELLGARD^{12,13}, SAMAR AOUN⁷, ANNE HOGDEN¹⁴, KEITH MALPRESS¹⁴, GEOFFREY THOMAS¹⁴, GETHIN THOMAS¹⁴, CLARE SULLIVAN¹⁴, CATHERINE HANSEN¹⁵, KATRINA SANGSTER¹⁶, LURA ZISER¹⁹ ARABELLE DOUGLAS^{3,18}, PAUL TALMAN^{16,18}</i></p> <p>¹UNIVERSITY OF SYDNEY, NSW ²NEUROSCIENCE RESEARCH AUSTRALIA, NSW ³CALVARY HEALTH CARE BETHLEHEM, VIC ⁴FLINDERS MEDICAL CENTRE, SA ⁵SUNSHINE COAST UNIVERSITY HOSPITAL, NSW ⁶ROYAL BRISBANE AND WOMEN'S HOSPITAL, QLD ⁷UNIVERSITY OF WESTERN AUSTRALIA, WA ⁸LAUNCESTON GENERAL HOSPITAL, TAS ⁹FLINDERS MEDICAL CENTRE, SA ¹⁰NORTHERN HEALTH, VIC ¹¹ST JOHN OF GOD, WA ¹²UNIVERSITY OF EAST LONDON, UK ¹³QUEENSLAND UNIVERSITY OF TECHNOLOGY, QLD ¹⁴UNIVERSITY OF NEW SOUTH WALES, NSW ¹⁵MND AUSTRALIA, ACT ¹⁶DEAKIN UNIVERSITY, VIC ¹⁷MND AUSTRALIA, ACT ¹⁸BARWON HEALTH, VIC ¹⁹UNIVERSITY OF QUEENSLAND, QLD</p>
	C-P-DS/S007	<p>DETECTION OF CONDUCTION BLOCK MAY HELP DIFFERENTIATING MULTIFOCAL MOTOR NEUROPATHY FROM EARLY STAGE UPPER LIMB ONSET AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>¹SHIH-YU, FANG; ^{1,2,3}YI-CHUNG LEE</i></p> <p>¹DEPARTMENT OF NEUROLOGY, TAIPEI VETERANS GENERAL HOSPITAL, TAIPEI, TAIWAN, ²DEPARTMENT OF NEUROLOGY, NATIONAL YANG MING CHIAO TUNG UNIVERSITY SCHOOL OF MEDICINE, TAIPEI, TAIWAN, ³BRAIN RESEARCH CENTER, NATIONAL YANG MING CHIAO TUNG UNIVERSITY, TAIPEI, TAIWAN</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
DISEASE SPECTRUM/ STRATIFICATION	C-P-DS/S008	<p>METALS: A STUDY TO INVESTIGATE THE ROLE OF METABOLIC PARAMETERS AND BODY COMPOSITION ON DISEASE PHENOTYPE AND PROGRESSION IN AMYOTROPHIC LATERAL SCLEROSIS (ALS)</p> <p><i>¹CHIWERER THERESA; ²NGO S; ¹AL-CHALABI A</i></p> <p>¹DEPARTMENT OF BASIC AND CLINICAL NEUROSCIENCE, KING'S COLLEGE LONDON, MAURICE WOHL CLINICAL NEUROSCIENCE INSTITUTE, LONDON, UNITED KINGDOM, ²DEPARTMENT OF BIOMEDICAL SCIENCES, AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, UNIVERSITY OF QUEENSLAND, BRISBANE, AUSTRALIA</p>
	C-P-DS/S009	<p>THE CLINICAL AND PARACLINICAL CHARACTERISTICS OF SPINAL AND BULBAR MUSCULAR ATROPHY AT THE UNIVERSITY MEDICAL CENTER OF HO CHI MINH CITY, VIETNAM</p> <p><i>VU THI THUY</i></p> <p>DEPARTMENT OF NEUROLOGY, UNIVERSITY MEDICAL CENTER OF HO CHI MINH CITY, 215 HONG BANG STREET, WARD 11, DISTRICT 5, HO CHI MINH CITY, VIETNAM</p>
	C-P-DS/S010	<p>CLUSTERING OF LONGITUDINAL AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE REVISED (ALSFRS R) SCORES IN KOREAN ALS POPULATION</p> <p><i>¹YONG SUNG KIM, ¹HYUNKEE KIM, ¹WONJAE SUNG, ¹JINSEOK PARK; ²BUGYEONG SON; ³KYONG JIN SHIN; ¹KI-WOOK OH, ¹SEUNG HYUN KIM</i></p> <p>¹DEPARTMENT OF NEUROLOGY, HANYANG UNIVERSITY HOSPITAL, COLLEGE OF MEDICINE, HANYANG UNIVERSITY, SEOUL, REPUBLIC OF KOREA, ²CELL THERAPY CENTER, DEPARTMENT OF NEUROLOGY, HANYANG UNIVERSITY SEOUL HOSPITAL, SEOUL, REPUBLIC OF KOREA, ³DEPARTMENT OF NEUROLOGY, HAEUNDAE-PAIK HOSPITAL, INJE UNIVERSITY, REPUBLIC OF KOREA</p>
EPIDEMIOLOGY	C-P-E001	<p>ALS VARIANTS OF ALS IN KOREAN POPULATION</p> <p><i>HYUNKEE KIM^{A,B}, BYUNG WOO CHOI^A, HYE SUN LEE^C, JINSEOK PARK^{A,B}, YOUNG SUNG KIM^{A,B}, WONJAE SUNG^{A,B}, SEUNG HYUN KIM^{A,B}, KI-WOOK OHA^B</i></p> <p>^ADEPARTMENT OF NEUROLOGY, HANYANG UNIVERSITY COLLEGE OF MEDICINE, SEOUL, REPUBLIC OF KOREA. ^BCELL THERAPY CENTRE, HANYANG UNIVERSITY HOSPITAL, SEOUL, REPUBLIC OF KOREA ^CDEPARTMENT OF NEUROLOGY, ASAN MEDICAL CENTER, SEOUL, REPUBLIC OF KOREA</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
EPIDEMIOLOGY	C-P-E002	<p>FROM ENVIRONMENT TO SYMPTOMS: MAPPING PREMORBID RISK FACTORS ONTO AMYOTROPHIC LATERAL SCLEROSIS CLINICAL FEATURES IN A LARGE PATIENT REPORTED DATABASE IN CHINA</p> <p><i>¹XINYU LI; ²QIANRUI CHEN; ³DONGSHENG FAN, ³LU CHEN</i></p> <p>¹PEKING UNIVERSITY HEALTH SCIENCE CENTER, PEKING UNIVERSITY, BEIJING, CHINA ²SCHOOL OF HEALTH HUMANITIES, PEKING UNIVERSITY, BEIJING, CHINA ³DEPARTMENT OF NEUROLOGY, PEKING UNIVERSITY THIRD HOSPITAL, BEIJING, CHINA</p>
	C-P-E003	<p>CURRENT BURDEN OF MOTOR NEURON DISEASES IN CHINA AND PREDICTION OF FUTURE TRENDS</p> <p><i>^{1,2,3}ZHAO, CHEN; ^{4,5}GÀO, XĪN; ^{4,5}LIU, ZHIKE; ^{1,2,3}FAN, DONGSHENG</i></p> <p>¹DEPARTMENT OF NEUROLOGY, PEKING UNIVERSITY THIRD HOSPITAL, BEIJING, CHINA ²BEIJING KEY LABORATORY OF BIOMARKER AND TRANSLATIONAL RESEARCH IN NEURODEGENERATIVE DISEASES, BEIJING, CHINA ³KEY LABORATORY FOR NEUROSCIENCE, NATIONAL HEALTH COMMISSION/MINISTRY OF EDUCATION, PEKING UNIVERSITY, BEIJING, CHINA ⁴DEPARTMENT OF EPIDEMIOLOGY AND BIOSTATISTICS, SCHOOL OF PUBLIC HEALTH, PEKING UNIVERSITY, BEIJING, CHINA ⁵KEY LABORATORY OF EPIDEMIOLOGY OF MAJOR DISEASES, PEKING UNIVERSITY, MINISTRY OF EDUCATION, BEIJING, CHINA</p>
GENOMICS	C-P-G001	<p>CLINICAL IMPLICATIONS OF VARIANTS OF UNCERTAIN SIGNIFICANCE IDENTIFIED BY MULTI GENE PANEL IN KOREAN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS</p> <p><i>^{1, 2}JIN-AH KIM; ^{1, 3}JUNG-JOON SUNG; ^{1, 4}YOON-HO HONG</i></p> <p>¹DEPARTMENT OF TRANSLATIONAL MEDICINE, SEOUL NATIONAL UNIVERSITY COLLEGE OF MEDICINE, SEOUL, REPUBLIC OF KOREA ²GENOMIC MEDICINE INSTITUTE, MEDICAL RESEARCH CENTER, SEOUL NATIONAL UNIVERSITY, SEOUL, REPUBLIC OF KOREA ³DEPARTMENT OF NEUROLOGY, SEOUL NATIONAL UNIVERSITY HOSPITAL, SEOUL, REPUBLIC OF KOREA ⁴DEPARTMENT OF NEUROLOGY, SEOUL NATIONAL UNIVERSITY SEOUL METROPOLITAN GOVERNMENT BORAMAE MEDICAL CENTER, 20 BORAMAERO-5-GIL, SEOUL, REPUBLIC OF KOREA</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
GENOMICS	C-P-G002	<p>TARDBP VARIANTS IN TAIWANESE ALS PATIENTS: GENETIC SPECTRUM, CLINICAL FEATURES, AND FOUNDER EFFECTS</p> <p><i>^{1,2,3} KANG-YANG JIH, ^{1,2}SHIH-YU FANG, ^{1,2}YI-CHUNG LEE</i></p> <p>¹DEPARTMENT OF NEUROLOGY, TAIPEI VETERANS GENERAL HOSPITAL, TAIPEI, TAIWAN ²DEPARTMENT OF NEUROLOGY, NATIONAL YANG MING CHIAO TUNG UNIVERSITY SCHOOL OF MEDICINE, TAIPEI, TAIWAN ³DEPARTMENT OF PHYSIOLOGY, NATIONAL YANG MING CHIAO TUNG UNIVERSITY SCHOOL OF MEDICINE, TAIPEI, TAIWAN</p>
	C-P-G003	<p>SOD1: MUTATION SPECTRUM, GENOTYPE PHENOTYPE CORRELATIONS AND DISEASE OUTCOME IN AN INDIAN ALS COHORT</p> <p><i>¹MUDDASU KEERTHIPRIYA, ¹ANANTHAPADMANABHA KOTAMBAIL, ²GAUTHAM ARUNACHAL, ³PRIYA TREESA THOMAS, ¹SARASWATI NASHI, ¹SEENA VENGALIL, ¹NALINI A</i></p> <p>¹DEPARTMENT OF NEUROLOGY, NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES, STREET HOSUR ROAD, BENGALURU, INDIA. ²DEPARTMENT OF HUMAN GENETICS, NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES, STREET HOSUR ROAD, BENGALURU, INDIA. ³DEPARTMENT OF PSYCHIATRIC SOCIAL WORK, NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES, STREET HOSUR ROAD, BENGALURU, INDIA</p>
	C-P-G004	<p>FUNCTIONAL VERIFICATION AND CLINICAL PHENOTYPES OF AMYOTROPHIC LATERAL SCLEROSIS WITH NOVEL MUTATIONS OF VAPB GENE</p> <p><i>¹QI, YIXIN; ¹CHEN, JIANMIN; ¹CHEN, SHENG; ¹LU, YINGQIAN; ¹LIU, CHANGYUN; ^{1*}ZOU ZHANGYU</i></p> <p>¹DEPARTMENT OF NEUROLOGY, FUJIAN MEDICAL UNIVERSITY UNION HOSPITAL, NO. 29, XINQUAN ROAD, FUZHOU, CHINA</p>
	C-P-G005	<p>GENETIC SPECTRUM OF KOREAN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>YOUNG-EUN KIM^A, WONJAE SUNG^B, JONG EUN PARK^C, KI-WOOK OH^{B,D}, JINSEOK PARK^{B,D}, SEUNG HYUN KIM^{B,D}</i></p> <p>^ADEPARTMENT OF LABORATORY MEDICINE, HANYANG UNIVERSITY COLLEGE OF MEDICINE, SEOUL, KOREA ^BDEPARTMENT OF NEUROLOGY, HANYANG UNIVERSITY COLLEGE OF MEDICINE, SEOUL, KOREA ^CDEPARTMENTS OF LABORATORY MEDICINE, HANYANG UNIVERSITY MEDICAL CENTER, GURI HOSPITAL, GURI, KOREA ^DCELL THERAPY CENTER, HANYANG UNIVERSITY HOSPITAL, SEOUL, KOREA</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
NEUROINFLAMMATION	C-P-N001	<p>IMMUNE CHECKPOINT CHANGES CORRELATE WITH THE PROGRESSION AND PROGNOSIS OF AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>¹CHEN, SHENG; ¹XU, CHUNZUAN; ¹LIU, CHANGYUN; ¹LU, YINGQIAN; ¹ZOU, ZHANGYU</i></p> <p>¹DEPARTMENT OF NEUROLOGY, FUJIAN MEDICAL UNIVERSITY UNION HOSPITAL, 29# XINQUAN ROAD, FUZHOU, CHINA</p>
	C-P-N002	<p>IMMUNE CELLS AND PROTEINS RELEVANT TO DISEASE PROGRESSION IN AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>¹FUJITA K; ²ITOU T; ²OKUZONO Y; ²WARUDE D; ^{2S}HUUICHI M; ¹MIHARA Y; ¹MATSUI N; ³MORINO H; ²KIKUKAWA Y; ¹IZUMI Y</i></p> <p>¹DEPARTMENT OF NEUROLOGY, TOKUSHIMA UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, TOKUSHIMA, JAPAN, ²ONCOLOGY DRUG DISCOVERY UNIT JAPAN, PHARMACEUTICAL RESEARCH DIVISION, TAKEDA PHARMACEUTICAL COMPANY LIMITED., FUJISAWA, JAPAN, ³DEPARTMENT OF MEDICAL GENETICS, TOKUSHIMA UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, TOKUSHIMA, JAPAN</p>
NUTRITIONAL MANAGEMENT	C-P-NM001	<p>THE IMPACT OF BLOOD LIPID CLASSES ON RISK OF DEVELOPING AMYOTROPHIC LATERAL SCLEROSIS: A SYSTEMATIC REVIEW AND GRADE ANALYSIS</p> <p><i>^{1,2}SEWELL-GREEN, AMBER; ³KUIPER M; ³BEELEN A; ^{1,4}STEYN FJ; ^{4,5}NGO ST; ^{2,6}MATTHEWS-RENSCH KL</i></p> <p>¹SCHOOL OF BIOMEDICAL SCIENCES, FACULTY OF MEDICINE, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA, ²DEPARTMENT OF DIETETICS AND FOOD SERVICES, ROYAL BRISBANE AND WOMEN'S HOSPITAL, AUSTRALIA, ³DEPARTMENT OF REHABILITATION, PHYSICAL THERAPY SCIENCE AND SPORTS, UNIVERSITY MEDICAL CENTRE UTRECHT, UTRECHT, THE NETHERLANDS, ⁴DEPARTMENT OF NEUROLOGY, ROYAL BRISBANE AND WOMEN'S HOSPITAL, AUSTRALIA, ⁵AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA, ⁶QUEENSLAND CENTRE FOR MENTAL HEALTH RESEARCH, THE PARK CENTRE FOR MENTAL HEALTH TREATMENT, RESEARCH AND EDUCATION, WACOL, AUSTRALIA</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
RESPIRATORY MANAGEMENT	C-P-RM001	<p>UP TAKE OF RESPIRATORY SUPPORTS THROUGH COMMUNITY BASED RESPIRATORY CARE IN INDIVIDUALS WITH MOTOR NEURONE DISEASE (MND)</p> <p><i>¹TRAVLOS, J. VIVIENNE</i></p> <p>¹CLINICAL SERVICES, MOTORNEURONE DISEASE ASSOCIATION OF WESTERN AUSTRALIA, 1/184 RALEIGH STR, CARLISLE 6101, PERTH, AUSTRALIA</p>
	C-P-RM002	<p>THE COMBINATION OF IPV AND MI E FOR THE CARE OF AIRWAY CLEARANCE</p> <p><i>¹OGINO, MIEKO; ²TAIRA A; ¹OGINO A; ¹TOMINAGA N</i></p> <p>¹DEPARTMENT OF NEUROLOGY, INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE, ICHIKAWA HOSPITAL, ICHIKAWA, CHIBA, JAPAN, ²DEPARTMENT OF NEUROLOGY, INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE, NARITA HOSPITAL, NARITA, CHIBA, JAPAN</p>
OTHERS	C-P-O001	<p>DOXYCYCLINE INHIBITS MMP 9 AND INACTIVATES MICROGLIA TO PRESERVE PERINEURONAL NETS IN THE SOD1 G93 A ALS MICE</p> <p><i>¹CHEUNG, SANG WON; ²RIDDER, MARGREET; ¹BELLINGHAM, MARK C, AND; ^{1,2}NOAKES, PETER G.</i></p> <p>¹SCHOOL OF BIOMEDICAL SCIENCE, THE UNIVERSITY OF QUEENSLAND, ST LUCIA, AUSTRALIA, ²QUEENSLAND BRAIN INSTITUTE, THE UNIVERSITY OF QUEENSLAND, ST LUCIA, AUSTRALIA</p>
	C-P-O002	<p>EVALUATION OF LONG TERM PROGNOSIS OF EDARAVONE IN ALS PATIENTS: A REAL WORLD COMPARATIVE STUDY USING SUNRISE JAPAN AND JACALS REGISTRY DATA</p> <p><i>¹GEN SOBUE; ²NAOKI ATSUTA; ³KAORU ISHIZAKI; ³RIE UEBA; ³RISA UEKI; ³TAKAFUMI HASHIMOTO; ³SATOSHI YUKI</i></p> <p>¹AICHI MEDICAL UNIVERSITY, 1-1 YAZAKOKARIMATA, NAGAKUTE, JAPAN, ²DEPARTMENT OF NEUROLOGY, AICHI MEDICAL UNIVERSITY, 1-1 YAZAKOKARIMATA, NAGAKUTE, JAPAN, ³mitsubishi TANABE PHARMA CORPORATION, 1-1-1 MARUNOUCHI CHIYODA-KU, TOKYO, JAPAN</p>

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
OTHERS	C-P-0003	<p>THE ALL ENCOMPASSING NATURE OF CARE IN MND</p> <p><i>¹NEVILLE, SALLY; ²NGO, SHYUAN; ¹STEYN, FREDERIK; ³PACKER, REBECCA</i></p> <p>¹SCHOOL OF BIOMEDICAL SCIENCES, FACULTY OF HEALTH, MEDICINE AND BEHAVIOURAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, BRISBANE QUEENSLAND AUSTRALIA. ²AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, THE UNIVERSITY OF QUEENSLAND, BRISBANE QUEENSLAND AUSTRALIA. ³SCHOOL OF HEALTH AND REHABILITATION SCIENCES, FACULTY OF HEALTH, MEDICINE AND BEHAVIOURAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, BRISBANE QUEENSLAND AUSTRALIA</p>
	C-P-0004	<p>CHARACTERISTICS OF FLEXIBLE ENDOSCOPIC EVALUATION OF SWALLOWING (FEES) DURING INTAKE OF SOLIDS IN PERSONS WITH AMYOTROPHIC LATERAL SCLEROSIS (PALS)</p> <p><i>¹BELUR YK; ¹THUVASSERY P; ¹VALIYAPEEDIYYEKKAL A; ²VENGALIL S; ²MASARADDI HN; ²KEERTHIPRIYA M; ³THOMAS TP;²ATCHAYARAM N</i></p> <p>¹DEPARTMENT OF SPEECH PATHOLOGY AND AUDIOLOGY, NIMHANS, BENGALURU-560029, INDIA ²DEPARTMENT OF NEUROLOGY, NIMHANS, BENGALURU-560029, INDIA ³DEPARTMENT OF PSYCHIATRIC SOCIAL WORK, NIMHANS, BENGALURU-560029, INDIA</p>
	C-P-0005	<p>LEVEL OF KNOWLEDGE ON AMYOTROPHIC LATERAL SCLEROSIS AMONG NURSING STUDENTS IN SELECTED COLLEGES IN THE PHILIPPINES</p> <p><i>¹DURANTE, CHERRY ANN; ²SAN JUAN, ESTRELLA</i></p> <p>¹DEPARTMENT OF NURSING, PHILIPPINE WOMEN'S UNIVERSITY, MANILA, PHILIPPINES ²DEPARTMENT OF NURSING, UNIVERSITY OF PERPETUAL HELP – DR JOSE G TAMAYO MEDICAL UNIVERSITY, LAGUNA, PHILIPPINES</p>

PACTALS 2025

CLINICAL POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
OTHERS	C-P-0006	<p>DYSARTHRIA AND ASSOCIATED IMPACTS ACROSS INDIVIDUALS WITH MOTOR NEURON DISEASE (MND): A MULTIPLE CASE REPORT STUDY</p> <p><i>^{1,2}CHARANIA, SALMA; ¹PACKER R; ¹SCARINCI N; ³CORNWELL PL; ¹RUMBACH A</i></p> <p>¹SCHOOL OF HEALTH AND REHABILITATION SCIENCES, THE UNIVERSITY OF QUEENSLAND, BRISBANE, AUSTRALIA, ²SCHOOL OF HEALTH, MEDICAL AND APPLIED SCIENCES, CENTRAL QUEENSLAND UNIVERSITY, ROCKHAMPTON, AUSTRALIA, ³SCHOOL OF ALLIED HEALTH, SPORT AND SOCIAL WORK, GRIFFITH UNIVERSITY, GOLD COAST, AUSTRALIA,</p>

MNDA CARE FORUM

ORAL PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
INNOVATIONS & NEW HORIZONS	M-O-I&NH001	<p>AMPLIFYING THE LIVED EXPERIENCE OF MND VOICE IN AUSTRALIA</p> <p><i>¹LABRA J; CAMDEN P; MALPRESS K; ²YAP MY; SKLAVENITIS L; SIMPSON J.</i></p> <p>¹MND AUSTRALIA, 20 BRADLEY ST, WODEN, AUSTRALIAN CAPITAL TERRITORY, AUSTRALIA, ²FIGHTMND, PO BOX 3073 BURNLEY NORTH, VICTORIA, AUSTRALIA</p>
	M-O-I&NH002	<p>DEVELOPING A MOTOR NEURONE DISEASE MASSIVE OPEN ONLINE COURSE (MND MOOC) TO INCREASE GLOBAL KNOWLEDGE, UNDERSTANDING AND AWARENESS OF MND</p> <p><i>PERRY SHARN; ATKINSON RA; PHIPPS A; HANDLEY E; VICKERS J</i></p> <p>WICKING DEMENTIA RESEARCH AND EDUCATION CENTRE, UNIVERSITY OF TASMANIA, 17 LIVERPOOL STREET, HOBART 7000, TASMANIA, AUSTRALIA</p>
	M-O-I&NH003	<p>CONTINUING THE GAME IN SPITE OF THE BEAST: SUPPORTING GAMING ACCESSIBILITY FOR PEOPLE WITH MND</p> <p><i>¹EDWARDS, ALICIA</i></p> <p>¹MND QUEENSLAND, 1/89 FACTORY ROAD, OXLEY QUEENSLAND AUSTRALIA</p>
	M-O-I&NH004	<p>OCCUPATIONAL THERAPY MEETS MCGYVER – SOLVING FUNCTIONAL CHALLENGES WITH CREATIVITY AND INNOVATION</p> <p><i>SARAH SOLOMON</i></p> <p>CALVARY HEALTH CARE BETHLEHEM</p>

MNDA CARE FORUM

ORAL PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
INTERNATIONAL PERSPECTIVES IN CARE AND SUPPORT	M-O-IPIC&S001	<p>INTERNATIONAL NETWORK FOR ALS RESEARCH AND CARE (INARC)</p> <p><i>JULIETTE FOUCHER^{1,2,3}, TOMMY M BUNTE^{3,4,5}, VANESSA BERTONE^{3,6}, MATHIAS COUILLARD^{3,6}, COREY STRAUB^{6,7}</i></p> <p>¹DEPARTMENT OF CLINICAL NEUROSCIENCE, KAROLINSKA INSTITUTET, STOCKHOLM, SWEDEN ²DEPARTMENT OF NEUROLOGY, ME NEUROLOGY, KAROLINSKA UNIVERSITY HOSPITAL, STOCKHOLM, SWEDEN ³INTERNATIONAL NETWORK FOR ALS RESEARCH AND CARE, INARC, CANADA ⁴DEPARTMENT OF NEUROLOGY, UMC UTRECHT BRAIN CENTER, UNIVERSITY MEDICAL CENTER UTRECHT, UTRECHT, THE NETHERLANDS ⁵TREATMENT RESEARCH INITIATIVE TO CURE ALS, TRICALS, THE NETHERLANDS ⁶GENGE PARTNERS INC., MONTREAL, CANADA ⁷QURALIS INC. CAMBRIDGE, UNITED STATES OF AMERICA</p>
THE LATEST IN EVIDENCE-BASED CARE – INCL. MULTIDISCIPLINARY CARE, INTERVENTIONS ETC	M-O-TLIEBC001	<p>'INVEST' IN YOUR VOICE: HOW A NOVEL CO DESIGNED VOICE BANKING SERVICE SUPPORTS PEOPLE WITH MND</p> <p><i>¹KRIKHELI, LILLIAN; ²JACKSON, NICHOLAS</i></p> <p>¹DISCIPLINE OF SPEECH PATHOLOGY, LA TROBE UNIVERSITY, MELBOURNE, AUSTRALIA. ²SPEECH PATHOLOGY, CALVARY HEALTH CARE BETHLEHEM, MELBOURNE, AUSTRALIA</p>
	M-O-TLIEBC002	<p>DEVELOPING THE AUSTRALIAN MOTOR NEURONE DISEASE GUIDELINE: A COLLABORATIVE, EVIDENCE BASED APPROACH USING GRADE METHODOLOGY</p> <p><i>ZACHARY MUNN¹, CINDY STERN¹, DANIELLE POLLOCK¹, TIMOTHY BARKER¹, STEVE VUCIC² FOR THE AUSTRALIAN MND GUIDELINE DEVELOPMENT GROUP</i></p> <p>¹HEALTH EVIDENCE SYNTHESIS, RESEARCH, AND IMPACT (HESRI), UNIVERSITY OF ADELAIDE, AUSTRALIA ²BRAIN AND NERVE RESEARCH CENTRE, CONCORD CLINICAL SCHOOL, THE UNIVERSITY OF SYDNEY, SYDNEY, AUSTRALIA</p>
	M-O-TLIEBC003	<p>EXPLORING THE NARRATIVE BEHIND THE NUMBERS: USING DATA TO IMPROVE CARE AND SUPPORT FOR THOSE LIVING WITH MOTOR NEURONE DISEASE (MND)</p> <p><i>¹TULL, VICTORIA</i></p> <p>¹ACCESS & EDUCATION, MND VICTORIA, 265-267 CANTERBURY RD, CANTERBURY VIC 3126, AUSTRALIA</p>

MNDA CARE FORUM

ORAL PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
THE LATEST IN EVIDENCE-BASED CARE – INCL. MULTIDISCIPLINARY CARE, INTERVENTIONS ETC	M-O-TLIEBC004	<p>EXPLORING THE UPTAKE OF NON INVASIVE VENTILATION BY PEOPLE WITH MOTOR NEURONE DISEASE IN AUSTRALIA: A QUALITATIVE STUDY</p> <p><i>MARNIE GRACO^{*,1,2} KYLIE RUSSO^{*,1,2,3} NICOLE GRIVELL^{1,2,4} KATE CAREY^{1,2} CHARISSA ZAGA^{1,2} KRISHA SARAVANAN¹ NICOLE L SHEERS^{1,2} DAVID J BERLOWITZ^{1,2}</i></p> <p>¹INSTITUTE FOR BREATHING AND SLEEP, AUSTIN HEALTH, HEIDELBERG, VIC, AUSTRALIA; ²DEPARTMENT OF PHYSIOTHERAPY, FACULTY OF MEDICINE, DENTISTRY AND HEALTH SCIENCES, THE UNIVERSITY OF MELBOURNE, MELBOURNE, VIC, AUSTRALIA; ³FACULTY OF HEALTH SCIENCES AND MEDICINE, BOND UNIVERSITY, GOLD COAST, QLD, AUSTRALIA; ⁴FHMRI SLEEP HEALTH, FLINDERS HEALTH AND MEDICAL RESEARCH INSTITUTE, COLLEGE OF MEDICINE AND PUBLIC HEALTH, FLINDERS UNIVERSITY, BEDFORD PARK, SA, AUSTRALIA</p>
	M-O-TLIEBC005	<p>TRIAL AND TRIUMPHS IN COMMUNITY BASED RESPIRATORY CARE FOR ADULTS WITH MOTOR NEURONE DISEASE (MND): WEST AUSTRALIAN EXPERIENCE</p> <p><i>¹TRAVLOS, J. VIVIENNE</i></p> <p>¹CLINICAL SERVICES, MOTORNEURONE DISEASE ASSOCIATION OF WESTERN AUSTRALIA, 1/184 RALEIGH STR, CARLISLE 6101, PERTH, AUSTRALIA</p>

MNDA CARE FORUM

ORAL PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
THE LATEST IN EVIDENCE-BASED CARE – INCL. MULTIDISCIPLINARY CARE, INTERVENTIONS ETC	M-O-TLIEBC006	<p>BRIDGING HEALTH EQUITY GAPS FOR AUSTRALIANS WITH MND: CO DESIGNING SOLUTIONS WITH THE MND COMMUNITY</p> <p>¹HUTCHINSON, K., ²LABRA, J., ³DYSON, N., ³CULLEN, M., ⁴GRACO, M., ⁵GILES, L., ⁶WINKEL, A., ⁷AOUN, S., ⁸FRANCIS, R., ⁹JOHNSON, K., +TRAVLOS, V., AND ¹HOGDEN, A.</p> <p>¹ SCHOOL FOR POPULATION HEALTH, UNIVERSITY OF NSW, ROOM 317, LEVEL 3, SAMUELS BUILDING, SYDNEY, NEW SOUTH WALES, AUSTRALIA ² MND AUSTRALIA, 20 BRADLEY STREET, AUSTRALIAN CAPITAL TERRITORY, AUSTRALIA, ³ NATIONAL LIVED EXPERIENCE NETWORK, MND AUSTRALIA, 20 BRADLEY STREET, AUSTRALIAN CAPITAL TERRITORY, AUSTRALIA, ⁴INSTITUTE FOR BREATHING AND SLEEP, AUSTIN HEALTH,145 STUDLEY ROAD, MELBOURNE, VICTORIA, AUSTRALIA, ⁵DEPARTMENT OF NEUROSCIENCE, LAUNCESTON GENERAL HOSPITAL, 280 CHARLES STREET, LAUNCESTON, TASMANIA, AUSTRALIA, ⁶DEPARTMENT OF NEUROSCIENCES, SUNSHINE COAST HEALTH, 6 DOHERTY ST, BIRTINYA, QUEENSLAND, AUSTRALIA, ⁷PERRON INSTITUTE, GROUND RR BLOCK QE II MEDICAL CENTRE RALPH & PATRICIA SARICH NEUROSCIENCE BUILDING, 8 VERDUN ST, NEDLANDS WESTERN AUSTRALIA, AUSTRALIA, ⁸COLLEGE NURSING HEALTH SCIENCES, FLINDERS UNIVERSITY AND CARING FUTURES INSTITUTE, STURT ROAD, BEDFORD PARK, ADELAIDE, SOUTH AUSTRALIA, AUSTRALIA, ⁹MND VICTORIA, 256 CANTERBURY ROAD, CANTERBURY, VICTORIA, AUSTRALIA, ¹⁰CLINICAL SERVICES, MOTOR NEURONE DISEASE ASSOCIATION OF WESTERN AUSTRALIA, U1/184 RALEIGH ST, CARLISLE, PERTH, WESTERN AUSTRALIA, AUSTRALIA</p>
	M-O-TLIEBC007	<p>DYSPHAGIA IN NEURODEGENERATIVE DISEASES: IMPLICATIONS FOR SWALLOWING, DRY MOUTH, AND ORAL HEALTH</p> <p>VICTORIA TAMARA PERCHYONOK</p> <p>ORAL HEALTH THERAPIST WITH ADULT SCOPE, SPECIAL NEEDS ORAL CARE, CLINICAL LECTURER, THE UNIVERSITY OF MELBOURNE</p>
	M-O-TLIEBC008	<p>ENHANCING MND CARE: EVALUATING THE EFFECTIVENESS OF IN PERSON MND UPSKILL WORKSHOPS</p> <p>¹WARRAICH ST; ¹JEWEL S; ¹GIBBS A; ¹OPIE G; ¹COLLINS A</p> <p>¹MOTOR NEURONE DISEASE NSW, BUILDING 4 GLADESVILLE HOSPITAL, VICTORIA ROAD, GLADESVILLE, NSW, AUSTRALIA</p>

MNDA CARE FORUM

ORAL PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
THE LATEST IN EVIDENCE-BASED CARE – INCL. MULTIDISCIPLINARY CARE, INTERVENTIONS ETC	M-O-TLIEBC009	<p>MEETING THE ASSISTIVE TECHNOLOGY NEEDS OF PEOPLE WITH MND – NSW AND VIC COLLABORATIVE MODEL</p> <p><i>¹ALICIA GIBB, ²AMY SCHNEIDER, ³JO WHITEHOUSE</i></p> <p>¹MND NSW FLEXEQUIP (EQUIPMENT SERVICE) MANAGER ²MND VICTORIA EQUIPMENT SERVICE TEAM LEADER ³MND VICTORIA GENERAL MANAGER SUPPORT SERVICES</p>
WELLBEING & COMMUNICATION	M-O-W&C001	<p>TIPS AND TRICKS ON WELLBEING AND COMMUNICATION TO NOT JUST SURVIVE BUT THRIVE WITH MND</p> <p><i>SKLAVENITIS, LEANNE</i></p> <p>122 HOSKINS STREET SANDGATE 4017, BRISBANE, AUSTRALIA</p>
	M-O-W&C002	<p>EXPLORING PREFERENCES FOR MANAGEMENT OF COGNITIVE AND BEHAVIOURAL CHANGES IN MOTOR NEURONE DISEASE</p> <p><i>^{1,2}FRANCIS, REBECCA; ³ATTRILL, S; ^{1,2}DOELTGEN, S</i></p> <p>¹SPEECH PATHOLOGY, COLLEGE OF NURSING AND HEALTH SCIENCES, FLINDERS UNIVERSITY, ADELAIDE, AUSTRALIA. ²CARING FUTURES INSTITUTE, FLINDERS UNIVERSITY, ADELAIDE, AUSTRALIA. ³ADELAIDE UNIVERSITY, ADELAIDE, AUSTRALIA</p>
	M-O-W&C003	<p>THE ALL ENCOMPASSING NATURE OF CARE IN MND</p> <p><i>¹NEVILLE, SALLY; ²NGO, SHYUAN; ¹STEYN, FREDERIK; ³PACKER, REBECCA</i></p> <p>¹SCHOOL OF BIOMEDICAL SCIENCES, FACULTY OF HEALTH, MEDICINE AND BEHAVIOURAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, BRISBANE QUEENSLAND AUSTRALIA. ²AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, THE UNIVERSITY OF QUEENSLAND, BRISBANE QUEENSLAND AUSTRALIA. ³ SCHOOL OF HEALTH AND REHABILITATION SCIENCES, FACULTY OF HEALTH, MEDICINE AND BEHAVIOURAL SCIENCES, THE UNIVERSITY OF QUEENSLAND, BRISBANE QUEENSLAND AUSTRALIA</p>

MNDA CARE FORUM

ORAL PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
WELLBEING & COMMUNICATION	M-O-W&C004	<p>SLEEP FOR PEOPLE WITH MOTOR NEURON DISEASE AND THEIR FAMILIES IN NEW ZEALAND, A QUESTIONNAIRE STUDY</p> <p>^{1,2}GAULD, N; ²HIKAKA, J; ³BUCHANAN, S; ⁴FALETAU, J; ⁵CLELAND, J. ⁶RUTHERFORD, S; ⁷BUETOW, S.</p> <p>¹MOTOR NEURONE DISEASE NEW ZEALAND, 14 ERSON ST, ROYAL OAK, AUCKLAND, NEW ZEALAND, ²DSCHOOL OF PHARMACY, THE UNIVERSITY OF AUCKLAND, PARK RD, GRAFTON, AUCKLAND, NEW ZEALAND; ³UNIVERSITY OF OTAGO, LEITH ST, DUNEDIN. NEW ZEALAND; ⁴PACIFIC PUBLIC HEALTH DIRECTORATE, NATIONAL PUBLIC HEALTH SERVICE, TE WHATU ORA, CLAUDE RD, GREENLANE, AUCKLAND, NEW ZEALAND; ⁵TE WHATU ORA BAY OF PLENTY, CAMERON RD, TAURANGA, NEW ZEALAND; ⁶CENTRE FOR PERSON CENTRED RESEARCH, AUCKLAND UNIVERSITY OF TECHNOLOGY, AUCKLAND, NEW ZEALAND; ⁷DEPARTMENT OF GENERAL PRACTICE AND PRIMARY HEALTH CARE, UNIVERSITY OF AUCKLAND, PARK RD, GRAFTON, AUCKLAND, NEW ZEALAND</p>

MNDA CARE FORUM

POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
INNOVATIONS & NEW HORIZONS	M-P-I&NH001	<p>INNOVATIONS IN MND CARE: AN AFFORDABLE STRATEGY MONITORING WEIGHT AT HOME</p> <p><i>¹SHEEHY TP; ²YOUNG CM</i></p> <p>¹DEPARTMENT OF PHYSIOTHERAPY, CALVARY HEALTH CARE BETHLEHEM, 476 KOOYONG RD, MELBOURNE, AUSTRALIA ²DEPARTMENT OF NUTRITION AND DIETETICS, CALVARY HEALTH CARE BETHLEHEM, 476 KOOYONG RD, MELBOURNE, AUSTRALIA</p>
	M-P-I&NH002	<p>INNOVATIONS IN MND CARE: ACHIEVING QUALITY OF LIFE GOALS FOR VENTILATED INDIVIDUALS THROUGH ACCESS TO HYDROTHERAPY. A CASE STUDY</p> <p><i>¹SHEEHY TP; ¹PARKER KF</i></p> <p>¹DEPARTMENT OF PHYSIOTHERAPY, CALVARY HEALTH CARE BETHLEHEM, 476 KOOYONG RD, MELBOURNE, AUSTRALIA</p>
	M-P-I&NH003	<p>THE ROLE OF THE MND PALLIATIVE CARE CLINICIAN IN MND EDUCATION IN VICTORIA</p> <p><i>TURTON JANE. MND PALLIATIVE CARE CLINICIAN- SOUTHERN METRO REGION PALLIATIVE CARE CONSORTIUM, MAIN ST MORNINGTON, VIC, AUSTRALIA</i></p> <p>MITCHELL SAMANTHA. TEAM LEADER, MND ADVISOR/ SUPPORT COORDINATOR, MND VICTORIA, CANTERBURY RD, SURREY HILLS, VIC, AUSTRALIA BARBELER CAROL. MND PALLIATIVE CARE CLINICIAN- GIPPSLAND PALLIATIVE CARE CONSORTIUM, 412 LANDSBOROUGH ST, WARRAGUL, VIC, AUSTRALIA</p>
	M-P-I&NH004	<p>LUNCHTIME SESSIONS FREE ONLINE MND EDUCATION FOR ALL</p> <p><i>TURTON JANE</i></p> <p>MND PALLIATIVE CARE CLINICIAN- SOUTHERN METRO REGION PALLIATIVE CARE CONSORTIUM. MAIN STREET MORNINGTON, VICTORIA, AUSTRALIA</p>

MNDA CARE FORUM

POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
THE LATEST IN EVIDENCE-BASED CARE – INCL. MULTIDISCIPLINARY CARE, INTERVENTIONS ETC	M-P-TLIEBC001	<p>THE IMPACT OF BLOOD LIPID CLASSES ON RISK OF DEVELOPING AMYOTROPHIC LATERAL SCLEROSIS: A SYSTEMATIC REVIEW AND GRADE ANALYSIS</p> <p><i>^{1,2}SEWELL-GREEN, AMBER; ³KUIPER M; ³BEELEN A; ^{1,4}STEYN FJ; ^{4,5}NGO ST; ^{2,6}MATTHEWS-RENSCH KL</i></p> <p>¹SCHOOL OF BIOMEDICAL SCIENCES, FACULTY OF MEDICINE, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA, ²DEPARTMENT OF DIETETICS AND FOODSERVICES, ROYAL BRISBANE AND WOMEN'S HOSPITAL, AUSTRALIA, ³DEPARTMENT OF REHABILITATION, PHYSICAL THERAPY SCIENCE AND SPORTS, UNIVERSITY MEDICAL CENTRE UTRECHT, UTRECHT, THE NETHERLANDS, ⁴DEPARTMENT OF NEUROLOGY, ROYAL BRISBANE AND WOMEN'S HOSPITAL, AUSTRALIA, ⁵AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA, ⁶QUEENSLAND CENTRE FOR MENTAL HEALTH RESEARCH, THE PARK CENTRE FOR MENTAL HEALTH TREATMENT, RESEARCH AND EDUCATION, WACOL, AUSTRALIA</p>
	M-P-TLIEBC002	<p>EVALUATING THE IMPACT OF WEIGHT LOSS AND ACCURACY OF PREDICTIVE ENERGY EQUATIONS IN AUSTRALIANS WITH AMYOTROPHIC LATERAL SCLEROSIS</p> <p><i>^{1,2}SEWELL-GREEN, AMBER; ¹CAPSTICK R; ^{2,3}MATTHEWS-RENSCH KL; ⁴HENDERSON R; ^{4,5}NGO ST; ^{1,4}STEYN FJ</i></p> <p>¹SCHOOL OF BIOMEDICAL SCIENCES, FACULTY OF MEDICINE, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA, ²DIETETICS AND FOODSERVICES, ROYAL BRISBANE AND WOMEN'S HOSPITAL, AUSTRALIA, ³QUEENSLAND CENTRE FOR MENTAL HEALTH RESEARCH, THE PARK CENTRE FOR MENTAL HEALTH TREATMENT, RESEARCH AND EDUCATION, WACOL, AUSTRALIA, ⁴DEPARTMENT OF NEUROLOGY, ROYAL BRISBANE AND WOMEN'S HOSPITAL, AUSTRALIA, ⁵AUSTRALIAN INSTITUTE FOR BIOENGINEERING AND NANOTECHNOLOGY, THE UNIVERSITY OF QUEENSLAND, AUSTRALIA</p>
	M-P-TLIEBC003	<p>SURVEY OF CONSTIPATION IN AUSTRALIANS WITH MND USING THE LIVED EXPERIENCE NETWORK</p> <p><i>¹WERTH, BARRY; ¹FISHER, MURRAY</i></p> <p>¹SUSAN WAKIL SCHOOL OF NURSING AND MIDWIFERY, FACULTY OF MEDICINE AND HEALTH, UNIVERSITY OF SYDNEY, SYDNEY, AUSTRALIA</p>

MNDA CARE FORUM

POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
THE LATEST IN EVIDENCE-BASED CARE – INCL. MULTIDISCIPLINARY CARE, INTERVENTIONS ETC	M-P-TLIEBC004	<p>PRIORITISING THE FACTORS INFLUENCING NON INVASIVE VENTILATION UPTAKE BY PEOPLE WITH MOTOR NEURONE DISEASE: A MODIFIED DELPHI STUDY</p> <p><i>1,2,3</i>RUSO K; <i>1,2</i>CAREY K; <i>1,2,4</i>GRIVELL N; <i>1,2</i>BERLOWITZ, DJ; <i>1,2</i>GRACO, M; THE NIV IN MND STAKEHOLDER ADVISORY GROUP</p> <p>¹ INSTITUTE FOR BREATHING AND SLEEP, AUSTIN HEALTH, HEIDELBERG, VICTORIA, AUSTRALIA, ²DEPARTMENT OF PHYSIOTHERAPY, FACULTY OF MEDICINE, DENTISTRY AND HEALTH SCIENCES, THE UNIVERSITY OF MELBOURNE, MELBOURNE, VICTORIA, AUSTRALIA, ³FACULTY OF HEALTH SCIENCES AND MEDICINE, BOND UNIVERSITY, GOLD COAST, QLD, AUSTRALIA, ⁴ FHMRI SLEEP HEALTH, FLINDERS HEALTH AND MEDICAL RESEARCH INSTITUTE, COLLEGE OF MEDICINE AND PUBLIC HEALTH, FLINDERS UNIVERSITY, BEDFORD PARK, SOUTH AUSTRALIA, AUSTRALIA</p>
	M-P-TLIEBC005	<p>FROM TEAM TO MODEL: EMBEDDING TRUE MULTIDISCIPLINARY CARE FOR PEOPLE LIVING WITH MND IN THE COMMUNITY</p> <p><i>DAN CHARNY¹, ALICIA EDWARDS¹</i></p> <p>¹MND QUEENSLAND, OXLEY, QLD, AUSTRALIA</p>
	M-P-TLIEBC006	<p>DEVELOPMENT OF A SPECIALTY DRIVEN HOME PALLIATIVE CARE SERVICE IN MOTOR NEURONE DISEASE</p> <p><i>KRISHNAN P¹, CAPELLE D², HAMZAH E¹, SHAHRIZAILA N³</i></p> <p>¹HOSPIS MALAYSIA, KUALA LUMPUR, MALAYSIA, ²PALLIATIVE DEPARTMENT, UNIVERSITI MALAYA MEDICAL CENTRE, KUALA LUMPUR, MALAYSIA, ³NEUROLOGY DEPARTMENT, UNIVERSITI MALAYA MEDICAL CENTRE, KUALA LUMPUR, MALAYSIA</p>
INTERNATIONAL PERSPECTIVES IN CARE AND SUPPORT	M-P-IPIC&S001	<p>AN EVALUATION OF THE ALSSQOL SF IN THE MALAYSIAN CONTEXT THROUGH COGNITIVE INTERVIEWING</p> <p><i>Wafa Sabirin¹, Fazlina Ahmad², Saiful Adni Abd Latif², Sheriza Izwa Zainuddin¹, Chee-Loong Lam¹, Chun-Ian Soo¹, Kee-Huat Chuah¹, Sakinah Sabirin¹, Nortina Shahrizaila¹, David Paul Capelle¹</i></p> <p>¹DEPARTMENT OF MEDICINE, FACULTY OF MEDICINE, UNIVERSITY OF MALAYA, 50603, KUALA LUMPUR, MALAYSIA. ²DEPARTMENT OF BIOMEDICAL SCIENCE, FACULTY OF MEDICINE, UNIVERSITY OF MALAYA, 50603, KUALA LUMPUR, MALAYSIA</p>

MNDA CARE FORUM

POSTER PRESENTATION

AREA OF INTEREST	CODE	ABSTRACT TITLE AND AUTHOR NAME
WELLBEING & COMMUNICATION	M-P-W&C001	<p>THE EXPERIENCE OF SUFFERING IN ALS: A CASE REPORT</p> <p>¹ANG CM, ⁵RASYID M, ⁵KRISHNAN P, ¹ZAINUDDIN S, ¹LAM CL, ⁴PEK EW, ³SOO CI, ²SHAHRIZAILA N, ¹CAPELLE D</p> <p>¹PALLIATIVE DEPARTMENT, UNIVERSITI MALAYA MEDICAL CENTRE, LEMBAH PANTAI, KUALA LUMPUR, MALAYSIA, ²NEUROLOGY DEPARTMENT, UNIVERSITI MALAYA MEDICAL CENTRE, LEMBAH PANTAI, KUALA LUMPUR, MALAYSIA, ³RESPIRATORY DEPARTMENT, UNIVERSITI MALAYA MEDICAL CENTRE, LEMBAH PANTAI, KUALA LUMPUR, MALAYSIA, ⁴REHABILITATION DEPARTMENT, UNIVERSITI MALAYA MEDICAL CENTRE, LEMBAH PANTAI, KUALA LUMPUR, MALAYSIA, ⁵HOSPIS MALAYSIA, CHERAS, KUALA LUMPUR, MALAYSIA</p>
	M-P-W&C002	<p>EMOTIONAL ADJUSTMENT AND MND: THE BENEFITS OF AN IN HOUSE COUNSELLING PROGRAM FOR PEOPLE WITH MND AND THEIR FAMILIES</p> <p>¹BRADHURST, B; ¹WHITEHOUSE, J; ¹HAMILTON, K; ¹CRASK, E</p> <p>¹MND VICTORIA, 265-267 CANTERBURY ROAD, CANTERBURY, VIC, AUSTRALIA</p>
	M-P-W&C003	<p>DESCRIPTIVE ANALYSIS OF PATIENTS WITH MOTOR NEURONE DISEASE WHO UNDERWENT VOLUNTARY ASSISTED DYING</p> <p>¹NATHANI, DEV</p> <p>¹PERRON INSTITUTE FOR NEUROLOGICAL AND TRANSLATIONAL SCIENCE, GROUND FLOOR, RR BLOCK, QE II MEDICAL CENTRE, RALPH & PATRICIA SARICH NEUROSCIENCE BUILDING, 8 VERDUN ST, NEDLANDS, WA 6009</p>
	M-P-W&C004	<p>DIRECTING CARE TOWARDS THE CARER: EMPOWERING CARERS TO SUPPORT LOVED ONES WITH MOTOR NEURONE DISEASE (MND)</p> <p>¹O'CONNOR M; ²WHITEHOUSE J; ³TULL V</p> <p>^{1,2,3}SUPPORT SERVICES, MND VICTORIA, 265-267 CANTERBURY RD, CANTERBURY VIC 3126, AUSTRALIA</p>

Thank You to Our Sponsors

Diamond Sponsors



Platinum Sponsors



Gold Sponsors



Silver Sponsor



Standard Sponsors



PACTALS 2025



Theme:

Towards Precision in ALS/MND Treatments and Care

SOUVENIR PROGRAMME BOOK

7 - 9 September 2025

Melbourne Convention and Exhibition Centre, Australia

Organised by:



PACTALS
Pan-Asian Consortium for Treatment and Research in ALS



Medical Conference Partners
Officially Appointed Congress Secretariat
Tel : +6016 335 0036
Email : secretariat@pactalscongress.com